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Abstract 
 Inherited metabolic diseases (IMDs) are a large class of heterogeneous genetic 
disorders caused by dysfunction within a single pathway of intermediary metabolism. In 
many of these diseases, the dysfunction of metabolic enzymes leads to the accumulation of 
toxic metabolites which disrupts the normal development of the central nervous system. With 
the advent of treatments that positively influence neuropsychological outcomes, there is a 
need for sensitive and objective neuropsychological measures that allow patients to be 
systematically tracked in order to understand the efficacy of existing treatments. 
In this thesis, a neuropsychological test battery consisting of attention, language and 
oculomotor measures was developed to accurately describe individual and developmental 
differences between IMD patients and healthy developing controls. The functioning of five 
diseases was examined: Morquio syndrome (N = 12), Hurler syndrome (N = 3), Maroteux-
Lamy syndrome (N = 2), Tyrosinemia type I (N = 13) and Tyrosinemia type III (N = 5). 
Findings indicated that disease effects were not homogeneous across tasks, and that 
performance on the same tasks was not uniform across diseases. The obtained data offers a 
promising basis for understanding how biological factors influence the severity and 
timecourse of developmental effects in future research. 
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1.0 INTRODUCTION 
Inherited metabolic diseases (IMD’s) are large class of heterogeneous genetic 
disorders that are caused by dysfunction within a single pathway of intermediary metabolism. 
For the majority of these diseases it is the dysfunction of metabolic enzymes that leads to the 
accumulation of toxic metabolites, which disrupts the normal development of the central 
nervous system. Depending on the specific role of the dysfunctional enzymes, the severity of 
symptoms associated with IMDs can vary widely. Mild symptoms can include physiological 
abnormalities such as skeletal dysplasia and impaired endurance (Davison, Kearney, & 
Horton, 2012; Wraith, 2006), while severe consequences can include mental retardation, 
central nervous system (CNS) complications, and reduced life expectancy (Bendadi et al., 
2014a; De Laet et al., 2011; Masurel-Paulet et al., 2008; Thimm et al., 2011, 2012). 
To date there has been abundance of animal-model and genetic research detailing the 
biological and genetic factors that relate to inherited metabolic disease (IMD) (Leonard, 
2006; Wendel & Baulny, 2006; Wraith, 2006). In comparison, neuropsychological research 
into the cognitive development of IMDs has been limited to standardised intelligence tests, 
achievement tests and adaptive behaviour scales (Bax & Colville, 1995; Biernacka, 
Jakubowska-Winecka, & Tylki-Szymanska, 2010; Davison et al., 2012; Shapiro et al., 2009) 
that are not always suitable or the tracking of the impact of disease progression upon 
neuropsychological function (Martin et al., 2008). In particular, it is unclear how disease 
progression across IMDs affects cognitive function; does cognitive function decline globally 
or are specific cognitive domains affected more severely than others? The lack of research in 
this area is surprising considering the emergence of interventions (enzyme replacement 
therapy, haematopoietic stem cell transplantation) over the past decade that are able to 
stabilise symptoms and extend the life expectancy of patients (Desnick & Banikazemi, 2006; 
Eapen et al., 2007; Escolar et al., 2005; Patterson, Vecchio, Prady, Abel, & Wraith, 2007). 
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Consequently, there is a demand for measures of cognitive function that are able to accurately 
and objectively track the natural progression of IMDs, which can evaluate the efficiency of 
therapeutic interventions, and can inform clinicians and researchers which therapies produce 
the best cognitive outcomes for patients. 
To our knowledge no set of neuropsychological measures exists that are tailored 
towards IMD populations; this is mainly due to the unavailability of a commercial source that 
utilises a “toolkit” approach and also to the complex heterogeneous nature of these diseases. 
This is surprising since the combined prevalence of IMDs is 1 in 784 live births within the 
West Midlands (Sanderson, Green, Preece, & Burton, 2006). In addition, a greater number of 
IMDs are now being included in neonatal screening programs (Marsden & Levy, 2010) so 
detailed longitudinal tracking of these diseases is important. Thus, the current project aims to 
be the first to develop a sensitive and efficient battery of neuropsychological tests that is 
specifically tailored to measure the functional capabilities of children with rare inherited 
metabolic diseases. To achieve this, the project will focus on developing tasks that assess the 
cognitive abilities of language, motor control and attention in order to assess how the diseases 
selectively or generally disrupts cognitive abilities as a result of disease progression.  
The rationale for the selection of tasks was based upon several criteria. Firstly, due to 
the rarity of these disorders, early formulation of tasks was based upon input from clinically 
collaborators to select domains of cognitive function where impairments are suggestive of 
metabolic disease. For example, disruption of the oculomotor system (vertical and horizontal 
gaze palsy) is pathognomic of several metabolic disorders oculomotor symptoms (Niemann-
Pick Type C and Gaucher’s disease), while attention and language deficits are common 
features in other metabolic diseases (Hurler Syndrome and Tyrosinemia I respectively). 
Secondly, tasks needed to be sensitive to developmental change across a wide age range and 
be influenced minimally by floor or ceiling effects. This was particularly important in order 
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to identify mild and substantially cognitive impariments in patient groups, since a primary 
outcome of this work is to produce measures which could potentially screen for neurological 
symptoms. For this reason I focused on including tasks (e.g. visual search task, non-word 
learning task, saccadic eye movement), which have been successfully employed in 
neuropsychological research to examine both cognitive development across a wide age range 
and cognitive impairments in very young patient populations (T. J. Anderson & MacAskill, 
2013; Brenner, Turner, & Müller, 2007; Gray, 2004; Hommel, Li, & Li, 2004a; Karatekin, 
2007). In addition, I intended to minimise the influence of ceiling and floor effects by 
employing several tasks which produced reaction times as outcome measures. This is because 
reaction times continue to provide a measure developmental change even after response 
accuracy levels are at ceiling (Thomas, Annaz, & Ansari, 2009). Finally, standardised 
measures (British Picture Vocabulary Scale) were included to yield mental age equivalent 
scores that would allow a more detailed description of cognitive dysfunction in the future 
analysis of this work. 
Ultimately, it is hoped that the test battery can meet the clinical need for an instrument 
that can be used to accurately track disease progression, provide a sensitive means to evaluate 
positive and negative outcomes of therapeutic interventions, and can fulfil the research need 
for information on the specific impact of neurodevelopmental disorders on language, motor 
control and attention.  
 
The work described in this thesis is considered to make an original contribution to the 
body of knowledge involving the cognitive function of children diagnosed with an IMD by 
answering the following principle questions:  
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(i) What are the best measures (most sensitive and efficient) to use to track disease 
progression during different stages of the disease? 
 (ii) Does the functioning ofspecific cognitive domains develop/decline differently along the 
time course of a disease? 
(iii) What is the homogeneity across and within diseases for the cognitive areas that are most 
and least affected by disease? 
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2.0 LITERATURE REVIEW 
2.1 Introduction 
 A broad set of research areas are integrated to form the theoretical background for the 
research reported in this thesis. In brief, the subject matter can be considered to fall into two 
areas:  1) cognitive profiles of inherit metabolic disorders (IMDs), and 2) models and 
methods associated with the development of attention, language, and oculomotor function. In 
the case of cognitive function in IMD, the vast majority of the literature does not relate study 
findings to models of cognitive development. For this reason, in documenting this literature 
survey the two areas have been categorically organised into separate bodies of review.  
The first section of the review covers IMD cognitive function, describing the clinical 
features with the inclusion of a description of relevant findings from studies detailing the 
intellectual function. In addition, the section explores known cortical abnormalities 
discovered through imaging techniques and attempts to link them to cognitive dysfunction. In 
the second section, models and methods of three cognitive domains (attention, language, and 
oculomotor function) are described in depth. Studies reviewed in this section discuss 
established methodologies and include a discussion of cortical areas associated with each 
cognitive domain. Finally, evidence from neurological disorders will be integrated to 
illustrate how these methodologies have been used to investigate cognitive dysfunction.  
The purpose of this literature survey is to firstly, describe the cognitive profiles of 
specific IMDs and the homogeneity of cognition within and across disorders and, secondly, 
to describe neuropsychological methods commonly employed with neurological and 
developmental disorders that have received substantial research attention. 
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2.2 Inherited Metabolic Diseases  
 Inherited metabolic diseases are a complex heterogeneous group of genetic disorders 
that result from the dysfunction of one or more metabolic enzymes that are necessary for 
normal central nervous system development (Martins, 1999). This first section of the 
literature survey introduces a number of these diseases: lysosomal storage diseases 
(specifically muccopolysaccharide disorders) and inborn errors of amino acid metabolism 
(specifically Tyrosinemias). Evidence will be presented from materials and papers that 
describe the clinical presentation, neurological symptoms, and any known brain anatomy 
found through positron emission tomography (PET) or magnetic resonance imaging (MRI). 
Disorders discussed here are grouped according to the metabolic basis of the disease.  
2.2.1 Lysosomal Storage Diseases (Mucopolysaccharide Disorders) 
Lysosomal storage diseases are a group of chronic, progressive multisystem disorders 
caused by dysfunctional lysosomes within cell bodies (Wraith, 2006). Here we will review 
several lysosomal storage diseases categorised as mucopolysaccharide diseases (MPS 
diseases, also termed glycosaminoglycans (GAGs)). MPS diseases are caused by the 
deficiency of degradative enzymes that are required to break down specific 
mucopolysaccharides within lysosomes. Eleven distinct MPS disorders are known to exist 
that are each caused by specific enzyme deficiencies (Neufeld & Muenzer, 2001). Inheritance 
of these disorders is autosomal recessive for all except MPS-II (Hunter’s syndrome), which is 
an X-linked recessive disorder, while epidemiological data (Brown, 2011) report the 
prevalence of these disorders ranges from 1 in 100,000 to 1 in 600,000 live births.  
There are several shared clinical features among the eleven identified MPS disorders. 
Severe symptoms range from neurological abnormalities, bone dysplasia, 
hepatosplenomegaly, and facial dysmorphism, to developmental regression and reduced life 
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expectancy. Conversely, in the more attenuated MPS disorders patients can present with an 
almost normal clinical phenotype and life span (Wraith, 2006). 
A description of three MPS diseases that are investigated in the current project is 
given below which include: Hurler/Hurler-Scheie syndrome (MPS IH/IHS); Morquio Disease 
(MPS IV); and Maroteaux-Lamy syndrome (MPS VI).  
Hurler / Hurler-Scheie Syndrome (MPS-IH/IS) 
MPS-I is caused by the deficiency of the enzyme α-L-iduronidase which in turn leads 
to the accumulation of dermatan and heparin sulphate. MPS-I has an incidence of 0.61-1.30 
per 100,000 live births (Moore, Connock, Wraith, & Lavery, 2008). Elevated levels of these 
glycosaminoglycans (GAGs) in tissue produces psychomotor retardation, respiratory and 
cardiac complications, and impaired vision and hearing, and cardiac complications (Neufeld 
& Muenzer, 2001; Wraith, 2006). Presentation of short stature, cardiac disease, corneal 
clouding, facial dysmorphia, and hepatosplenomegaly are common symptoms that appear in 
the second and third years of life. The severity of these symptoms occupies a wide continuum 
across individual cases of MPS-I, with the most severe cases being detected during the first 
year of life; typically presenting with skeletal deformities and endocardial fibroelastosis 
(Stephan et al., 1989). In these cases developmental delay is apparent by 12-24 months and 
the maximal functional age is typically around 2 to 4 years (Neufeld & Muenzer, 2001). In 
contrast the less severe cases of MPS-I are characterised by normal intelligence, normal 
height and life expectancy, with a likelihood of disability from joint stiffness and cardiac 
valve lesions (Wraith, 2006). On the basis of the severity of the disease manifestations, MPS-
I can be divided into 3 disease subtypes. These subtypes include, in order of most to least 
severe, Hurler (MPS-IH), Hurler-Scheie (MPS-IHS), and Scheie (MPS-IS) subtypes.  
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Treatment of MPS-I includes enzyme replacement therapy (ERT), which can elevate 
the majority of the disease manifestations (Moore et al., 2008; Wiseman et al., 2013) but has 
no impact on neurological complications since ERT is unable to by-pass the blood-brain 
barrier. Another form of treatment is allogenic haematopoietic stem cell transplantation 
(HSCT) that has been reported to significantly improve functional outcomes and life 
expectancy (Aldenhoven, Boelens, & de Koning, 2008; Neufeld & Muenzer, 2001; Shapiro et 
al., 2009).  
The neurological signs of MPS I are progressive learning difficulty, fatigue, 
developmental regression, and hydrocephalus. In addition, patients may present with hearing 
loss as a result of conductive and sensorineural problems. Vision impairment is common due 
to optic nerve head swelling with atrophy (Müller-Forell, Schulze Frenking, Amraoui, & 
Beck, 2007). The development of cognitive function of MPS-I patients has been investigated 
over the past decade as a means to measure the impact of HSCT. A review of 10 children 
following HSCT (Shapiro et al., 2009) revealed deficits in attention and executive functions, 
lower than average verbal IQ, and normal memory. Results from this study also showed that 
the rate of cognitive decline increased with the age at which the patients received the HSCT 
procedure. Other research has examined the effect of ERT in preventing nervous system 
degradation (Biernacka et al., 2010) by measuring IQ using the Psyche Cattell Infant’s 
Intelligence Scale. Here children with MPS-I were found to have a measurable decrease in IQ 
and rate of new skill learning with advancing age. Despite these findings, the majority of 
research identifies the need for a more accurate measure to distinguish the cognitive 
development of the disorder (Biernacka et al., 2010) due to the limitations of current 
standardised measures in longitudinal disease tracking (Martin et al., 2008). 
Neuroimaging features of MPS IH patients typically include diffuse white matter 
changes in the periventricular white matter (Seto et al., 2001). It is believed that these 
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changes may reflect delayed myelination or progressive demyelination through the course of 
the disease (Müller-Forell et al., 2007) that contribute to developmental regression in MPS-I 
(Gabrielli et al., 2004). Another commonly reported neuroimaging feature of MPS-I is 
cerebral atrophy, specifically the widening of the cortical sulci and inter-hemispheric fissure 
(Matheus et al., 2004). 
Morquio Syndrome (MPS-IVa)  
Morquio syndrome (MPS-IVa) is caused by the defiency of the enzyme N-
acetylgalactosamine-6-sulfase which has a role in the sequential degradation of keratan 
sulphate and chondroitin-6-sulfate (Neufeld & Muenzer, 2001; Wraith, 2006). Keratan 
sulphate chronically and progressively accumulates within connective tissue, including the 
cornea, cartilage and heart valve (Hendriksz et al., 2013). Subsequently, patients present with 
severe skeletal dysplasia, hip dysplasia, marked short stature, genu valgum, and cornea 
clouding (Hendriksz et al., 2013; Wraith, 2006). Like other MPS disorders treatment can 
include ERT and HSCT as a means to alleviate the majority of the skeletal and coronary 
complications. 
In contrast to other MPS disorders, MPS-IV patients are not reported to possess 
neurological or neurocognitive impairments (Dvorak-Ewell et al., 2010; Wraith, 2006). 
Though, recent research has suggested that MPS-IV patients could possess mild cognitive 
impairments in comparison to other MPS disorders. Davison et al. (2012) reviewed the 
performance of 14 MPS-IV children on a set of standardised IQ measures and found that 37% 
of the sample scored below the 78
th
 percentile on a measure of full scale IQ. Additionally, 
parents of patients reported behavioural problems, highlighting several problems such as 
anxiety, attention and somatic complaints. The authors concluded that the presence of mild 
neurocognitive complications in children with MPS-IV is likely given the role of keratan 
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sulphate and chondroitin-6-sulfate in the coordination of neuroaxonal connection formation 
during foetal and neonatal brain development (Miller, Sheppard, & Pearlman, 1997).  
 Here, reported behavioural difficulties require further clarification; are these 
behaviour problems linked to an impairments of executive function, and how are the 
behavioural problems related to other domains of cognition? This is one research question 
that will be addressed in the current body of work. 
Neuroimaging findings have reported an absence of neuroanatomical abnormalities 
within MPS-IV patients (Koto, Horwitz, Suzuki, & Tiffany, 1978). In contrast, animal model 
research (Tomatsu et al., 2008) has revealed abnormal storage materials in neurons and glia 
of the hippocampus. Furthermore, excess storage material can be cleared in mice with a high 
dose of ERT. Lastly, the neuropsychological assessment of MPS-IV patients conducted by 
Davison et al. (2012) observed mild neuroanatomical abnormalities in more than half the 
patients. Abnormalities included mild asymmetry of the lateral ventricles, prominent 
perivascular spaces, and high signal white matter areas of the right frontal lobe. 
Maroteaux-Lamy Syndrome MPS VI 
 Maroteaux-Lamy Syndrome (MPS VI) is caused by a deficiency or dysfunction of the 
enzyme N-acetylgalactosamine- 4-sulfatase  which is required for the degradation of 
dermatan –sulphate ( Wraith, 2006). MPS VI has an estimated incidence ranging from 1 in 
248,095 to 1 in 300,000 (Meikle, Hopwood, Clague, & Carey, 1999; Nelson, 1997; 
Sanderson et al., 2006) and patients usually either die in their teens or early 20s or may live 
into their 40s and 50s depending on the severity of disease progression (Giugliani, Harmatz, 
& Wraith, 2007). Similar to other MPS disorders, MPS VI is a clinically heterogeneous 
multisystem disorder (de Almeida-Barros et al., 2012; Giugliani et al., 2007; Wraith, 2006) 
with a variable age of onset. The most common complications associated with MPS VI are 
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structural due to the important role that dermatan-sulphate has within connective tissue. 
Consequentially, early presentations of MPS VI include reduced growth velocity, enlarged 
head and chest deformities (de Almeida-Barros et al., 2012; Giugliani et al., 2007). As the 
disease progresses, at approximately 2-3 years of age, emerging symptoms include coarse 
facial features, hepatosplenomegaly, joint stiffness, and heart and respiratory abnormalities 
(Azevedo et al., 2004). Typically MPS VI is not associated with any manifestations of 
progressive intellectual impairment, however the physical limitations of MPS VI are expected 
to indirectly produce delays in learning and motor skill development (Giugliani et al., 2007). 
The current body of work will be one of the first investigations of cognitive function in 
children diagnosed with MPS VI.  
2.2.2 Tyrosinemia 
Tyrosinemia is an inborn error of metabolism where the patient is unable to break 
down the amino acid tyrosine. Three different types of tyrosinemia exist (type I, II, and III), 
each classified by the deficiency of a specific enzyme within the tyrosine metabolic pathway 
(De Laet et al., 2011; Scott, 2006). All types of tyrosinemia are characterised by the 
accumulation of tyrosine in tissue and body fluids. Tyrosinemia-I is the most severe form of 
the three disorders in which patients present with progressive liver disease, painful neurologic 
crises, rickets and hepatocarcinoma (Bendadi et al., 2014a; Scott, 2006; Thimm et al., 2012). 
Tyrosinemia-II and III are more benign than tyrosinemia-I; the presentation of tyrosinemia-II 
is associated with hyperkeratotic plaques on the hands and soles of feet, and photophobia. 
Tyrosinemia-III patients present with a more variable phenotype, while neurological 
symptoms such as developmental regression and ataxia are common (Cerone et al., 1997; 
Ellaway et al., 2001).  
Treatment of these disorders varies depending on the type of tyrosinemia. 
Tyrosinemia-II and III is typically managed with a controlled diet to ensure levels of 
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tyrosinemia are maintained at safe levels. However the more severe form, type-I, is presently 
treated with the administration of 2-nitro-4-trifluromethylbenzoyl (NTBC) which prevents 
the accumulation of toxic metabolites affecting liver function (Bendadi et al., 2014a). One 
documented side-effect of NTBC is the risk of developing mental retardation (Bendadi et al., 
2014a; Masurel-Paulet et al., 2008; Thimm et al., 2012) at the cost of alleviating liver 
function complications. 
Here, literature and materials describing the cognitive function and neural anatomy of 
patients diagnosed with tyrosinemia-I and III is reviewed. This will include literature that 
observes the impact of NTBC treatment on the cognition of tyrosinemia-I patients, and 
findings from reports on the cognition of tyrosinemia-III patients. An important research 
question for this group of disorders is to discover the heterogeneity of cognition among 
tyrosinemia-I and III patients. More specifically, does the treatment of NTBC with 
tyrosinemia-I patients produce a cognitive profile that is comparable to the cognitive profile 
of tyrosinemia-III patients? 
Tyrosinemia Type-I 
Tyrosinemia-I is an autosomal recessive disorder that results from the deficiency of 
fumarylacetoacetase, the final enzyme in the tyrosine metabolic pathway. Symptoms arise 
from the accumulation of fumaryl- and maleylacetoacetate, toxic agents that gather in body 
fluid and tissue. The range of clinical manifestations associated with tyrosinemia-I include 
hepatocellular carcinoma complications (Russo & O’Regan, 1990) and renal problems such 
as secondary rickets (Masurel-Paulet et al., 2008; Russo & O’Regan, 1990). The prevalence 
of tyrosinemia-I worldwide is rare. An occurrence of 1 in 100,000 live births has been 
reported (Scott, 2006). 
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Since 1992, NTBC has been used as an effective pharmacological treatment 
(Lindstedt, Holme, Lock, Hjalmarson, & Strandvik, 1992), prior to which the only curative 
procedure was liver transplantation. The function of NTBC is to replicate the metabolic block 
which occurs in tyrosinemia-III as a means to maintain levels of hepatotoxic metabolites 
(Thimm et al., 2012). Ultimately, the mechanisms of the tyrosine metabolic pathway in 
tyrosinemia-I patients are transformed into those of a tyrosinemia-III patient. However, 
progressive accumulation of tyrosine occurs as a side-effect of the NTBC drug (Lindstedt et 
al., 1992). Thus, patients are required to maintain a low tyrosine diet as part of the NTBC 
treatment (Lindstedt et al., 1992; Masurel-Paulet et al., 2008). 
A growing body of research has investigated the long-term outcomes of tyrosinemia-I 
patients undergoing NTBC treatment. Recent studies have examined whether the possible 
toxicity of long-term NTBC use has an impact upon cognitive function (Bendadi et al., 
2014a; De Laet et al., 2011; Masurel-Paulet et al., 2008; Thimm et al., 2012). A reoccurring 
finding has been that patients present with cognitive impairments later on in life, which is 
expected to be caused by elevated tyrosine levels that have not been sufficiently controlled 
with diet. For example, the study by Thimm et al. (2012) assessed the neurocognitive 
development of nine tyrosinemia-I patients using standardised psychometric tests. Here a 
high proportion of patients performed below normal on motor function, speech, and 
development. With regards to MRI findings, a study by Thimm et al. (2011) discovered an 
absence of neuroanatomical abnormalities in a sample of three tyrosinemia-I patients. 
Tyrosinemia type-III 
Tyrosinemia-III is an autosomal recessive disorder caused by the deficiency of 4-
hydroxyphenylpyruvate dioxygenase, the second enzyme within the tyrosine metabolic 
pathway. This results in the accumulation and increased excretion of tyrosine. Unlike 
tyrosinemia-I, patients diagnosed with tyrosinemia-III have normal liver and renal function 
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(Ellaway et al., 2001; Scott, 2006). Despite this, several case studies (Cerone et al., 1997; 
D’Eufemia et al., 2009) have reported neurological impairments within tyrosinemia-III 
patients. The current treatment for tyrosinemia III patients consists of administration of 
ascorbic acid and a low-protein diet (Scott, 2006). 
 
2.3  Models and Methods of Cognitive Development 
 Here models and methods from three areas of cognitive development are discussed: 
attention, language, and oculomotor function. For each domain, established models and 
methods, developmental trajectories, and findings from disorders groups are described.  
2.3.1 Attention 
The concept of attention (executive function) within psychology covers a broad set of 
functions: planning, attentional flexibility, error correction and detection, working memory, 
inhibitory control, and self-regulation (Welsh, Pennington, & Groisser, 1991; Zelazo, Carter, 
Reznick, & Frye, 1997). In the current thesis we will explore whether an attention deficit 
exists in any of the patient cohorts by employing a simple reaction time and visual search 
task. 
The classic visual search paradigm captures the real life instances in which humans 
scan their visual environment to locate a visual target when presented with many different 
objects simultaneously. This might be when a child searches for their favourite toy from 
within a brimming toy box, or when a young adult tries to identify a friend whilst visiting a 
crowded bar. Both behaviours require the allocation of attention to specific visual features of 
the target whist inhibiting irrelevant visual features. Search will be deemed to be easy if the 
target can be identified based only on a single feature (feature search; perhaps the friend at 
the bar has a particularly unique hair colour). Search requires more attentional effort if 
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success depends on the combination of visual features (conjunction search; the child’s 
favourite toy is a red ball that is among greens balls and red building blocks). Consequently, 
unlike feature search, conjunction search time increases linearly with the number of 
distractors in the visual scene (Duncan & Humphreys, 1989; Wolfe, 1998). 
 The Feature Integration theory (Treisman & Gelade, 1980) proposes the existence of 
two distinct mechanisms that enable accurate searching behaviours. First, a parallel search 
mechanism efficiently processes feature maps (e.g. colour, orientation, etc) of the visual 
scene in parallel. In a sense, this process enables the visual target to “pop-out” among 
distractors, thus negating the frequency of distractors. The second mechanism of visual 
search is a serial search mechanism, whereby the target is located through the conjunction of 
separate feature maps. In other words, no one feature map can be inspected to find the target. 
Here successfully locating a target requires the participant to sequentially shift attention from 
one search item to the next until the target is found, or all items are scrutinised. 
The development of visual search across the lifespan has been extensively 
investigated (Hommel et al., 2004a; Plude, Enns, & Brodeur, 1994; Trick & Enns, 1998). The 
developmental trajectory for visual search across the entire life span is characterised by a U-
shaped trajectory; performance improves gradually through childhood, plateaus at young 
adulthood and declines during later life. In addition, this pattern of development is more 
pronounced for serial search tasks compared to parallel search tasks (Hommel, Li, & Li, 
2004b); serial search proficiency is more vulnerable to age-related degeneration than parallel 
search. Studies of visual search development during childhood have shown that search times 
(Ruskin & Kaye, 1990) and the influence of distractor frequency on search time decrease as a 
function of age (Trick & Enns, 1998). Interestingly, this trend is more pronounced for serial 
search than parallel search, with participants producing better performance and shallower set-
size slopes for the latter. It is hypothesised (Hommel et al., 2004b) that the pronounced 
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development of serial search is due to age-related increases in top-down attentional control, 
while the negligible changes in parallel search originate from bottom-up perceptual 
performance. 
Neuroimaging studies have revealed a large network of brain regions to be involved 
in visual search. These include the superior parietal lobule, lateral premotor cortex, anterior 
cingulate gyrus, and the frontal eye fields (FEF) (Mesulam, 1999). The FEF and lateral 
premotor cortex are involved in exploratory eye movements (Booth et al., 2003) while the 
anterior cingulate is involved in response monitoring (Botvinick, Nystrom, Fissell, Carter, & 
Cohen, 1999). Comparison of conjunction and feature search has revealed substantially more 
activation in the superior parietal lobule during conjunction search (Corbetta, Shulman, 
Miezin, & Petersen, 1995; Coull, Walsh, Frith, & Nobre, 2003). This suggests that the 
superior parietal lobule has a greater role in serial search than parallel search (Ashbridge, 
Walsh, & Cowey, 1997; Walsh, Ellison, Ashbridge, & Cowey, 1999). Other cortical areas 
important in visual search are prefrontal regions and the basal ganglia, which relate to 
response inhibition (Casey, Durston, & Fossella, 2001).  
Several developmental disorders are known to exhibit variations of attention deficits 
or  present with abnormal visual search behaviours (Brenner et al., 2007; Kemner, van der 
Geest, Verbaten, & van Engeland, 2004; Scerif et al., 2005). For instance, autistic individuals 
exhibit unusual fixation trajectories when observing complex social scenes (Klin, Jones, 
Schultz, Volkmar, & Cohen, 2002), and young autistic children and toddlers display an 
elevated number of saccades during visual search tasks (Kaldy, Kraper, Carter, & Blaser, 
2011; Kemner et al., 2004). In contrast, Williams and Fragile-X syndrome children present 
typical saccadic eye movement during visual search but produced a larger number of errors 
compared with typically developing children (Scerif et al., 2005).  
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2.3.2 Language 
 Understanding how children with IMDs acquire new words, both in terms of 
comprehension and production is explored in the current body of work. Specifically, we’ll 
investigate the existing size of the children’s vocabulary, for production and comprehension, 
as well as the rate at which individuals can acquire new words. In order to acquire new 
words, it is vital to segment them from utterances and store enough semantic, syntactic, 
nonverbal, and phonological information to retrieve them consistently over time (Gathercole, 
1999; Gray, 2006). In part, this function relies upon phonological working memory 
mechanisms - the individual must process and store the order and identity of phonemes 
within an utterance to accurately recall the new word or to successfully transfer the new word 
on to long-term memory (Baddeley, 2003; Gathercole, 1999). Consequently, difficulties at 
either the storage or retrieval phase may lead to problems in new word learning (Gray & 
Brinkley, 2011; Gray, 2006). One other mechanism involved in word acquisition is “fast 
mapping” (Carey, 1978) which enables children to immediately and accurately “map” a 
phonological form to the corresponding semantic meaning (Gray, 2006; Kan & Kohnert, 
2008). It has been hypothesised that this ability is a significant contributor to the rapid 
vocabulary expansion which occurs at about 18 months of age (Heibeck & Markman, 1987). 
In addition, following the initial exposure to a new word a process called “slow-mapping” 
(Carey, 1978) can occur, whereby the existing phonological, lexical, and semantic 
representation of a word can be strengthened through repeated exposures. The proficiency of 
fast- and slow-mapping increases as a function of age and existing vocabulary knowledge 
(Alt, Plante, & Creusere, 2004; Chiat, 2006; Gray, 2006; Storkel & Adlof, 2009; Storkel, 
2003).  
 A significant proportion of the patients included in the current thesis have a bilingual 
background. As mentioned above, successful fast-mapping is influenced by both age and 
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existing vocabulary knowledge. Hence, research has suggested that bilingualism can reduce 
the success rate of fast-mapping for second language words, potentially delaying English 
vocabulary proficiency during childhood (Kan & Kohnert, 2008; Leseman, 2000; Uccelli & 
Paez, 2007). In a typical word learning task participants are exposed to several novel objects / 
characters and are required to learn the names of the respective referents (Alt et al., 2004; 
Gray & Brinkley, 2011; Gray, 2004; Kan & Kohnert, 2008). The speed of learning is partially 
dependent on the accuracy with which words are mapped to the referent during the first 
exposure (fast-mapping) and particially on the following number of exposures required to 
consistently reproduce a referent’s name over time (slow-mapping). During the task, a single 
exposure will involve introducing the child to a set of novel words (e.g. ‘yurk’) and 
corresponding referents (e.g. a novel figure). The child then receives an expressive or 
receptive probe and is required to name or point to the correct novel referent respectively. 
 The disruption of fast-mapping proficiency has been widely reported in children with 
specific language impairment (SLI)(Gray & Brinkley, 2011; Gray, 2004; Rice, Buhr, & 
Oetting, 1992; Rice, Oetting, Marquis, Bode, & Pae, 1994), which is believed to be due to 
problems creating and storing semantic representations of new words (Alt et al., 2004; 
Gathercole, 1999). When compared to healthy developing children, children with SLI require 
a greater number of exposures to successful map referents to novel targets.  
2.3.3 Oculomotor Function 
  Eye tracking tasks provide a non-invasive and objective insight into the 
neurophysiological underpinnings of disease. Therefore, they are appealing as early stage 
biomarkers of neurodegenerative disease (Anderson & MacAskill, 2013).  In broad terms 
there are two classes of eye movements. One class are ballistic movements (saccades) that 
allow us to bring peripheral targets quickly into foveal focus. The second class of eye 
movement stabilise foveal vision in relation to the movements of our surroundings through 
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the employment of fixations, smooth pursuit and vestibular-ocular reflexes. In the current 
thesis, these oculomotor functions are examined in IMD individuals through the examination 
of eye movements during fixation, pro-saccade, anti-saccade, and smooth pursuit tasks.  
 There is a substantial body of research detailing the neural mechanisms which control 
saccadic eye movements. Typically, saccadic eye movement is assessed using pro- and anti-
saccade tasks. Pro-saccade tasks measure the reflexive properties of externally-guided 
saccades, whereby participants must look towards a peripherally presented target as soon as it 
appears. Common measures for this paradigm include the time in which a reflexive saccade is 
initiated after the target onset, saccade velocity, and the spatial accuracy of saccades. Anti-
saccade tasks follows a similar paradigm, however the moment the peripheral object appears 
the individual must suppress a reflexive saccade and instead produce a voluntary saccade in 
the direction opposite the visual stimulus. Here the individual must inhibit the automatic and 
peremptory response of looking towards the visual stimulus, a behaviour which encompasses 
several executive functions: response inhibition, response preparation, working memory 
(Klein, Raschke, & Brandenbusch, 2003; Klein, 2001). Age-related change has been 
observed in both pro- and anti-saccade tasks (Fischer & Weber, 2010; Klein & Foerster, 
2001; Klein et al., 2003; Klein, 2001; Luna, Velanova, & Geier, 2008; Munoz & Everling, 
2004; Salman et al., 2006). In general, the reaction time of pro-saccades decrease gradually 
until around adolescence, while anti-saccade reaction time and error rate exhibit far steeper 
improvements during this stage of development. 
Smooth pursuit is defined as the ability to track small, slow moving objects by 
maintaining the dynamic object within foveal vision (Fukushima, 2003). This behaviour is 
achieved by employing non-ballistic eye movements that match target velocity to gaze 
velocity. A typical paradigm will require the participant to follow a small stimulus that 
travels horizontally or vertically along a sinusoidal path across the visual field. In these tasks 
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performance can be measured as “gain” (the mean target velocity divided by mean eye 
velocity), which indicates how accurately the individual can match eye-to-target velocity. 
One other measure is the frequency of saccades during tracking and, in particular, the number 
of catch-up saccades that are executed (Hutton & Kennard, 1998; Ross, Hommer, Radant, 
Roath, & Freedman, 1996). A catch-up saccade occurs when the individual is unable to 
maintain accurate gaze velocity matchted to target velocity which leads to gaze falling behind 
the target. In response, the individual employs a ballistic eye movement in order to re-
establish gaze to target velocity. A high frequency of catch-up saccades indicates an 
impairment of the pursuit system and the saccadic system is being recruited to compensate. 
An important element of eye movements is that different oculomotor functions (pro-
saccadic eye movement, anti-saccadic eye movement, and smooth pursuit) have distinct 
neurobiological bases (Karatekin, 2007). Saccades are generated by the six extra-ocular 
muscles  (Demer, 2004)  through innervation from oculomotor, trochlear and abducens  
motor neurons, which receive burst signals from premotor burst neurons in the brainstem. 
Horizontal and vertical saccades are generated by independent extraocular muscles, motor 
and premotor neurons (Horn, Buttner-Ennever, Suzuki, & Henn, 1995). For example, 
horizontal extra-ocular muscles receive input from motor neurons in the abducens nucleus 
which receive saccadic commands from the paramedian pontine reticular formation (PPRF). 
Vertical extra-ocular muscles are innervated by motorneurons in the oculomotor nucleus, 
which receive saccadic signals from burst neurons in the rostral interstitial nucleus of the 
medial longitudinal fasciculus (riMLF). The discharge rate of premotor neurons is 
proportionate to the size of the executed saccade (Leigh & Kennard, 2004). During times of 
fixation, premotor neurons are inactive due to inhibitory signals received from omnipause 
neurons in the pontine nucleus raphe interpositus ( Horn, Büttner-Ennever, Wahle, & 
Reichenberger, 1994). Another important brain region involved in saccade production is the 
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cerebellum. The primary role of the cerebellum is to determine the time when saccades need 
to stop in order to accurately land on a visual target (Noda & Fujikado, 1987).  
The neurons in the brainstem and cerebellum are responsible for the temporal 
properties of saccades (size, start and stop time). Evidence from fMRI and TMS studies has 
highlighted the role of several cortical and subcortical regions that interact with the superior 
colliculus (SC) to program the spatial properties of saccades. It is suggested that the SC is 
responsible for the spatial-temporal transformation of saccadic information (Leigh & 
Kennard, 2004). The SC receives topological spatial information representing the direction 
and distance of visual stimuli from the frontal (FEF), parietal (PEF) and supplementary eye 
fields (SEF), and the dorsal lateral prefrontal cortex (DLPC). From these areas, the SC 
acquires both direct excitatory input and indirect inhibitory input via basal ganglia 
(specifically substantia nigra par recticulata and caudate nucleus). The SC encodes this 
spatial information on a ‘motor map’ in polar coordinates; activation of rostral and caudal 
areas elicits smaller and larger saccades respectively. Stimulation of the rostral pole 
suppresses saccades through the transmission of excitatory signals to omnipause neurons, 
thus maintaining fixation (D P Munoz & Wurtz, 1992). The caudal distance of collicular 
neuron stimulation from the rostral pole is relative to the magnitude of gaze displacement 
(Bergeron & Guitton, 2001; D P Munoz & Wurtz, 1992).  
Distinct cortical regions are involved in the function of specific oculomotor 
behaviours. The input from the PEF to the SC has been shown to be important in triggering 
reflexive visually guided saccades (pro-saccades) (Shadlen & Newsome, 2001; Wurtz, 
Sommer, Paré, & Ferraina, 2001), while frontal regions, the FEF and DLPC, have been 
shown to be important in the suppression of reflexive saccades and production of voluntary 
saccades (anti-saccades)(Connolly, Goodale, Menon, & Munoz, 2002; DeSouza, Menon, & 
Everling, 2003; Mort et al., 2003). The DLPC has also been linked to the maintenance of 
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fixations by inhibiting saccade neurons in the SC and FEF (Tinsley & Everling, 2002). 
Smooth pursuit eye movements utilise many of the cortical regions involved in saccade 
generation and several regions exclusive to pursuit (Fukushima, 2003). For example, the 
caudal area of the FEF is suggested to employ an eye velocity feedback function through the 
incorporation of target velocity signals from the vestibular and cerebellar systems (Robinson 
& Fuchs, 2001). This feedback loop enables the accurate prediction of target velocity in order 
to maintain the target within the retinal image of the foveae.  
The neurobiological basis of eye movements has been extensively studied, therefore 
eye movements are potentially valuable biomarkers for several neurodegenerative and 
developmental disorders. For example, Niemann-Pick C disease (a lysosomal storage 
disorder) causes the degeneration of midbrain premotor neurons (Rottach et al., 1997), which 
leads to progressive vertical saccade slowing and preserved horizontal saccade velocity. 
Degeneration of cortical and subcortical areas has been shown to affect eye movements in 
Parkinson’s disease (PD), frontotemporal dementia (FTD) and Alzheimer’s disease (AD). In 
PD, the over-activity of the basal ganglia (specifically the substantia nigra), which sends 
inhibitory output to the superior colliculus, has been linked to the production of hypometric 
saccades early in the disease course (Liu & Basso, 2008). Prolonged latencies of voluntary 
saccades are also characteristic in PD (Bronstein & Kennard, 1985; Crawford, Goodrich, 
Henderson, & Kennard, 1989), whereby the extent of latency increase correlates with disease 
severity. These latter features are believed to represent wider cognitive degeneration 
associated with the spread of non-dopaminergic neural dysfunction rather than over-activity 
within the substantia nigra (T. J. Anderson & MacAskill, 2013). For dementias, oculomotor 
behaviours are compromised depending on the region of neurodegeneration. For example, 
AD patients that possess degeneration of the parietal and frontal lobes will exhibit prolonged 
reflexive saccade initiation and reduced saccade suppression respectively (Garbutt et al., 
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2008). In contrast, FTD patients, who are spared parietal degeneration, only exhibit reduced 
saccade suppression (Currie, Ramsden, McArthur, & Maruff, 1991). 
Finally a robust finding within the schizophrenia literature is that schizophrenic 
individuals possess an impaired smooth-pursuit system (Broerse, Crawford, & den Boer, 
2001; Hutton & Kennard, 1998; Karatekin, 2007; Reuther & Kathmann, 2004; Trillenberg, 
Lencer, & Heide, 2004). Studies have consistently demonstrated that schizophrenic 
individuals exhibit reduced gain during pursuit tasks (Jacobsen et al., 1996; Kumra et al., 
2001; Ross et al., 1996; Ross, 2003). Interestingly, these findings are also evident in remitted 
patients and unaffected relatives of schizophrenic individuals.  
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3.0 GENERAL METHODS 
3.1 Introduction 
 The following section details the methodology of the tasks used within the test 
battery. Description of the tasks are organised into sections based on the three cognitive 
domains – attention, language, and oculomotor function. Task descriptions include the 
experimental procedure, outcome measures, and the treatment of data prior to analysis. The 
specific details of how the data were analysed is described in later chapters. For example, the 
method for analysing healthy developmental trajectories is given in the control results chapter 
(Chapter 4), while the method used to compare patients to controls is described in the first 
patient chapter (Chapter 5).  
3.2 Attention 
Attention was measured with two tasks: a simple reaction time task and a visual 
search task. The simple reaction time task always preceded the visual search task. This 
allowed participants to be familiarised with the stimuli (red ladybird) used as the target in the 
following visual search task. 
Apparatus & Procedure 
For both tasks, stimuli were created using Experiment Builder (SR Research Ltd., 
Mississauga, Ontario, Canada). Participants viewed the stimuli from 60 cm away on a 41 x 30 
cm (width x height) desktop monitor, producing a search area of 37.73° x 28.07° (width x 
height) of visual angle for participants to complete the tasks. Stimuli in both tasks consisted 
of cartoon red ladybirds, green ladybirds and red beetles. Responses were recorded using a 
Cedrus button box. (http://cedrus.com/). 
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Simple Reaction Time Task 
The task measured the speed of visual target detection. Participant completed 20 trials 
where a red ladybird (5.73° x 7.64°) was presented in one of four quadrants of the screen 
against a white background. The size of each quadrant was 10° x 8.8°, and was at a diagonal 
distance of 11.89° from the screen centre. Across trials the target appeared at each quadrant 5 
times, with the order of the target locations being randomised between participants. The 
participant needed to respond using the a single button on a button box as quickly as possible, 
with their preferred hand, when the target appeared (Figure 3.2.1). 
 
Figure 3.2.1: Example of a simple reaction time trial. Here the visual target is presented in the bottom-left 
quadrant of the display. Participants are required to respond to the presence of the visual stimulus as soon as it 
appears.   
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Trials began with a centrally presented fixation cross (1.15° x 1.15° of visual angle) 
for 1000ms, which was followed by the appearance of the quadrants. After a variable delay 
(500 - 3000ms) the red ladybird target stimulus was presented in one of the four quadrants. 
The stimulus remained on the blank screen until the participant made a response or if 3000ms 
passed without a response. Following a response a blank screen was presented for 1000ms 
prior to the presentation of the fixation cross of the following trial.  
For the simple reaction time task the time taken to detect and respond to a target, 
relative to the target’s appearance, was measured in milliseconds (ms). Mean (RTmean) and 
standard deviations (RTstd) were calculated for the response times of individual target 
quadrants and for response times collapsed across quadrants. 
 
Visual Search Task 
The visual search task consisted of 3 feature search blocks and 3 conjunction search 
blocks. In both task types participants indicated whether a target character (red ladybird) was 
present with a “Yes” button, or absent using a “No” button, on a Cedrus button box. During 
feature search trials (Figure 3.2.2, panel A) the participant was required to search for the red 
ladybird among a set of green ladybird distracters (Stimuli size = 3.80° x 5° of visual angle). 
For the conjunction search trials (Figure 3.2.2, panel B) participants needed to search for the 
red ladybird among green ladybirds and red beetle distractors. Each block contained 12 
feature or conjunction search trials (a total of 36 feature search trials and 36 conjunction 
search trials) with 3 set sizes (4, 8, and 12 items). The target was present in half the trials of 
each block, and absent in the other half. Block order was randomised between participants. 
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A total of 16 locations were created by dividing the screen into a 4x4 grid, with each 
grid location having a size of 9.80° x 7.35° of visual angle. For each trial the target and 
distractors had a possibility of randomly appearing in any of the 16 grid locations. The 
stimuli items were presented at the centre of the grid location. In order to make target and 
distractor displays appear more natural, each item’s x and y axis position was jittered 
between ±1.9° and ±0.95° of visual angle respectively. During feature search blocks, all 
stimuli items of the target-absent trials were green ladybirds; for target-present trials the 
target stimulus replaced one of the distractor items. For conjunction search blocks, half the 
items were red beetles and half were green ladybirds during target-absent trials; for target-
present trials a red beetle distractor was replaced with the target red ladybird to ensure the 
number of red and green elements were equal. 
The Visual Search Task began with 4 practice trials in order to familiarise participants 
with the task. During these practice trials feedback was provided on screen (“correct” or 
“incorrect”, presented centrally) to the participants. Following the practice trials, the 
participant began the first block of the task. Each trial began with a centrally presented 
fixation cross for 1000ms that was followed by the stimulus presentation. When the stimulus 
appeared the participant used a Cedrus button box to make a response; press the left button if 
target is present or the right button if target is absent. The stimuli presentation disappeared 
upon the participant’s response or if no response was registered within 10 seconds. A blank 
screen was displayed for 1000ms prior to the following trial. At the beginning of each block 
participants were presented with a screen that informed them of the type of upcoming search 
task, feature or conjunction. This was achieved by displaying which items would be shown 
(feature: ‘red ladybird’ and ‘green ladybird’, or conjunction: ‘red ladybird’, ‘green lady bird’ 
and ‘red beetle’) and from verbal instruction given by the experimenter. 
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Two measures were taken for the feature and conjunction conditions: mean response 
time (VSmean) of correct responses measured in milliseconds (ms) and set-size search 
efficiency (VSslope). Latency was calculated as the time taken to respond correctly from 
stimulus presentation onset. Search efficiency represented the time that participants required 
to scrutinise each additional item in the search display. Search efficiency was calculated as 
the change in mean responses as a function of the set size conditions (4, 8, and 12 items).  
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Figure 3.2.2: Visual search trial example.  Feature and conjunction search shown in panel A and B respectively. 
In both examples the target (red ladybird) is present. 
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3.3 Language 
Three tasks were used to assess children’s language function, i.e. the Boston Naming 
Task (BNT; Kaplan, 2000), the British Picture Vocabulary Scale (BPVS; Dunn et al., 1997) 
and a novel non-word learning task.  
Boston Naming Task (BNT) 
The BNT is a measure of picture-naming and has been frequently used in various 
clinical settings; such as the evaluation of patients with acquired brain damage and the effects 
of progressive dementia in Alzheimer’s disease (Mack, Freed, Williams, & Henderson, 1992; 
Neils et al., 1995). It has also been successfully utilised in the examination of individual 
differences produced by bilingualism (Kohnert, Hernandez, & Bates, 1998) and educational 
background (Neils et al., 1995). The BNT is a 60-item task where the examiner sequentially 
presents pictures to the participant which increase in difficulty (high- to low- frequency 
words). Participants will be initially presented with high-frequency items (“bed”) and will be 
presented with low-frequency items (“abacus”) if they are able to successfully progress 
through the test. Cues are offered if the participant cannot find the item’s name. The first cue 
offered is always semantic and a phonetic cue is offered if a semantic cue does not produce a 
correct response. For the item “bed”, the semantic cue was “It’s a piece of furniture” and the 
phonetic cue was “It begins with the sounds ‘Bi’”. An item was scored as correct if the 
participant was able to produce the name with or without a semantic cue, and incorrect if the 
participant failed to produce the item name or if production was only possible with a phonetic 
cue. The task was terminated if the participant made more than 5 consecutive errors or if all 
60 items were completed. 
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British Picture Vocabulary Scale (BPVS) 
The BPVS is a measure of receptive vocabulary that is typically used with children 
aged 3-15 years. It is a popular language measure since vocabulary is considered to be a 
sensitive measure for a wide range of language skills. The test was administered from a test 
book where each page presents the child with four black and white line drawings. For each 
page the experimenter verbally presents the child with a name and the child is asked to match 
the name to the correct picture (by pointing to it) from the set of 4 pictures. This is important 
as it does not require an articulated response; hence, vocabulary can be assessed for children 
who possess speech production deficits. There are 14 sets of 12 items, resulting in 168 stimuli 
in total, with the complexity of word sets increasing as the child progresses through the sets. 
The test terminates once the child makes eight or more errors on a single set. The child’s test 
score is based upon the total number of words that are correctly identified. BPVS raw scores 
will be used in the analysis to draw comparisons between patients and controls. 
 
Non-Word Learning Task 
The non-word learning task required participants to identify and verbally produce the 
names of non-words that had not been previously learned. All non-words were 2-syllable 
words that respected the phonotactic constraints of the English language. Children learned the 
non-words as names for a set of 5 cartoon monsters that were each presented on 15 x 21cm 
cards (width x height; Appendix 1). The task was administered in 2 stages: a learning and 
delayed recall stage. Prior to stage 1, children were asked to repeat the names 3 times to 
ensure name production was possible. 
 32 
 
In the first stage, learning was measured during 6 learning iterations. Each learning 
iteration consisted of 3 phases. Phase 1 was the model phase – the 5 monsters were 
sequentially modelled by the experimenter (“This is [Monster Name]. Can you say that?”) 
and participants were required to repeat the names as they were given. Phase 2 was the 
comprehension phase – the experimenter administered a comprehension probe (“Can you 
point to [Monster Name]”) for each monster, the participant was required to point to the 
correct monster. Phase 3 was the production phase – the experimenter administered a 
production probe (‘What is this monster’s name”) for each monster, the participant was 
required to produce the name of the relevant monster. During the two probe phases, 
participants received 1 point for each correct probe response and were given feedback about 
the accuracy of responses. For production only, participants received half a point if they were 
able to accurately produce one the first syllables of a monster’s name.  The order that 
monsters were modelled and probed was randomised between the iterations. The sum of 
points acquired over the course of the 6 learning iterations (total: 30 points for production and 
30 points for comprehension) was taken as the measure of non-word learning. 
 
3.4 Oculomotor function 
 We investigated oculomotor function using four established oculomotor paradigms 
within developmental and atypical developmental research – a fixation task (Gould, Bastain, 
Israel, Hommer, & Castellanos, 2001; Klockgether, Petersen, Grodd, & Dichgans, 1991), a 
pro- and anti-saccade task (Fischer & Weber, 2010; Christoph Klein, 2001; Douglas P Munoz 
& Everling, 2004; Salman et al., 2006) and a smooth-pursuit task (Katsanis, Iacono, & Harris, 
1998; Tregellas et al., 2004). The inclusion of these tasks enabled the assessment of distinct 
components of the oculomotor system; specifically the saccadic eye movement system and 
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smooth-pursuit system. Therefore, we were able to observe whether impairments of the 
ocular motor system affected only specific mechanisms (i.e. saccadic eye movements) or 
whether mechanisms were globally impaired. The methodology of the four ocular motor 
tasks is described in the following section. 
Apparatus 
For all ocular motor tasks, participants were seated 60cm away from a 32 × 26cm 
CRT-monitor with dimensions of 1024 by 768 pixels and a refresh rate of 60 Hz . Eye 
movements were recorded via eye-tracking equipment (EyeLink® 1000 Tower Mount Head 
Supported System; SR Research Ltd., Ontario, Canada). The equipment provides information 
on the location and duration of fixations by measuring corneal reflection via an infrared 
camera. Participant head movements were stabilized with forehead and chin rests. All stimuli 
were created using programming software (SR Research Experiment Builder, version 
1.10.165) suitable for conducting eye-tracking experiments. Eye movements were recorded at 
1000 Hz with the tower setup. Eye movements were calibrated to an accuracy of at least 1
º 
using a nine-point calibration array. Drift correction was employed on each task at the 
beginning of each trial in order to assess the quality of calibration. Participants could be 
recalibrated if excessive head movements disrupted calibration. 
Procedure 
Fixation Task 
In the fixation task, participants completed 20 trials where they maintained fixation on 
an elephant face target (1.5
 º 
in size) which could appear in one of four randomly selected 
locations around the screen centre (Figure 3.4.1).  
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Figure 3.4.1: Fixation task trial example. Participants are initially presented the target centrally for 1000ms. The 
target then disappears and immediately reappears at one of the four surrounding locations for 5000ms.  
The possible target locations were marked with small circle markers (0.5
 º 
in size) to 
indicate the locations the target could appear. These locations were positioned immediately 
above, below or to the left or right of a central fixation point at an eccentricity of 8
º
. Prior to 
the beginning of each trial, the quality of calibration was checked using a drift correction. 
Trails began with the presentation of the target centrally for 1000 milliseconds (ms). After 
1000ms, the target would disappear and immediately reappear (no gap or overlap) at one of 
the four surrounding locations. The target would remain at this location for 5000ms. At the 
end of the 5000ms, the stimulus was removed and the participant was presented with a blank 
white screen for 1000ms. 
 
Saccade Task (Pro- and Anti-Saccade) 
Two tasks were employed to investigate the saccadic eye movement of the patients: a 
pro-saccade and an anti-saccade task. In both tasks, participants viewed 48 trials where a 
target elephant face (1.5
º 
in size) randomly appeared at one of eight locations around a central 
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starting position. The same four locations were used from the fixation task (see above), with 
four additional locations positioned
 
above, below or to the left or right of the screen centre at 
an eccentricity of 4
º
. Each trial began with the stimulus appearing at the centre of the screen 
for a random amount of time between 1000 and 2000ms. The stimulus then disappeared and 
reappeared at one of the possible target locations for 1000ms (Figure 3.4.2) without any gap 
or overlap.  
 
Figure 3.4.2: Pro- and Anti-saccade task trial example. Participants are initially presented the target centrally for 
1000ms. After the target reappears, the participant has 1000ms to execute an eye movement towards location A 
or B for the pro- and anti-saccade task respectively.  
During the pro-saccade task, participants were asked to look as quickly and accurately 
as possible at the target after it moved to one of the target locations. For the anti-saccade task, 
participants were required to inhibit the production of a reflexive pro-saccade towards the 
stimulus after it moved. Instead, participants needed to produce a voluntarily eye movement 
to the mirror opposite location from the stimulus. For example, if the stimulus appeared 8
º 
to 
the right of the centre, the participant needed to look to the position 8
º 
to the left. 
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Smooth Pursuit Task 
For the smooth pursuit task participants were instructed to maintain fixation for 10 
seconds on a moving target stimulus (1.5
º 
in size) on 3 separate movement trajectories - 
horizontal movement, vertical movement, and elliptical movement. Each movement 
trajectory was presented at slow and fast velocities, resulting in 6 distinct trajectory and 
velocity combinations. Participants completed 24 trials, organised into 6 blocks (4 trials per 
block), where each block consisted of trials of a single trajectory and velocity combination. 
The order of blocks was randomised across participants. 
For horizontal and vertical trajectories, the target moved left/right and up/down, 
respectively, along a 16
º 
path positioned in the middle of the screen. The target moved at two 
sinusoidal velocities of 0.2 and 0.5 Hz, equating to an average target velocity of 6.5
º
 and 16
º
 
of visual angle per second respectively. For vertical trajectory trials, trials always began with 
the target presented at the centre of the screen. Sinusoidal movement of the target would 
commence along an upward trajectory on slow velocity trials, and a downwards trajectory 
during fast velocity trials. On horizontal trials, the starting position of the target depended 
upon the target’s velocity. The target’s starting position was at the limit of the sinusoidal 
trajectory, either 8
º 
to the left or right of the screen centre for slow and fast velocities 
respectively. 
  For the elliptical trajectories, the target moved around the centre of the screen at a 
constant eccentricity of 8
º
. The target moved at two constant velocities; either at 0.2 or 0.3 Hz 
over 10 seconds, which averaged at 10
º
 and 15
º
 of visual angle per second respectively. For 
both trajectory velocities the position of the target at the beginning of each trial was 8
º
 to the 
left of the screen centre. From this starting position the target moved in a clockwise or an 
anti-clockwise direction, for slow and fast velocities respectively.  
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Measures 
For the fixation and saccade tasks eye position data were transferred to a computer 
(Eyelink 1000, SR Research) in real time to determine saccade detection and fixation 
location. The onset of a saccade was detected if the velocity of an eye movement velocity 
exceeded 22
º
/second and eye position changed more than 0.3
 º
. Saccade amplitude was 
defined as the difference between eye position at the onset and offset of a detected saccade. 
Both velocity and amplitude differences were based on instantaneous calculations of the 
previous 19 samples. Prior to analysis, trials from all tasks were visually inspected to ensure 
that participants were engaged in the task and to remove artefacts. 
Fixation Task 
For the Fixation task we measured participant's ability to maintain fixation by 
observing target fixation duration (FixDwell) and target engagement (FixSacc). For each 
target, a surrounding 2.8 x 2.8° box classified the target’s respective region of interests 
(ROI). Fixations that fell within these ROIs counted as fixations on a target. FixDwell was 
defined as the length of time that participants maintained eye position within the target’s ROI 
once it appeared. FixSacc was measured as the frequency of saccades (greater than 2°) that 
moved the participant’s gaze outside the target ROI, and was intended to indicate deviation of 
attention. 
Pro-saccade Task 
For the pro-saccade task we investigated the basic operation of patients’ reflexive 
ocular motor function. Saccades were required to meet several criteria in order to be 
classified as a pro-saccade. First, at onset, the saccade must have been positioned at the centre 
of the screen, at the location of the stimulus prior to moving. Secondly, the direction of the 
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saccade needed to be made in the direction of the peripheral stimulus location. For saccades 
that met the inclusion criteria, we measured the saccadic reaction time (SaccOnset) of the 
first eye movement executed towards the peripherally presented target location. In addition, 
the velocity of eye movements was quantified by peak velocity (SaccVelocity); the peak of 
velocity during an eye movement. 
Anti-saccade Task 
For the anti-saccade task we investigated participants’ ability to inhibit reflexive eye 
movements towards peripherally presented cues, instructing them to instead to fixate on a 
position situated directly opposite the cue – i.e. produce an anti-saccade. We quantified this 
behaviour using several measures: the offset of the saccade which brings the participants gaze 
to the anti-saccade target (AntiOffset), the proportion of trials where a pro-saccade error was 
produced (AntiErr), and the proportion of errors that were corrected (AntiCorr).   
Saccades were qualified as anti-saccades if the following criteria were met: 1) the 
position of the saccade at onset was located at the screen centre; 2) the saccade was the first 
saccade during the trial; 3) the saccade latency was greater than 135ms; 4) the direction of the 
saccades was made in the direction opposite to the peripheral stimulus cue. A saccade was 
classified as a anti-saccade error (AntiErr) if it followed the same criteria as a pro-saccade 
from the pro-saccade task and occurred before an anti-saccade. The proportion of trials where 
errors occurred reflected the failure to inhibit reflective saccades towards a peripheral cue. 
Error correction (AntiCorr) was expressed as the proportion of trials where an error was 
corrected. Errors were classified as corrected if the saccade following an anti-saccade error 
was produced in the direction of the anti-saccade target and had a larger amplitude than the 
preceding pro-saccade error. Latency of anti-saccade target fixation (AntiOffset) was 
measured as the time taken for the participant to locate the anti-saccade location. 
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Smooth Pursuit 
Smooth pursuit analysis was accomplished by manually extracting the sampling data 
of each trial.  This resulted in 10,000 available samples that were first prepared using a 
computer program, written in R, to extrapolate separate target and eye information for 
velocity, positional coordinates, and saccade frequency. In order to compare smooth pursuit 
across the 3 movement trajectory conditions we only included eye movement data that was 
recorded whilst the target was moving at a constant velocity. Therefore, for horizontal and 
vertical trajectories, we excluded all samples that were recorded whilst the target was 
positioned within a 1.5 ̊ region at either end of the trajectory (the tails of the sinusoidal 
movement). In addition, samples that were classified as blinks or saccades were removed 
from the smooth pursuit analysis. 
 Smooth pursuit performance was measured by velocity gain (VeloGain) and 
frequency of catch-up saccades (ForwSacc). For each of these variables we explored the 
effect of the 3 movement trajectories (horizontal, vertical, and elliptical) and the 2 movement 
velocities (slow and fast). Velocity gain was defined as the average eye velocity divided by 
the average target velocity. Higher velocity gain scores equated to a closer match between the 
target and eye velocity, thus the target is likely to be maintained in foveal vision. Catch-up 
saccades were eye movements where the velocity was more than 5 SD from the mean eye 
velocity based on the SD of the velocity in the smoothly moving part of the trial.These were 
expressed as the average number of catch-up saccades per second on each trial. A higher 
number of catch-up saccades may indicate problems in the pursuit system and therefore the 
saccade system is relied upon to minimise distance between the target and eye. 
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4.0 HEALTHY DEVELOPING CONTROL RESULTS 
4.1  Introduction 
Detecting cognitive impairments, whether global or domain specific, is a challenge 
when investigating rare and neurologically complex populations (Martin et al., 2008). Firstly, 
due to the rarity and geographical dispersed nature of individual inherited metabolic disorders 
(IMDs), neuropsychological research within this area has been extremely limited.  A small 
range of studies exist examining the cognitive function of metabolic disorders (Bendadi et al., 
2014a; Davison et al., 2012; Shapiro et al., 2009), but due to their limited sample sizes 
finding robust statistical support has been challenging. Secondly, the heterogeneous onset and 
severity of neuropsychological features associated with IMDs further complicate the 
identification of cognitive developmental features and trajectories within these populations. 
Together with the advent of many promising treatments, such as enzyme replacement therapy 
and haematopoietic stem cell transplantation, it is vital that a sensitive method of quantifying 
the neurodegenerative effects of these disorders is established. 
Identifying the presence of cognitive impairment in the current thesis, whether global 
or domain-specific, is achieved through two means: The direct comparison of individual 
patients to a large group of healthy developing controls, and the comparison of 
developmental trajectories between patients and healthy developing controls. To this end, 
tasks in the test battery have been standardised with a large sample of healthy developing 
controls in order to identify which tasks are most sensitive to developmental effects, to 
establish development trajectories for each task, and provide a means to compare patient 
performance. In this section we analyse results from healthy controls to determine which 
developmental trajectory model is appropriate for each of the measures outlined in Chapter 3. 
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4.2 Data Analysis – Developmental Trajectories 
We compare models for developmental trajectories (ages 5-19) using Akaike’s 
Information Criterion (AIC) as a model selection paradigm. We fit three functions to the data: 
linear, quadratic, and plateau. Figure 4.2.1 outlines each model fit and the related parameters. 
These three models were chosen since they can each provide unique fits that can explain 
different patterns in cognitive development.  Quadratic and plateau functions (both nonlinear) 
typically fit developmental data taken from a wide range of ages more accurately than linear 
functions, as the rate of cognitive change for many tasks is not constant.  Early gains are 
faster and later progress shows slow gains or no change with age.  For some of the tasks, 
children may reach developmental maturation early on within the age range of the sample. In 
these cases a plateau will fit the developmental data more accurately than a quadratic function 
since they include an age range where performance changes very slowly or does not change 
at all with time (and there is no age-related decline in the range we are testing). To 
statistically answer the question “which function provides the best representation of the 
developmental data?” we inspected the Akaike’s Information Criterion (AIC) values for 
different functions. In addition, these methods were extended to inspect differences between 
experimental conditions within tasks to determine the necessity of condition-specific 
trajectories during healthy cognitive development. 
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Figure 4.2.1: Description of fitted models and parameters. The 3 fitted models and related parameters of the 3 
functions fitted to the developmental data during the model selection stages.  
 
Linear Model 
Model 
Y = b + Age * a 
Parameters 
Intercept (b): the value of Y at the youngest 
age of measurement 
Slope (a): The rate of development as a 
function of age. 
 
Quadratic Model 
Model 
Y = b + Age* a1 + Age
2
 * a2 
Parameters 
Intercept (b): The value of Y at the youngest 
age of measurement 
Linear Term (a1): The steepness of 
development as a function of age. 
Quadratic Term (a2): The direction and 
gradient of slope bend as a function of age. 
Plateau Model 
Model 
Y = b + (p – b) * (exp(-k * Age)) 
Parameters 
Intercept (b): The value of Y at the youngest 
age of measurement 
Plateau (p): The value of Y when Age is 
expressed as an infinite – value of Y at the 
age of cognitive maturation. 
Rate Constant (k): The magnitude of 
development between intercept and plateau 
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Akaike’s Information Criterion (AIC) 
Using AIC for model selection is a statistical method grounded in information theory 
that “allows the data-based selection of a ‘best’ model and a ranking and weighting of any 
remaining models from a pre-defined set” (Burnham & Anderson, 2002). AIC can be used as 
an alternative to likelihood ratio test model comparisons (using F-values and based on null-
hypothesis testing), as a means to identify whether a model adequately fits a dataset without 
overfitting the noise that would not be represented in a different sample; If a model is fit with 
noise in one sample it will not generalise well to a new sample. A good balance between fit 
and parsimony is what AIC is designed to achieve. Unlike F-test model comparisons, AIC 
can be used to compare both nested and non-nested models whereas the F-test is only suitable 
for the comparison of nested models. This is important since we are interested in comparing 
both nested (e.g. linear and quadratic) and non-nested (e.g. linear and plateau) models. 
Equation 1 is the formula for calculating the AIC statistic of a model. Similar to an F-test 
comparison, the equation utilises the sum-of-squared residuals (SS) created by the model to 
provide an indication of how well the model minimises the vertical error of data points from 
the fitted function. In addition, AIC considers the complexity of a model by including the 
number of parameters (K) fitted by the regression. N is the number of observations. Lastly, in 
the current work we used corrected AIC values (AICC  ; Equation 2) which are used for 
comparing models based on smaller sample sizes (Burnham & Anderson, 2002).  
 
1) AIC = N ∙ ln (
SS
N
) + 2K 
 
2) AICC = AIC +  
2K(K+1)
N−K−1
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  The absolute value of AIC is not meaningful.  It is the numerical difference between 
AIC values (without respect to the absolute size) that indicates how far model candidates are 
from the ‘best’ model in the set.  For the purpose of model comparisons, the first step is to 
calculate the difference in the AIC values (∆AIC; Equation 3) produced by a set of models, 
whereby each model’s AIC is compared to the AIC of the ‘best’ model (model with lowest 
AIC; AICj). 
 
3) ∆AIC𝑖 = AIC𝑖 −  AIC𝑚𝑖𝑛 
 
Consequentially the ‘best’ model will have an ∆AIC of 0, while the ∆AIC of the remaining 
model candidates will reveal how close they are to being the ‘best’ model, thus all models in 
the set will be ranked. There is not a set method for interpreting ∆AIC values, but rules of 
thumb exist (Burnham & Anderson, 2002). An ∆AIC of 0-2 indicates nearly equivalent 
likelihood between the candidate model and the ‘best’ model, an ∆AIC of 4-7 shows the 
candidate model has considerably less support, and an ∆AIC > 10 indicates there is virtually 
no support for the candidate model. Using ∆AIC it is possible to calculate two further useful 
values - the AIC weight (AICw) and then the Evidence Ratio. AICw is a relative probability 
expressing how likely each model is of being the best fit to the data set. Thus the sum of all 
model AICw within a set will equal 1 (Burnham & Anderson, 2002). It is calculated as 
follows: 
AIC𝑤𝑖 =
𝑒(−
1
2 ⁄ ∆AIC𝑖)
∑ 𝑒(
−1
2⁄ ∆AIC𝑟)𝑅
𝑟=1
 
 
In general, candidate models with large ∆AIC values will produce smaller AICw, and 
thus present less evidence of being the ‘best’ model. Below is an example output from a 
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comparison of the 3 model types (linear, quadratic, and plateau) fitted to a fictitious dataset. 
The models are ranked in order according of ∆AIC. 
Model AIC value ∆AIC AICw 
Evidence 
ratio 
Quadratic 100 0 0.95 1 
Plateau 107 7 0.03 32 
Linear 108 8 0.02 56 
 
In the above example the ∆AIC values show that the quadratic model is preferred (has 
the lowest AIC value) and, given the model set, has the highest relative probability by some 
margin (AICw = .95 ; the relative probability of being the best model out of these 3 is 95%). 
In this example, it would be appropriate to accept the quadratic model as the only appropriate 
model for the dataset. In a less clear example (below), the likelihood of two models 
(quadratic and plateau) are nearly equivalent (∆AIC < 2); While a quadratic model provides 
the best description of the data, a plateau model also offered a reasonally good fit as well. In 
this case, it may be appropriate to choose a plateau model over a quadratic model if the fit 
provided by the plateau model make more developmental sense (i.e. a quadratic model might 
suggest an unrealistic U-shape developmental curve inorder to achieve a closer stastical fit). 
 
Model AIC value ∆AIC AICw 
Evidence 
ratio 
Quadratic 100 0 0.57 1 
Plateau 101 1 0.35 1.6 
Linear 104 4 0.08 7 
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A further way of explaining the relative differences between a set of models is to 
calculate evidence ratios (Eratio) for a model set. An evidence ratio can be computed for a 
candidate model by dividing its AICw by the largest ‘best’ model AICw from the model set. 
The ratio expresses how many times more likely the ‘best’ model is of being correct than the 
model of interest. For example, in the above example we can see that the quadratic model is 
33 (.954 / .029) and 56 times (.954 / .017) more likely to be correct than the plateau and 
linear models respectively. Together with the AICw values, evidence ratios help to quantify 
relative differences between models when choosing a “best” model (or models) from a model 
set.  
Using AIC to compare development across experimental conditions 
We use model selection with AIC to determine the best way of describing rates of 
change in development, but also to test for condition-specific trajectories within tasks. For 
example in the language tasks, does verbal production develop differently to verbal 
comprehension? To answer these questions we used non-linear mixed effect model analysis 
(nlme) to compare models that include main effects and interactions. In the context of 
trajectory comparisons, main effects indicate whether the developmental trajectories of two 
or more tasks / conditions are offset. Whereas the presence of interactions (which factor in 
age – Task x Age) indicate whether the gradient of two or more developmental trajectories 
differ with age. Figure 4.2.2 provides an example of two possible trajectory comparison 
outcomes. Panel A shows an example of a main effect without an interaction. The 
development of the two conditions is offset but the rate of change is the same. Panel B 
displays an example of a main effect and an interaction. The development is of the two 
conditions is offset and the rate of development differs. 
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Figure 4.2.2: Trajectory comparison method. Example of main effect and interaction comparison method of two 
conditions. Panel A illustrates an instance where the development between two tasks is offset, but the rate of 
development is the same (main effect with no interaction). Panel B illustrates an instance where the 
development between two tasks is offset and the rate of development differs (main effect and interaction).  
 For instances where three or more tasks / conditions are compared and main effects 
and / or interactions are revealed, it is necessary to identify where the differences between 
trajectories reside. This is achieved through the construction and comparison of model sets, 
where each model represents particular experimental factor combinations. For example, in 
the fixation task, 3 separate models could be compared: a 1-term model where a single 
trajectory defines saccade speed across all target positions, a 2-term model with separate 
trajectories for up/down and left/right target positions, and a 4-term model that has separate 
trajectories for all the 4 target positions. In this case, the comparison of AIC values will 
indicate whether development proceeds uniformly for saccades in all directions, or occurs at a 
different rate in some directions rather than others. 
 
Definition of Confidence Intervals 
  Confidence limits for developmental trajectories are defined using a bootstrap method 
to create 3 comparable function types (linear, quadratic and plateau). These functions are 
fitted to the 95% interval of the bootstrapped t-distributions of the age groups to construct 
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smooth curves. This method of defining confidence limits is preferable to traditional 
prediction bands as it minimises the impact of any idiosyncratic variance estimates produced 
from individual age samples. 
 The precise method used to define the 95% CIs of the development trajectories is as 
follows (Figure 4.2.2 provides an illustration). First, the age of participants were rounded to 
the nearest year to create a set of bins representing different age groups (6 year olds, 8 year 
olds, 10 year olds, etc.). A new sample is created (random sampling of raw data with 
replacement; blue dots in Figure 4.2.3, panel A) for each age bin from which upper and lower 
95% t-based CIs are acquired (red dots in Figure 4.2.3, panel A). Using these CI values a set 
of 3 functions are fitted (linear, quadratic and plateau) (Figure 4.2.3, panel B).  This process 
was replicated 1000 times (bootstrapped) in order to build a population of parameter 
estimates for each of the 3 function types. An average was calculated across each population 
of parameter estimates to produce the best single linear, quadratic and plateau function. The 
AIC values of these final functions were compared to identify which function best 
characterised the confidence limits of the developmental trajectory. 
 
 
Figure 4.2.3: Process of defining developmental trajectory confidence intervals. In panel A, the upper and lower 
95% t-based CIs (red dots) were calculated from a random sample (with replacement) of the data (blue dots) in 
each age bin. In panel B, 3 regression functions (quadratic is illustrated here) were fitted to the lower and upper 
points of the 95% CI. This process was replicated 1000 times (bootstrapped) to build a population of fitted 
curves. Parameter averages were computed from the population of curves to produce a final curve.  
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4.3 Attention 
Participants: 
 Control data for the attention tasks was collected from a sample of 104 children, 
teenagers and young adults (age range: 72 – 228 months). Data was collected from primary 
schools, secondary schools and undergraduate psychology students. Prior to testing, informed 
consent was taken from undergraduate students or from parents of children who took part 
from primary or secondary school. 
 
Simple Reaction Time Task 
The simple response time latency (RTmean) of healthy controls was examined at 4 
target locations. In the first step of the analysis, an AIC comparison was conducted to test the 
2-way interaction between TargetLocation and Age. Here a model which included an 
interaction term (∆AIC = 0; AICw = .971) was better than a model that did not (∆AIC = 7 ; 
AICw = .029). This means the healthy development of simple response time (RTmean) 
proceeded at different rates for the 4 target locations. To answer whether trajectories were 
systematically grouped, the AIC values of the following 4 models were compared. A 1-term 
model with a single trajectory representing all target locations (‘Combined’ model), a 2-term 
model with separate trajectories for left and right targets (‘Left top & bottom/Right top & 
bottom’ model), a 2-term model with separate trajectories for top and bottom targets (‘Top 
left & right/Bottom left & right’ model), and a 4-term model with response time trajectories 
for each of the four target locations (‘Separate’ model). Results (Table 4.3.1) revealed that 
the ‘Left/Right’ model provided the best description of simple reaction time development 
(AICw = .702). The model with different trajectories for all four target locations (‘Separate’ 
model) enjoyed less support than the ‘Left/Right’ model, but did have some degree of 
support.  The ‘Combined’ and ‘Top/Bottom’ models were poor. This means that healthy 
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development occurred at different rates for targets presented to the left and right of the screen 
centre.  
 
 
Table 4.3.1: Healthy controls simple reaction time - AIC condition comparison 
RTmean    
Model ∆AIC AICw Evidence ratio 
    
Left/Right 0 .702 1 
Separate 1.9 .386 2.6 
Combined 7.1 .020 34.8 
Top/Bottom 9.8 .005 134.3 
    
 
 Based on the ‘Left/Right’ model, the fit of developmental trajectories to linear, 
quadratic or plateau functions was analysed separately for left and right targets. For both left 
and right targets, results indicated that plateau functions provided the best description of 
development (Table 4.3.2). This is because of the downward sloping curves (Figure 4.3.1) 
that characterise development, where the majority of developmental change occurred during 
the first few years of development, and little to no development occurred during later years. 
In addition, the difference in intercept parameters (Table 4.3.2) underlines the necessity for 
separate developmental trajectories for left and right targets; at the earliest age of 
measurement response times are slower for right targets (613ms) compared to left targets 
(566ms). Differences between left and right target response times disappear once reaction 
times reach their plateau (left = 264ms ; right = 267ms). 
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Table 4.3.2: Healthy controls simple reaction time - AIC trajectory comparison 
   
Plateau Models   
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
Linear Quadratic Plateau 
 
Intercept 
Rate 
Constant 
Plateau 
Term 
 
R
2 
          
Left Targets 21. / <.01 3.1 / .17 0 / .83  566 .02 .264  .62 
          
Right Targets 25.9 / <.01 1.9 / .27 0 / .73  613 .02 .267  .65 
          
Note: Reponses recorded in milliseconds   
 
 
Figure 4.3.1: Healthy controls simple reaction time developmental trajectories. Development of healthy 
developing controls (blue dots) shown for left and right targets. The developmental trajectories (red solid line) 
are expressed as plateau functions.  95% CI (dashed black line) are also presented.  
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Visual Search Task 
 
 
Figure 4.3.2: Healthy controls visual search mean search times. Mean response latencies (ms) of the different 
age groups for each set size for feature search (left panel) and conjunction search tasks (right panel).  
 Results for healthy developing controls on the visual search set size conditions are 
presented in Figure 4.3.2. Older participants demonstrated faster mean visual search times 
than younger participants in both feature and conjunction search tasks. It is also evident that 
the response time patterns for feature and conjunction search tasks that are typically observed 
in healthy individuals are present in the current sample; response time only increases as a 
function of set size for conjunction search but not feature search. In addition, search 
efficiency changed relatively little compared to the constant offset between ages. This is 
shown in the devopmental change which moves the mean search time slopes down without 
affecting the gradient of slopes. Therefore, developmental differences do not appear to be 
related to the efficiency of item-by-item processing, but rather to the maturation of processes 
that are not sensitive to the number of items, such as decision time or response preparation. 
To identify whether search efficiency (VSslope) developed at different rates on feature 
and conjunction tasks, an AIC comparison was conducted to test the 3-way interaction 
between Task, Setsize and Age. Here, a model which included an 3-way interaction term was 
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better (AICw = .908) than a null-model (∆AIC = 4.6 ; AICw = .091). This means that the 
efficiency of search developed differently on the feature and conjunction search tasks. To 
answer how search efficiency developed differently on the feature and conjunction search, 
separate AIC comparisons were conducted for each task examining the 2-way interactions 
between Setsize and Age. When compared to null-models, there was minimal evidence of a 
slope change for feature search (test-model: ∆AIC = 1.9 ; AICw = .28, null-model: ∆AIC = 0 
; AICw = .72) and substantial evidence of slope changes in on conjunction search (test-
model: ∆AIC = 0 ; AICw = .95, null-model: ∆AIC = 20 ; AICw = .05). This suggests that the 
efficiency of search was likely to change with age for conjunction search but not feature 
search. Finally, an AIC comparison testing the 2-way interaction between Task and Age was 
evaluated to determine if the development of mean response time (collapsed across set-size) 
differed between the 2 tasks. Results revealed an interaction model to be better (AICw = 
.999) than a null-model (∆AIC = 116.5 ; AICw < .001). Together these results suggest that 
changes with age in conjunction search were larger than in feature search for mean search 
time (VSmean) and search efficiency (VSslope). 
The fit of VSmean and VSslope developmental trajectories to linear, quadratic or 
plateau functions was analysed separately for feature and conjunction search tasks (Table 
4.3.3).  
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Table 4.3.3: Healthy controls  visual search task - AIC trajectory comparison 
   
Quadratic Models   
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
Linear Quadratic Plateau 
 
Intercept 
Linear 
Term 
Quadratic 
Term 
 
R
2 
          
FS – VSmean 13.3 / <.01 0 / .57 .5 / .43  1132 -7.424 .021  .79 
          
CS – VSmean 16.6 / <.01 0 / .69 1.5 / .31  2074 -15.010 .045  .77 
          
          
Linear Models   
 
 
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 
Fit 
Summary 
 Linear Quadratic Plateau  Intercept Slope   R
2
 
          
FS – VSslope 0 / .63 1.1 / .38 -  3 -.007   < .01 
          
CS – VSslope 0 / .67 1.4 / .33 -  64 -.142   < .01 
          
Notes: FS: Feature Search, CS: Conjunction Search, reponses recorded in milliseconds   
 
For VSmean, the relative likelihood that development was characterised by either a 
quadratic or plateau function was nearly equivalent (∆AIC < 2) on both feature and 
conjunction search. VSmean linear functions produced very poor fits. The quadratic functions 
explained a large proportion of variance (FS (R
2
)
 
= .786 ; CS (R
2
)
 
= .766), therefore, overall 
feature and conjunction search time offered a sensitive measure of developmental change. 
The model parameters of the two VSmean quadratic functions (Table 4.3.3) capture the 
differences in development between feature and conjunction search. VSmean at the earliest 
age of measurement (intercept) was much higher for conjunction search (2074ms) than 
feature search (1132ms). In addition, the rate of development (linear term) was greater for 
conjunction search (-15ms each month) in comparison to feature search (-7ms each month). 
Finally, the dominance of nonlinear functions can be further explained by the downward 
sloping curve that characterises the developmental change of VSmean (Figure 4.3.3, top 
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panels). For both trajectories the majority of developmental change occurred during the early 
years, while developmental change at later years was minimal.  
For VSslope, the relative likelihood of linear and quadratic functions was almost 
equivalent (∆AIC < 2) for feature and conjunction search. Model parameters of the linear 
functions capture the developmental differences in visual search proficiency between feature 
and conjunction search tasks. First, at the youngest age of measurement (intercept term) 
participants required more time for each addition search item for conjunction search (64ms 
per item) than feature search (3ms per items). Second, the rate of search efficiency 
development (slope term) was greater for the conjunction search (-.142ms each month) than 
feature search tasks (-.007ms each month). Finally, Figure 4.3.3 (bottom panels) shows that 
search proficiency improved marginally with age for conjunction search and was static for 
feature search. In addition, feature and conjunction search efficiency is much more variable at 
younger ages than at older ages.  
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Figure 4.3.3: Healthy controls visual search developmental trajectoies. Mean reaction time (VSmean) and search 
efficiency (VSslope) of healthy developing controls (blue dots) during the visual search task for feature and 
conjunction search conditions. Based on the Developmental trajectories for controls (red solid line) are 
expressed as quadratic and linear functions for VSmean and VSslope respectively. 95% CI (dotted black line) are 
also presented.  
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4.4 Language 
Participants: 
 Control data for the language tasks was collected from a sample of 104 children, 
teenagers and young adults (age range: 72 – 228 months). Data was collected from primary 
schools, secondary schools and undergraduate psychology students. Prior to testing, informed 
consent was taken from undergraduate students or from parents of children who took part 
from primary or secondary school. 
 
Production and Comprehension 
 Verbal production and comprehension performance were measured through the 
Boston-Naming Task (BNT) and British Picture Vocabulary Scale (BPVS). The AIC 
comparison of linear, quadratic and plateau function fits to the BNT and BPVS developmental 
data revealed that quadratic functions offered the best description of development (Table 
4.4.1). 
 
Table 4.4.1: Healthy controls verbal production and comprehension - AIC trajectory 
comparison 
  
   
Quadratic Models   
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
Linear Quadratic Plateau 
 
Intercept 
Linear 
Term 
Quadratic 
Term 
 
R
2 
          
BNT 4.6 / .05 0 / .51 0.4 / .43  384 -2.447 .005  .83 
          
BPVS 0.6 / .28 0 / .38 0.1 / .34  573 -6.074 .002  .84 
          
 
For BNT performance, the relative likelihood of a quadratic and plateau was nearly equivalent 
(∆AIC < 2), suggesting that developmental change was nonlinear. Figure 4.4.1 shows that the 
majority of developmental change occurred during earlier years (6 – 10 years). In contrast, 
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the relative likelihood between the 3 functions was minimal for BPVS development (∆AIC < 
1). However, based on an inspection of raw scores (Figure 4.4.1) a quadratic model was 
deemed as the most appropriate fit. This is because improvements in verbal comprehension 
are unlikely to increase linearly past the age of 19 years. Finally, changes in age explained a 
large proportion on the performance variance observed in BNT (R
2 
= .834) and BPVS (R
2 
= 
.839) suggesting these tasks are sensitive to developmental effects.  
 
 
Figure 4.4.1: Healthy controls verbal production and comprehension developmental trajectories. BNT and BPVS 
performance of healthy developing controls (blue dots). Developmental trajectory for controls is expressed as a 
non-linear plateau function (red solid line). 95% CI (dotted black line) are also presented.  
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Non-word Learning Task 
The non-word naming task examined the total number of non-words (max 30) 
participants are able to verbally produce (NonProd) and comprehend (NonComp) during a 
sequence of 6 learning iterations. The mean performance of the different age groups across 
these learning iterations is displayed in Figure 4.4.2. 
 
 
Figure 4.4.2: Healthy controls mean non-word production and comprehension scores. Mean number of monsters 
named and identified for production (left) and comprehension (right) respectively by healthy controls. The 
learning phase is represented by the initial 6 iterations.  
 Differences between the age groups for the production and comprehension of non-
words appeared evident. Specifically, during the first iteration of the learning phase, older 
participants are able to produce / comprehend more non-words. In terms of the rate of 
learning across the learning iterations (iteration 1 – 6), it is unclear whether the age groups 
exhibited differences for non-word production and comprehension. For the developmental 
trajectory comparisons, linear, quadratic and plateau functions were fitted to NonProd and 
NonComp measures separately. The comparison of AIC values for the linear, quadratic, and 
plateau functions (Table 4.4.2) revealed that development was best defined by plateau 
functions for both NonProd (AICw = 0.428) and NonComp (AICw = 0.565), but the relative 
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likelihood that development was described by a quadratic function was essentially equivalent 
(∆AIC < 1) to the likelihood of a plateau function on both measures. Linear functions 
provided fits that were substantially less likely than the nonlinear functions (∆AIC > 2). 
Changes in age explain a relatively large proportion of variance observed in both production 
(R
2 
= .503) and comprehension (R
2 
= .378). Model parameters of the two plateau models 
highlight differences in development between NonProd and NonComp. At the youngest age 
of measurement (intercept term) comprehension (26 monsters) was better than the production 
(12.5 monsters). Similarly, comprehension (29 monsters) was better than production (26 
monsters) at the peak of development (plateau term). 
 
Table 4.4.2: Healthy controls non-word learning - AIC trajectory comparisons   
   
Plateau Models   
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
Linear Quadratic Plateau 
 
Intercept 
Rate 
Constant 
Plateau 
  
          
NonProd 2.1 / .15 0.1 / .42 0 / .43  12.558 .035 25.951  .50 
          
NonComp 13.8 / <.01 0.5 / .44 0 / .56  26.064 .048 29.064  .38 
          
   
 
The upward sloping developmental curves presented in Figure 4.4.3 further explain 
the preference of nonlinear functions. The majority of development occurred rapidly during 
younger ages and plateaued after the age of 10 years. This effect was more prominent for 
NonProd than NonComp. However this is likely to be due to ceiling effects present in the 
latter measure. 
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Figure 4.4.3: Healthy controls non-word developmental trajectories. Developmental trajectories for the sum of 
monsters named (production; left panel) and recognised (comprehension; right panel) during the learning phase. 
Both trajectories were best defined by a plateau model.  95% CI (dotted black line) are also presented.  
4.5 OculoMotor 
Participants: 
 Control data for the oculomotor tasks was collected from a sample of 265 children, 
teenagers and young adults (age range: 72 – 228 months). Data was collected from primary 
schools, secondary schools and undergraduate psychology students. Prior to testing, informed 
consent was taken from undergraduate students or from parents of children who took part 
from primary or secondary school. 
 
Fixation Task 
The healthy development of fixation duration (FixDwell) and intrusive saccade 
frequency (FixSacc) was examined based on fixations to 4 horizontal and vertical targets. 
For fixation duration (FixDwell), an AIC comparison was conducted to test the 2-way 
interaction between TargetLocation and Age. Here a model which included an interaction 
term (∆AIC = 0; AICw = .99) was better than a model that did not (∆AIC = 46; AICw <.01). 
This means the rate which sustained fixation duration developed was different for the four 
target locations. To answer whether trajectories were systematically grouped the AIC of the 
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following 5 models were compared: a 4-term model with a separate trajectory for each of the 
four target locations (‘Separate’ model), and four 2-term models where development only 
differed for a single target location (‘Left’,’Right’,’Top’,’Bottom’ models). Results (Table 
4.5.1) revealed that the ‘Separate’ and ‘Top’ model provided essentially equivalent 
descriptions of sustained fixation development (AICw = .50). The relative likelihood of the 
remaining models was poor. This means that healthy development occurs at a different rate 
for top targets in comparison to targets presented in the other three locations 
 
Table 4.5.1: Healthy controls fixation duration - AIC condition comparisons 
    
Model ∆AIC AICw Evidence ratio 
    
Separate 0 .50 1 
Top .1 .50 1 
Bottom 20 <.01 >1000 
Left 28 <.01 >1000 
Right 31 <.01 >1000 
    
 
 Based on the ‘Top’ model, the fit of the developmental trajectories to linear, quadratic 
or plateau functions was analysed separately for the top target location; the development of 
left, right, and bottom targets were combined (‘L / R / B’ development). Results indicated 
that plateau functions clearly offered the best description of development for both the top 
target and the remaining targets (Table 4.5.2). This is because of the upward sloping curves 
(Figure 4.5.1) that characterise development, where the majority of developmental change 
occurred during the early years of development, and little to no development occurred during 
later years. In addition, the difference in intercept parameters underlines the necessity for 
development to be defined separately for top targets; at the earliest age of measurement 
fixation duration are higher for top targets (4319ms) compared to the other targets (4001ms). 
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Differences between target locations disappear once fixation durations reach their plateau 
(top= 4891ms ; L / R / B  = 4923ms). 
 
Table 4.5.2: Healthy controls fixation duration - AIC trajectory comparisons   
   
Plateau Models   
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
Linear Quadratic Plateau 
 
Intercept 
Rate 
Constant 
Plateau 
 
R
2 
          
Top 23.6 / <.01 8.3 / .01 0 / .98  4319 .08 4891  .153 
          
L / R / B 53.49 / <.01 10.1 / <.01 0 / .99  4001 .05 4923  .382 
          
Note: Durations recorded in milliseconds   
 
 
Figure 4.5.1: Healthy Controls fixation duration developmental trajectories. Mean fixation duration time 
(FixDwell) of healthy developing controls (blue dots). Development is best expressed by a plateau function (red 
line). Developmental trajectories were defined for top target and the remaining target (‘L / R / B’ target) 
separately. 95% CI (dotted black line) are also presented.  
 
For the frequency of intrusive saccades during fixation (FixSacc), an AIC comparison 
was conducted to test the 2-way interaction between TargetLocation and Age. Here a model 
which included an interaction term (∆AIC / AICw = 0 / .98) was clearly better than a model 
that did not (∆AIC / AICw = 8 / .02). Therefore, the rate that intrusive saccade suppression 
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develops differed between the four target locations. To answer whether trajectories were 
systematically grouped, the same 5 models from the FixDwell analysis were compared. 
Again, results (Table 4.5.3) revealed that the ‘Top’ (∆AIC / AICw = 0 / .58) and ‘Separate’ 
(∆AIC / AICw = .7 / .41) models offered the essentially equivalent descriptions of 
development. The remaining models were poor in comparison. This suggests that healthy 
development occurs at a different rate for top targets in comparison to targets presented in the 
other three locations. 
 
Table 4.5.3: Healthy controls intrusive saccades – AIC condition comparisons 
FixDwell    
Model ∆AIC AICw Evidence ratio 
    
Top 0 .58 1 
Separate .7 .41 1.4 
Left 11 <.01 257 
Right 26 <.01 >1000 
Bottom 29 <.01 >1000 
    
 
Based on the ‘Top’ model, the fit of the developmental trajectories to linear, quadratic 
or plateau functions was analysed separately for the top target location; left, right, and bottom 
targets were combined (‘L / R / B’ development). Similar to FixDwell, results indicated that 
plateau functions clearly offered the best description of development for both the top target 
and the remaining targets (Table 4.5.4). This is because of the downward sloping curves 
(Figure 4.5.2) that characterise development, where the majority of developmental change 
occurred during the first few years of development, and little to no development occurred 
during later years. In addition, the difference in intercept parameters underlines the necessity 
for development to be defined separately for top targets; at the earliest age of measurement 
intrusive saccades are less frequent for top targets (1.73) compared to the other targets (2.03). 
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Differences between target locations disappeared once the frequency of saccades reached the 
plateau of development (top= 1.06 ; L / R / B  = 1.05). 
 
Table 4.5.4: Healthy controls intrusive saccades – AIC trajectory comparisons   
   
Plateau Models   
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
Linear Quadratic Plateau 
 
Intercept 
Rate 
Constant 
Plateau 
 
R
2 
          
Top 14.1 / <.01 1.2 / .35 0 / .65  1.73 .03 1.06  .242 
          
L / R / B 53.49 / <.01 10.1 / <.01 0 / .99  2.03 .03 1.05  .417 
          
   
 
 
Figure 4.5.2: Healthy controls intrusive saccade developmental trajectories. Mean frequency of intrusive 
saccades (FixSacc) of healthy developing controls (blue dots). Development is best expressed by plateau 
functions (red line). Developmental trajectories were defined for top target and the remaining target (‘L / R / B’ 
target) separately. 95% CI (dotted black line) are also presented.  
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Prosaccade Task 
The development of 2 saccade parameters was examined for the pro-saccade task: 
latency of saccade initiation (SaccOnset) and saccade velocity (SaccVelo). AIC comparisons 
of the 2-way iterations between Targetlocation and Age for SaccOnset (test-model (∆AIC / 
AICw) = 0 / .99 ; null-model (∆AIC / AICw) = 46 / <.01) and SaccOnset (test-model (∆AIC / 
AICw) = 0 / .92 ; null-model (∆AIC / AICw) = 5 / .08) revealed that development did not 
occur uniformly across the 8 target locations on either task. In order to answer how 
development differed between target locations, the 5 following models were compared:  A 1-
term model with a single trajectory representing performance collapsed across target 
locations (‘Combined’ model), a 2-term model with separate trajectories for inner and outer 
target amplitudes (‘Amplitude’ model), a 2-term model with separate trajectories for vertical 
and horizontal target locations (‘Hori / Vert’ model), a 4-term model with a separate 
trajectory for each four target directions (left, right, up, down; ‘Direction’ model), and a 8-
term model with a  trajectory for each of the eight target locations (“Separate” model). AIC 
comparisons of the two pro-saccade measures are presented in Table 4.5.5. AIC comparison 
of the SaccOnset and SaccVelo model sets revealed that the best description of development 
across target location was offered by the “Separate” model (SaccOnset: AICw = .999; 
SaccVelo: AICw = .999).  For both measures, the evidence ratios demonstrated the ‘Separate’ 
model to be over 1000 times more likely than the 4 remaining models. 
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Table 4.5.5: Healthy controls pro-saccade task – AIC condition comparisons 
SaccOnset    
Model ∆AIC AICw Evidence ratio 
    
Separate 0 .999 1 
Directions 155 <.001 > 1000 
Hori / Vert 200 <.001 > 1000 
Amplitude 259 <.001 > 1000 
Combined 400 <.001 > 1000 
    
SaccVelo    
Model ∆AIC AICw Evidence ratio 
    
Separate 0 .999 1 
Amplitude 109 <.001 > 1000 
Directions 1161 <.001 > 1000 
Hori / Vert 1191 <.001 > 1000 
Combined 1222 <.001 > 1000 
    
 
 
To find the best developmental trajectories of saccade initiation latency (SaccOnset), 
the fit of linear, quadratic and plateau models were compared based on the ‘Separate’ model 
(separate trajectories for each target). Results (Table 4.5.6) found that plateau functions were 
best (∆AIC = 0) for 7 of the 8 target locations, while a linear function was best for a single 
target location (inner right). The likelihood that development followed a nonlinear trajectory 
for the 7 target locations is further explained by the downward sloping curves characterised 
SaccOnset development (Figure 4.5.3). The rate of development decreased as a function of 
age, whereby little or no differences were observed between the performance of the older 
participants (age 18 – 19 years). In addition, the model parameter estimates shown in Table 
4.5.4 highlight the necessity of target-specific developmental trajectories. Notably, a pattern 
between model intercepts emerged based on target amplitude and direction; The latency of 
saccade onsets were always shorter for inner versus outer targets, and latency increased for 
direction based on the following order: right, left, top, bottom. A similar pattern was evident 
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for the plateaus, whereby latencies were shorter for inner versus outer target amplitudes. The 
effects of target direction was less clear, but saccade latencies for bottom targets were greater 
than targets presented at other locations with the same amplitude. Rates in development (as 
expressed by rate constants) did not appear to differ systematically between target locations. 
Together these trends suggest that the speed in which children and adults program and 
execute saccades can be influenced by target direction and amplitude. 
 
Table 4.5.6: Healthy controls pro-saccade onset – AIC condition comparisons   
Linear Models   
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
Linear Quadratic Plateau  Intercept Slope   R
2 
          
Inner Right 0 / .57 2  / .21 2  / .21  195 -.311 -  .27 
          
Plateau Models   
 AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
 
 
 
Linear Quadratic Plateau 
 
Intercept 
Rate 
Constant 
Plateau 
 
R
2 
          
Inner Left 8.5 / < .01 0.8 / .39 0 / .60  217 .021 149  .22 
          
Inner Top .88 / .24 0.1 / .37 0 / .38  223 .010 142  .22 
          
Inner Bottom 1.81 / .18 0.3 / .36 0 / .46  255 .012 163  .23 
          
Outer Right 6.6 / .03 1.4 / .31 0 / .66  236 .013 152  .34 
          
Outer Left 15.31 / < .01 3.7 / .14 0 / .86  247 .022 162  .33 
          
Outer Top 3.9 / .07 .46 / .41 0 / .52  268 .015 177  .23 
          
Outer Bottom 13.9 / < .01 .92 / .38 0 / .61  299 .016 176  .41 
          
Note: Saccade onets recorded in milliseconds 
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Figure 4.5.3: Healthy controls saccadic onset development trajectories. Mean saccadic onset time of healthy 
developing controls (blue dots) during the pro-saccade task. Onset time is presented for each of the 8 target 
locations. 95% CI (dotted black line) are also presented.  
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The comparison of saccade velocity (SaccVelo) developmental trajectories to linear, 
quadratic and plateau functions was based on the ‘Separate’ model. Therefore, separate 
trajectories were defined for each target location. Results (Table 4.5.7) revealed that saccade 
velocity development was best defined (∆AIC = 0) by quadratic functions for 7 of the 8 target 
locations, while a single target location (outer right) was best defined by a linear function. 
The relative likelihood of a quadratic function for 6 target locations (inner left, inner right, 
inner top, inner bottom, outer left, outer top) was considerable (AICw range = .804 – .999). In 
addition, for 2 target locations (outer right, outer bottom) the relative likelihood between a 
quadratic and linear trajectory was equivalent (∆AIC < 2). Plateau functions could not be 
fitted to 4 target locations (inner bottom, outer right, outer top and outer bottom) due to the 
inability to obtain accurate intercept and plateau parameter estimates. However the effects of 
age on SaccVelo were unclear. The proportion of variance in SaccVelo that was explained by 
age was less than 10% for all target locations. In addition the examination of the linear slope 
terms for linear and quadratic functions revealed that the 95% confidence limits crossed 0. 
Therefore, it is unclear whether age-related changes for saccade velocity occured within the 
age range (6 – 19 years) of the current sample. The saccade velocity developmental slopes of 
the 8 target locations (Figure 4.5.4) further demonstrate the minimal change in performance 
as a function of age.  
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Table 4.5.7: Healthy controls pro-saccade velocity – AIC trajectory comparisons 
Linear Models 
 
AIC Results (∆AIC / AICw)  Model Parameter Estimates 
 Fit 
Summar
y 
Linear Quadratic Plateau  Intercept Slope   R
2 
          
Outer Right 0 / .54 0.8 / .37 3.5 / .10  386 -.065 -  < .01 
          
Quadratic Models 
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summar
y 
Linear Quadratic Plateau 
 
Intercept 
Linear 
Term 
Quadratic 
Term 
 R2 
          
Inner Left 5.5 / .06 0 / .94 -  252 -.534 .004  .05 
          
Inner Right 4.4 / .10 0 / .90 -  274 -.578 .004  .03 
          
Inner Top 16.3 / < .01 0 / .99  -  296 -1.349 .008  .06 
          
Inner Bottom 10.5 / < .01 0 / .974 7.7 / .02  306 -1.138 .006  .04 
          
Outer Left 2.8 / .20 0 / .80 -  350 -.545 .003  .02 
          
Outer Top 7.5 / .02 0 / .88 4.4 / .10  422 -1.507 .008  .05 
          
Outer Bottom 0.6 / .30 0 / .42 0.7 / .28  423 -.919 .004  .05 
          
 
 
 
 
 
 
 
 72 
 
 
Figure 4.5.4: Healthy controls saccade velocity developmental trajectories. Mean saccade velocity (SaccVelo) of 
healthy developing controls (blue dots) during the pro-saccade task. Saccade velocity is presented for each of 
the 8 target locations. 95% CI (dotted black line) are also presented.  
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Anti-saccade Task 
The development of 3 measures was examined during the anti-saccade task: The time 
taken for the participant’s gaze to reach the anti-saccade location (AntiOffset), the proportion 
of pro-saccade errors (AntiErr), and the proportion of corrected errors (AntiCorr).  AIC 
comparisons of the 2-way iteration between Targetlocation and Age revealed that 
development was not uniform across target locations for AntiOffset (test-model (∆AIC / 
AICw) = 0 / .99 ; null-model (∆AIC / AICw) = 46 / <.01), AntiErr (test-model (∆AIC / 
AICw) = 0 / .82 ; null-model (∆AIC / AICw) = 3 / .18)  and AntiCorr (test-model (∆AIC / 
AICw) = 0 / .92 ; null-model (∆AIC / AICw) = 14 / .08). As with the pro-saccade task, five 
models were set up and compared to determine the best model describing the developmental 
trajectories of these measures. AIC comparisons are presented in Table 4.5.8. 
Table 4.5.8: Healthy controls anti-saccade task – AIC condition comparisons 
AntiOffset    
Model ∆AIC AICw Evidence ratio 
    
Separate 0 .999 1 
Amplitude 34 <.001 > 1000 
Hori / Vert 107 <.001 > 1000 
Directions 110 <.001 > 1000 
Combined 136 <.001 > 1000 
    
AntiErr    
Model ∆AIC AICw Evidence ratio 
    
Separate 0 .999 1 
Amplitude 26 <.001 > 1000 
Directions 66 <.001 > 1000 
Combined 85 <.001 > 1000 
Hori / Vert 92 <.001 > 1000 
    
AntiCorr    
Model ∆AIC AICw Evidence ratio 
    
Directions 0 .556 1 
Seperate .976 .341 1.629 
Hori / Vert 3.748 .085 6.513 
Combined 6.962 .017 32.493 
Amplitude 14.373 <.001 1324 
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Based on the ‘Separate’ model, the fit of AntiOffset developmental trajectories to 
linear, quadratic or plateau functions was analysed separately for the 8 target location. 
Results (Table 4.5.9) found that quadratic functions offered the best description of 
development for the 7 of the 8 target locations, while for the outer left target development 
was best described by a plateau function. For all target locations the relative likelihood 
between quadratic or plateau functions was minimal (AIC < 2), with both functions providing 
accurate descriptions of development. Changes in age explained a large proportion of 
AntiOffset variance (R
2 
range = .477 - .622) across target locations. The dominance of 
nonlinear models is further explained by the downward sloping curves that characterise 
AntiOffset development (Figure 4.5.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 75 
 
Table 4.5.9: Healthy controls anti-saccade offset – AIC trajectory comparisons 
Quadratic Models 
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summar
y 
Linear Quadratic Plateau 
 
Intercept 
Linear 
Term 
Quadratic 
Term 
 R2 
          
Inner Left 12.5 / <.01 0 / .59 0.7 / .41  819 -4.729 .014  .62 
          
Inner Right 20.9 / <.01 0 / .52 0.2 / .48  842 -5.592 .019  .62 
          
Inner Bottom 8.2 / .01 0 / .63 1.1 / .37  852 -4.839 .015  .48 
          
Inner Top 11.2 / <.01 0 / .67  1.4 / .33  875 -4.855 .016  .52 
          
Inner Bottom 8.2 / .01 0 / .63 1.1 / .37  852 -4.839 .015  .48 
          
Outer Right 12.2 / <.01 0 / .61 0.9 / .39  881 -4.448 .013  .62 
          
Outer Bottom 8.37 / <.01 0 / .56 0.5 / .43  901 -4.322 .014  .48 
          
Outer Top 8.1 / <.01 0 / .55 0.4 / .44  922 -4.886 .015  .49 
          
Plateau Models 
 AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summar
y 
 Linear Quadratic Plateau  Intercept 
Rate 
Constant 
Plateau  
R
2 
          
Outer Left 11.7 / <.01 0.1 / .49 0 / .51  882 .012 435  .58 
          
Note: Anti-saccade offsets  recorded in milliseconds 
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Figure 4.5.5: Healthy controls anti-saccade offset developmental trajectories. Mean target offset time 
(AntiOffset) of healthy developing controls (blue dots) during the anti-saccade task. Offset time is presented for 
each of the 8 target locations. 95% CI (dotted black line) are also presented.  
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The rate of AntiOffset development decreased as a function of age, whereby 
developmental change occurred among the younger participants (age 6 – 11 years) and little 
to no differences were observed between the performance of the older participants (age 18 – 
19 years). In addition, the rates of development appeared to be more prominent for AntiSacc 
than the developmental rates reported for SaccOnset, where curves were very shallow. This 
suggests that AntiSacc developments reflect improvements in the top-down attentional 
processes involved in response inhibition and the execution of endogenously guided 
saccades. Finally, differences between the model parameters (Table 4.5.9) of the different 
trajectories highlight the need for target-specific developmental trajectories. Similar to 
SaccOnset, there was a trend for the intercepts of AntiSacc to have latencies that were shorter 
for inner vs. outer and horizontal vs. vertical targets. 
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AIC comparison of developmental trajectories (linear, quadratic, or plateau) for the 
proportion of anti-saccade errors (AntiErr) is presented in Table 4.5.10. The analysis is based 
on the ‘Separate’ model (Table 4.5.6) therefore developmental trajectories were created for 
each of the 8 target locations. 
 
Table 4.5.10: Healthy controls anti-saccade error production – AIC trajectory comparisons 
Linear Models 
 
AIC Results (∆AIC / AICw)  Model Parameter Estimates 
 Fit 
Summar
y 
Linear Quadratic Plateau  Intercept Slope   R
2 
          
Inner Bottom 0 / .51 0.1 / .49 -  .892 -.036   .36 
          
Outer Left 0 / .68 1.5 / .32 -  .921 -.045   .49 
          
Outer Bottom 0 / .66 1.3 / .34 -  .912 -.043   .50 
          
Quadratic Models 
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summar
y 
Linear Quadratic Plateau 
 
Intercept 
Linear 
Term 
Quadratic 
Term 
 R2 
          
Inner Left 3.4 / .16 0 / .84 -  .876 .002 -.003  .36 
          
Inner Right 8.1 / .02 0 / .98 -  .914 .013 -.003  .38 
          
Inner Top 4.6 / .09 0 / .91 -  .888 .008 -.003  .31 
          
Outer Right 1.4 / .33 0 / .67 -  .892 -.015 -.002  .48 
          
Outer Top 6.2 / .04 0 / .96 -  .883 .002 -.003  .46 
          
          
 
Three target locations (inner bottom, outer left and outer bottom) were best defined by 
a linear function and five target locations (inner left, inner right, inner top, outer right and 
outer top) were best defined by a quadratic function. A quadratic function always provides a 
pretty good fit, but a linear function does not. The fitting of plateau functions failed for all 
target locations since obtaining accurate model parameters (constant rate and plateau) was not 
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possible. All developmental trajectories revealed that changes in age explained a relatively 
large proportion of variance in AntiErr (R
2 
> .30). For 4 target locations (inner left, inner 
right, inner top and outer top) the relative likelihood of a quadratic developmental function 
(compared to linear functions) was substantial (∆AIC > 3). While the relative likelihood of 
linear and quadratic functions for the remaining 4 target locations were essentially equivalent 
(∆AIC < 2). The developmental curves presented in Figure 4.5.6 further explain the 
differences in model likelihood. For the target locations where a quadratic developmental 
trajectory was more likely, little change in performance occurred during the early years of 
development (6 – 9 years). For the target locations where linear and quadratic developmental 
trajectories were equivalent, changes in performance occurred earlier on in development.  
An important observation for AntiErr development was the high proportion of errors 
that the younger children produced. Model intercepts indicated that at the youngest age 
children produced at least 87% anti-saccade errors (close to ceiling). In addition, Figure 4.5.6 
shows that developmental change does not occur until approximately 10 years of age for 
many target locations. Furthermore Figure 4.5.6 shows an increase in between-participant 
variance (as expressed by the widening confidence limits) as a function of age. Here 
between-participant variance is considerable for the eldest year groups (18 – 19 years). 
Together, these observations indicated that the difficulty of the task was too high. Young 
healthy controls were too close to ceiling and the variance in older healthy controls was too 
large. This means mild impairments of saccade inhibition that could be expressed by patients 
would likely be masked. Therefore AntiErr was not used in the subsequent analysis of patient 
data in later chapters. 
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Figure 4.5.6: Healthy controls anti-saccade inhibition developmental trajectories. Proportion of anti-saccade 
errors (AntiErr) of healthy developing controls (blue dots) during the anti-saccade task. Corrected errors are 
presented for each of the 8 target locations. 95% CI (dotted black line) are also presented.  
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AIC comparison of developmental trajectories (linear, quadratic, or plateau) for the 
proportion of corrected errors (AntiCorr) is presented in Table 4.5.11. The analysis is based 
on the ‘Direction’ model (Table 4.5.6) therefore 4 developmental trajectories were created 
based on average AntiCorr performance across target directions (left, right, top and bottom).  
 
Table 4.5.11: Healthy controls anti-saccade error correction– AIC trajectory comparisons 
Plateau Models 
 AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summar
y 
 Linear Quadratic Plateau  Intercept 
Rate 
Constant 
Plateau  
R
2 
          
Left 4.9 / .06 1.8 / .27 0 / .68  .783 .341 .963  .15 
          
Right 81.1 / <.01 17.5 / <.01 0 / .99  .697 .515 .957  .27 
          
Top 26.6 / <.01 6.2 / .04 0 / .96  .733 .555 .967  .27 
          
Bottom 5.8 / .03 .95 / .37 0 / .60  .687 .233 .961  .23 
          
          
 
 Developmental trajectories of all target directions were best described a plateau model 
(∆AIC = 0) with age explaining at least 15% of variance in AntiCorr for the 4 trajectories. 
The relative likelihood of a plateau model was substantial for the right (AICw = .999) and top 
(AICw = .957) target directions. Quadratic model was offered reasonable good fits to targets 
positioned in the left (AICw = .267) and bottom directions (AICw = .370). Linear models 
produced poor fits for all 4 target directions. The preference of nonlinear models is further 
clarified by the upward sloping curves presented in Figure 4.5.7.  The rate of development is 
substantial during early years (6 – 8 years) and eventually lessens to a halt at approximately 
11 years of age. This is due to the majority of older participants obtaining ceiling scores 
(100% of errors corrected) and explains why development is described accurately by plateau 
models. Interestingly, the spread of variance between participants (expressed by the 
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confidence intervals) indicates that performance is highly variable (between 0 – 100%) for 
the youngest children and narrows as age increases. 
 
 
 
Figure 4.5.7: Healthy controls anti-saccade error correction developmental  trajectories. Proportion of corrected 
errors (AntiCorr) of healthy developing controls (blue dots) during the anti-saccade task. Most likely (∆AIC = 0) 
developmental trajectories are shown as red lines. Corrected errors are presented the performance averaged 
across the 4 target directions. 95% CI (dotted black line) are also presented.  
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Smooth Pursuit Task 
Smooth pursuit development of healthy controls was inspected based on 3 movement 
trajectories (horizontal, vertical, elliptical), which travelled at 2 different velocities (16 °/s 
and 6.5 °/s). Two measures were examined: the velocity gain of pursuit (VeloGain) and the 
frequency of forward saccades per second during pursuit (ForwSacc). First, AIC comparisons 
were conducted to test the 2-way interaction between Conditon and Age for VeloGain and 
ForwSacc. A model which included an interaction term was better than a model that did not 
for both VeloGain (test-model ∆AIC = 0; AICw = .99; null-model ∆AIC = 621; AICw < .01) 
and ForwSacc (test-model ∆AIC = 0; AICw = .99; null-model ∆AIC = 306; AICw < .01). To 
answer which pursuit conditions produced different developmental trajectories four models 
were defined and compared: A 1-term model with a single trajectory for all 6 pursuit 
conditions (‘Combined’ model), a 2-term model with separate trajectories for fast and slow 
target velocities (‘Velocity’ model), a 3-term model with separate trajectories for the 3 
pursuit patterns (‘Hori / Vert / Elip’ model), and a 6-term model with a trajectory for each of 
the 6 pursuit conditions (‘Separate’ model). AIC comparisons are presented in Table 4.5.12. 
Table 4.5.12: Healthy controls smooth pursuit task– AIC condition comparisons 
VeloGain    
Model ∆AIC AICw Evidence ratio 
    
Separate 0 .999 1 
Hori / Vert / Elip 416 <.001 > 1000 
Velocity 633 <.001 > 1000 
Combined 637 <.001 > 1000 
    
ForwSacc    
Model ∆AIC AICw Evidence ratio 
    
Separate 0 .999 1 
Velocity 214 <.001 > 1000 
Hori / Vert / Elip 301 <.001 > 1000 
Combined 307 <.001 > 1000 
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Inspection of the AIC of developmental trajectories (linear, quadratic, or plateau) for 
the velocity gain (VeloGain) is presented in Table 4.5.13. The analysis was based on the 
‘Separate’ model (Table 4.5.12) so 6 developmental trajectories are compared. Due to the 
scale of VeloGain (ratio of eye-target velocity), age is expressed in years (instead of months) 
in order to produce meaningful model parameters. 
 
Table 4.5.13: Healthy controls velocity gain– AIC trajectory comparisons 
Linear Models 
 
AIC Results (∆AIC / AICw)  Model Parameter Estimates 
 Fit 
Summar
y 
Linear Quadratic Plateau  Intercept Slope   R
2 
          
Slow Hori 0 / .54 1.7 / .23 1.7 / .23  .753 .011   .24 
          
Slow Vert 0 / .67 1.4 / .33 -  .844 .008   .12 
          
Fast Hori 0 / .43 0.9 / .27 0.7 / .30  .725 .010   .22 
          
Fast Elip 0 / .62 1.0 / .38 -  .692 .013   .38 
          
Quadratic Models 
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summar
y 
Linear Quadratic Plateau 
 
Intercept 
Linear 
Term 
Quadratic 
Term 
 R2 
          
Slow Elip 2.1 / .25 0 / .75 -  .585 .002 .0003  .34 
          
Fast Vert 4.2 / .11 0 / .89 -  .670 .001 .0004  .42 
          
 
Development of VeloGain for four conditions (slow hori, slow vert, fast hori and fast 
elip) was best defined (∆AIC = 0) by linear functions, and two conditions (slow elip and fast 
vert) were best defined by quadratic functions. Age explained over 20% of the observed 
variance in VeloGain for all pursuit conditions except ‘slow vert’. For the 4 pursuit 
conditions best defined by linear functions (slow hori, slow vert, fast hori and fast elip), the 
relative likelihood of a quadratic function was nearly equivalent (∆AIC < 2). While the 
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development of two pursuit conditions (slow elip and fast vert) was considerably more likely 
to have a quadratic function (∆AIC > 2). These different function preferences were further 
explained by the developmental slopes shown in Figure 4.5.8. For the 2 conditions fitted with 
quadratic functions (fast vert and slow elip) the change in performance among younger 
participants (6 – 10 years) was minimal; it was only at older ages that age-related changes 
occurred, which explained the preference for quadratic models in these cases. In contrast, the 
change in performance across the age range for the 4 remaining conditions (slow hori, fast 
hori, slow vert and fast elip) occurred linearly. 
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Figure 4.5.8: Healthy controls smooth pursuit velocity gain developmental trajectories. Mean velocity gain 
(VeloGain) of healthy developing controls (blue dots) during the smooth pursuit task. Most likely (∆AIC = 0) 
developmental trajectories are shown as red lines. Velocity gain is presented for each of the 8 target locations. 
95% CI (dotted black line) are also presented.  
Finally, the model parameters (Table 4.5.13) and developmental curves (Figure 4.5.8) 
for each VeloGain trajectory demonstrate the necessity for condition-specific developmental 
trajectories. There was a large difference between the VeloGain intercepts of fast and slow 
velocities for vertical (slow = .844 ; fast =  .670) and elliptical conditions (slow = .585 ; fast =  
.692). In contrast, the difference between the velocities of the horizontal condition was  
minimal (slow = .753 ; fast =  .725). Interestingly, for vertical conditions VeloGain was 
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greater for slow velocities, while for elliptical conditions VeloGain was greater for fast 
velocities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inspection of the AIC of developmental trajectories (linear, quadratic, or plateau) for 
the frequency of forward saccades per second (ForwSacc) is presented in Table 4.5.14. The 
analysis is based on the ‘Separate’ model (Table 4.5.12) so 6 developmental trajectories are 
compared. Due to the scale of ForwSacc (range: 0 – 5), age is expressed in years (rather than 
months) for the definition of model parameters. 
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Table 4.5.14: Healthy controls forward saccade frequency– AIC trajectory comparisons 
Linear Models 
 
AIC Results (∆AIC / AICw)  Model Parameter Estimates 
 Fit 
Summar
y 
Linear Quadratic Plateau  Intercept Slope   R
2 
          
Slow Hori 0 / .69 1.6 / .32 -   1.62 -.017   .01 
          
Fast Hori 0 / .63 1.0 / .37 -  2.63 -.059   .19 
          
Fast Vert 0 / .51 2.0 / .19 1.0 / .30  2.14 -.005   <.01 
          
Quadratic Models 
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summar
y 
Linear Quadratic Plateau 
 
Intercept 
Linear 
Term 
Quadratic 
Term 
 R2 
          
Fast Elip 3.4 / .15 0 / .85 -  2.09 -.010 .0003  <.01 
          
Plateau Models 
 AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summar
y 
 Linear Quadratic Plateau  Intercept 
Rate 
Constant 
Plateau  
R
2 
          
Slow Vert 1.2 / .28 1.8 / .21 0 / .51  2.07 1.074 1.766  .03 
          
Slow Elip 6.7 / .02 .82 / .39 0 / .59  1.98 .799 1.591  .05 
          
 
 
Forward saccade development of three pursuit conditions (slow hori, fast hori and fast 
vert) was best described by linear functions, 2 conditions (slow vert and slow elip) were 
described best by plateau functions, and 1 condition (fast elip) was described best by a 
quadratic function. For 5 pursuit conditions, changes in age only explained a small proportion 
of ForwSacc variance (R
2 
< .051). This suggests that little to no developmental change occurs 
within the age range of the sample for these conditions. For the remaining pursuit condition 
(fast hori), age explained 18% of the observed ForwSacc variance.The developmental slopes 
(Figure 4.5.9) further clarify these findings. ForwSacc performance on all (expect fast hori) 
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conditions remains relatively unchanged across of the different age groups. For the ‘fast hori’ 
condition younger participants (6 years) produce a larger number of saccades (2.633 saccades 
per second) in comparison to the other conditions, while the performance of older participants 
(19 years) is similar across conditions. 
 
 
 
Figure 4.5.9: Healthy controls smooth pursuit forward saccade developmental trajectories. Mean frequency of 
forward saccades (ForwSacc) of healthy developing controls (blue dots) during the smooth pursuit task. 
Forward saccades are presented for each of the 6 target locations. 95% CI (dotted black line) are also presented.  
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4.6 Chapter Conclusions 
In the current chapter a large sample of healthy developing participants were tested on 
measures of attention, language, and oculomotor function to define trajectories of normal 
cognitive development. To achieve this, AIC comparisons were conducted to identify the 
most likely descriptions of developmental change and to inspect the influence of 
experimental conditions. This is important as the following chapters of the thesis concern the 
comparison of rare metabolic patients to trajectories of healthy cognitive development. So 
having accurate representations of cognitive development is critical. 
 Attention was assessed using a simple reaction time and visual search task. Both tasks 
demonstrated clear developmental change with older participants producing faster response 
times on both tasks. For visual search, development trajectories were steeper and set-size 
effects were more prominent for conjunction in comparison to feature search. These findings 
are congruent with previous visual search research (Hommel et al., 2004b; Plude et al., 1994; 
Ruskin & Kaye, 1990; Trick & Enns, 1998), and is believed to reflect developmental 
differences between top-down attention (serial search – conjunction search) and bottom-up 
(parallel search – feature search) attentional processes (Duncan & Humphreys, 1989; 
Treisman & Gelade, 1980). In addition, on both task types it was found that developmental 
effects were greater for overall search time than for the efficiency of search. This suggests 
that the majority of developmental change was a reflection of improvements in processes 
related to decision time and response preparation. Developmental trajectories from both tasks 
will be used to identify attention deficits in metabolic patients. 
Three tasks were used to assess children’s language function: the British Picture 
Vocabulary Scale (BPVS; Dunn et al., 1997), the Boston Naming Task (BNT; Kaplan, 2000) 
and a novel non-word repetition task. The BPVS and BNT are standardised measures of 
receptive and productive vocabulary (respectively), and are commonly used to evaluate the 
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vocabulary proficiency of children. Unsurprisingly, developmental trajectories for these tasks 
were shown to be highly sensitive to changes in age. The non-word repetition task was a 
novel task designed to assess participants non-word learning proficiency in a supported 
learning context (Carey, 1978). The analysis revealed that older participants were able to 
recognise and produce more non-words than younger participants over the course of the 
learning phase. Developmental trajectories for receptive (BPVS) and productive (BNT) 
vocabulary, and non-word learning task will be used to identify language deficits in 
metabolic patients. 
The oculomotor function of healthy developing controls was inspected using 4 tasks: 
a fixation task, pro-saccade task, anti-saccade task, and smooth pursuit task. For the fixation 
task, developmental change occurred rapidly between 6 – 10 years of age with development 
plateauing thereafter. This corresponded to an increase in total fixation time (FixDwell) and 
decrease in frequency of saccadic intrusions (FixSacc). Reflexive saccades, as measured by 
the pro-saccade task, revealed a decrease in initiation latency (SaccOnset) but no change in 
saccade velocity (SaccVelo) as a function of age. However despite the lack of developmental 
change found in saccade velocity, this measure will still be included in the following patient 
analysis due to saccadic velocity being affected in several neurodegenerative disorders (e.g. 
Niemann-Pick type C, Gaucher’s Disease). For the anti-saccade task, participants 
demonstrated improved reflexive saccade suppression (AntiErr), improved self-error 
correction (AntiCorr), and decrease in anti-saccade target location latency (AntiOffset) as a 
function of age. However for the suppression of reflexive saccades, ceiling effects were 
present among younger participants (6 – 11 years) and the between-participant variance was 
substantial for older participants. This suggested that the difficulty of saccade suppression in 
the current paradigm was too high, which could be due to the requirement placed on 
participants to generate anti-saccades to a position based not only on direction but also 
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amplitude (inner / outer). Consequently, the difficulty of the anti-saccade task means the 
analysis of reflexive saccade suppression was removed from the patient analysis. Finally, for 
the smooth pursuit task healthy developing participants demonstrated reliable age related 
improvements for velocity gain (VeloGain). In contrast, the frequency of catch-up saccades 
(ForwSacc) was only sensitive to the pursuit condition where the target travelled vertically at 
a fast velocity. 
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5.0 LYSOSOMAL STORAGE DISORDERS 
In this section of the thesis I will detail findings from three patient groups that are 
diagnosed with lysosomal storage disorders: Morquio syndrome (MPS-IVa), Hurler-Scheie 
syndrome (MPS-IH) and Maroteaux-Lamy syndrome (MPS-VI). In accordance with findings 
from previous research (refer to Chapter 2), each of these disorders has been shown to 
possess very different neuropsychological profiles. Intellectual functioning in Hurler-Scheie 
patients deteriorates as a function of disease progression (Elkin et al., 2006), Morquio 
patients can display mild cognitive deficits in working memory and full-scale IQ (Davison et 
al., 2012) while Maroteaux patients are believed to possess a normal cognitive profile 
(Neufeld & Muenzer, 2001; J Ed Wraith, 2006). While previous work typically relies on 
scores from standardised test batteries, I will report more detailed cognitive testing of visual 
attention, non-word learning, and oculomotor function.  
The method for comparing patients to the healthy developmental trajectories defined 
in Chapter 4 will first be described. In general this includes the description of individual 
patient z-scores in comparison to healthy developing trajectories and the AIC comparison of 
patient and control developmental trajectories. Findings for each patient group will be 
presented separately with performance on each cognitive domain reported in turn. The 
current chapter intends to address two critical questions: first, is it possible to identify 
cognitive deficits in individual patients (z-scores) and, second, what is the likelihood (AIC 
comparison) that the development of these disorders differs to controls? 
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5.1 Data Analysis – Patient comparisons 
Comparing individual patients to healthy controls 
The performance of individual patients is expressed as z-scores. Each patient z-score 
is obtained through the comparison of the patient’s performance to the healthy developmental 
trajectories defined in the previous chapter. This was accomplished by first acquiring 
residuals (𝑌𝑟𝑒𝑠𝑖𝑑) for patients that were based on the comparison of patient performance (𝑌) to 
performance predictions (𝑌𝑝𝑟𝑒𝑑) acquired from healthy developing trajectories (Figure 5.1.1). 
Equation 1 below was used to calculate residuals where task improvements occurred in a 
positive direction (i.e. improvements were associated with higher raw scores). Equation 2 
was used to calculate residuals where task improvements were related to changes in a 
negative direction (i.e. improvements were associated with lower raw scores). This was to 
ensure that negative residual values always reflected patient performances that were below 
the predicted level across measures. 
 
Figure 5.1.1: Patient residual calculations. Two fictitious patient scores (green points) for mean response time 
during the simple reaction time task. Panel A shows the raw scores (Y) of the two patients and their scores 
predicted (Ypred) from the healthy developing trajectory (red line). Panel B presents the residuals (Yresid; 
vertical black dashed-line) of the two patients that are computed from the Y and Ypred values. While both 
patients possess equal Y values (500ms), the Yresid values differ with the older patient having a larger Yresid.  
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1) 𝑌𝑟𝑒𝑠𝑖𝑑 = 𝑌 − 𝑌𝑝𝑟𝑒𝑑   
 
2) 𝑌𝑟𝑒𝑠𝑖𝑑 = 𝑌𝑝𝑟𝑒𝑑 −  𝑌   
 
Residuals were transformed into z-scores to identify where patients fell within the healthy 
developing distribution for their age. This process first required a variance calculation (𝑌𝑆𝐷; 
Equation 3) that represented the relative estimated variance for the healthy sample at  the 
patient’s age. Using this 𝑌𝑆𝐷value it was then possible to calculate a patient’s z-score (𝑌𝑍; 
Equation 4).  
 
3) 𝑌𝑆𝐷 =
𝑌𝑝𝑟𝑒𝑑− 𝑌𝐶𝐼
1.96
 
 
4) 𝑌𝑍 =
𝑌𝑟𝑒𝑠𝑖𝑑
𝑌𝑆𝐷
 
 
A z-score of greater than ±1 means the patient is in a range that includes 84% of the control 
population. While a score of -1 means that the patient is worse than 84% of the control 
population, and a value of less than -2 means they are worse than 97.5% of the control 
population. 
 
The above process can be illustrated using the example shown in Figure 5.1.1. Here 
two patients of differing ages (120 and 180 months) produce mean reaction times of 500ms 
(Y) during the simple reaction time task. While the reaction times are the same, the predicted 
values (Ypred) are not. Leading to a greater negative residual for the older patient (𝑌𝑟𝑒𝑠𝑖𝑑 =
𝑌𝑝𝑟𝑒𝑑 −  𝑌  = 300 – 500 = -200) than the younger patient (𝑌𝑟𝑒𝑠𝑖𝑑 = 𝑌𝑝𝑟𝑒𝑑 −  𝑌  = 400 – 500 = 
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-100). Z-scores are then calculated to determine whether either patient fell outside the range 
of the healthy controls. The younger patient obtained a z-value of -1.307 (YZ =  
𝑌𝑟𝑒𝑠𝑖𝑑
(𝑌𝐶𝐼− 𝑌𝑝𝑟𝑒𝑑) 1.96⁄
  =   
−100
(550−400) 1.96⁄
  = -1.307) that indicated their performance to be in the 
predicted lower average range of healthy developing controls. In contrast, the older patient 
produced a z-value of -3.920 (YZ =  
𝑌𝑟𝑒𝑠𝑖𝑑
(𝑌𝐶𝐼− 𝑌𝑝𝑟𝑒𝑑) 1.96⁄
  =   
−200
(400−300) 1.96⁄
  = -3.920) that showed 
their performance to be clearly below the predicted range of healthy controls. 
 
Comparing groups of patients to healthy developing controls 
 Model selection with AIC was used to determine the best way of describing 
differences in development between patients and healthy controls. We used an arbitrary 
cutoff (N > 8) to define when we were willing to start looking at developmental differences 
beyond the scores of individual patients, since the number of data points required to represent 
a group trajectory cannot be too small. The model selection utilised the same non-linear 
mixed effects methodology used for describing the condition-specific trajectories of healthy 
controls that was outlined in Chapter 4. To account for differences between patients and 
controls, an additional factor representing Group was included in the analysis of main effects 
and interactions. Confidence limits of patient development are defined by prediction bands. 
This is because the method used to define confidence limits for healthy controls requires a 
substantial number of participants. 
 
 
 
 
 97 
 
5.2 5.2 Morquio Syndrome (MPS-IVa) 
 Morquio Syndrome (MPS-IVa) is a lysosomal disorder that is not typically linked to 
cognitive deficits. However, recent findings (Davison et al., 2012) have highlighted the 
possible presence of mild cognitive deficits in MPS-IVa. The authors argued that these 
deficits are due to the role of keratan sulphate and chondroitin-6-sulfate in the coordination of 
neuroaxonal connection formation during foetal and neonatal brain development (Miller et 
al., 1997).  
 It is predicted that MPS-IVa patients will demonstrate the same mild cognitive 
deficits for language comprehension that were described by Davison et al. (2012). In the 
same study, parents reported (via a behaviour checklist) that patients demonstrated 
difficulties with attention / concentration. Hence, it is expected that this observation may 
translate to deficits on tasks that contain attentional components (simple reaction time, visual 
search, and fixation tasks). This prediction is further supported by MRI findings (Davison et 
al., 2012) of frontal abnormalities in the form of enlarged CSF spaces and white matter signal 
abnormalities. Hence, frontal areas involved in visual search (FEF, orbitofrontal cortex, 
anterior cingulate) and sustained attention (DLPFC) may be affected. 
Patients 
Thirteen patients diagnosed with Morquio syndrome (8 male, 5 female; mean age: 
9.59 years, range: 5.27 – 14.39 years) were recruited by a research nurse at the Birmingham 
Children’s Hospital (demographics in Table 5.2.1). All patients were considered to have a 
severe phenotype of the disease; however, no patients had a presentation of corneal clouding.  
Patients completed the assessments over the course of one month during weekly hospital 
visits for enzyme replacement therapy. All assessments were conducted at the Wellcome 
Trust Clinical Research Facility at the Birmingham Children’s Hospital. Consent for all 
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children was obtained from the children’s parents prior to testing. One patient was removed 
from the analysis due to having a diagnosis of severe autism. 
 
Table 5.2.1: MPS-IVa summary of patient demographics 
PID Gender CA (Years) BPVS MA 
(Years) 
Linguistic Profile 
1 M 5.27 4.02 BL – English / Pashto 
2 F 6.44 5.00 BL – English / Pashto 
3 F 6.48 5.07 BL – Pashto / English 
4 M 7.77 8.02 BL – English / Pashto 
5 F 9.33 8.07 BL – Pashto / English 
6 F 9.79 10.08 ML – English 
7 M 9.84 7.07 BL – Manderin / English 
8 M 10.28 7.06 BL – Pashto / English 
9 M 11.71 15.10 ML - English 
10 M 11.78 7.10 ML - English 
11 F 12.05 11.04 BL – English / Pashto  
12 M 14.39 11.03 BL – English / Pashto 
Note: ML, Monolingual, BL, Bilingual 
 
Table 5.2.2 provides a summary of the measures where deficits were observed in the 
Morquio patients (MPS-IVa). Possible (*) and consistent deficits (**) were assigned to 
measures where a few or the majority of patients exhibited difficulties respectively. As 
predicted, patients displayed deficits on measures that contained attentional elements: simple 
reaction time task, visual search task, fixation task, and anti-saccade task. The performance of 
Morquio patients did not differ to healthy controls on several oculomotor tasks (pro-saccade 
task and smooth pursuit) or language tasks (BNT, non-word task). 
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Table 5.2.2: MPS-IVa summary of cognitive impairments across domains 
Domain Task  Measures 
Attention 
Simple RT Task * RTmean 
Visual Search Task ** VSmean 
    
Language 
BNT -  
BPVS *  
Non-Word Task -  
    
Ocular Motor 
Fixation Task ** FixDwell, FixCount 
Prosaccade Task -  
Antisaccade Task * AntiCorr 
Smooth Pursuit -  
    
Note: RTmean, Mean Reaction Time;  VSmean, Mean Visual Search Time; FixDwell, Fixation Duration Time; 
FixCount, Fixation Count; AntiCorr; Frequency of Error Correction; Forward Saccade Frequency 
*  Possible deficit, ** Consistent deficits 
 
 
 
5.2.1 Attention 
Attention task results were examined on an individual and group basis. No 
modifications were made to the test protocol in order for the patients to complete the 
assessment. MPS-IVa patients presented clear deficits on the visual search task and a possible 
deficit on the simple reaction time task for mean response time (RTmean) only.  
Simple Reaction Time Task 
Mean response time (RTmean) of MPS-IVa patients during the simple reaction time 
task is displayed in Figure 5.2.1. Individual paient responses that were greater than 3 SDs 
away from individual patient means were defined as outlier and removed. RTmean was 
normal (i.e. within the confidence limits of healthy development (dashed-black line)) for the 
majority of patients on all target locations. However, a trend existed where the RTmean of the 
group was shifted upward towards the lower average range of normal. 
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Figure 5.2.1: MPS-IVa simple reaction time indidual patient performance. Mean simple reaction time (RTmean) 
of MPS-IVa patients (green dots) and healthy developing controls (blue dots) in comparison to a healthy 
developmental trajectory (red line). The healthy control developmental trajectory is expressed as a quadratic 
function with 95% CI (dashed black line).  
 
 For specific target locations (Table 5.2.3), the frequency of patients producing 
extreme low response times (z-score > 2) was as follows: bottom-left (3/12 patients), bottom-
right (0/12 patients), top-left (1/12 patients), top-right (2/12 patients). When performance was 
averaged across target locations, no patients exhibited extreme low response times (z-score > 
2). 
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Table 5.2.3: MPS-IVa z-scores for simple reaction time (RTmean) 
PID Age 
(Years) 
Bottom Left Bottom Right Top Left Top Right Avg 
1 5.27 645  (-0.29) 1005  (-1.91) * 735  (-1.16) * 656  (0.14) 766  (-0.76) 
2 6.44 823  (-2.96) ** 573  (0.05) 717  (-1.86) 554  (0.21) 667  (-0.84) 
3 6.48 687  (-1.57) * 470  (0.88) 491  (0.48) 824  (-2.03) ** 618  (-0.43) 
4 7.77 509  (-0.41) 444  (0.57) 535  (-0.71) 508  (-0.13) 499  (-0.06) 
5 9.33 452  (-0.48) 455  (-0.42) 504  (-1.13) * 434  (-0.11) 461  (-0.45) 
6 9.79 305  (1.39) 307  (1.62) 303  (1.43) 323  (1.36) 309  (1.45) 
7 9.84 349  (0.73) 418  (-0.15) 406  (-0.08) 509  (-1.58) * 421  (-0.16) 
8 10.28 535  (-2.02) ** 465  (-1.16) 426  (-0.53) 562  (-2.75) ** 499  (-1.47) * 
9 11.71 415  (-0.90) 365  (-0.12) 432  (-1.16) * 389  (-0.55) 400  (-0.66) 
10 11.78 508  (-2.35) ** 411  (-0.98) 506  (-2.32) ** 382  (-0.46) 449  (-1.48) * 
11 12.05 445  (-1.48) * 425  (-1.36) 427  (-1.21) * 433  (-1.51) * 433  (-1.33) * 
12 14.39 312  (0.09) 381  (-1.26) 316  (0.02) 355  (-0.75) 342  (-0.51) 
Note: Reponses recorded in milliseconds, z-scores in parentheses 
* zscore > 1, ** zscore > 2 
 
To determine if the rate of development for simple response speed differed between 
MPS-IVa patients and controls, an AIC comparison was conducted to test the 2-way 
interaction between Group and Age. Here a model which included an interaction term (∆AIC 
= 0 ; AICw = .75) was slightly better than a model that did not (∆AIC = 2.2 ; AICw = .25). 
Thus, the overall rate of development of MPS-IVa patients and controls differed. Also, no 
specific target location influenced response time development differently between groups. 
This was shown in the lack of a 3-way interaction between Group, TargetLocation and Age 
(test-model (∆AIC / AICw) = 5.2 / .07 ; null-model (∆AIC / AICw) = 0 / .93). Finally, 
evidence for a main effect of Group (test-model (∆AIC / AICw) = 14 / <.01 ; null-model 
(∆AIC / AICw) = 0 / .99) and a 2-way interaction of Group and TargetLocation (test-model 
(∆AIC / AICw) = 2.7 / .21 ; null-model (∆AIC / AICw) = 0 / .79) was weak. Therefore, the 
response time of patients was not offset from the response time of controls. The 
developmental slopes of MPS-IVa patients and controls (Figure 5.2.2) elucidate the above 
findings. Here, the shape of the MPS-IVa developmental trajectory differed to controls. This 
is because MPS-IVa development was best defined by a plateau function (∆AIC = 0; AICw = 
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.796; Y = (766 – 366)*exp(-.032 * X) + 366), when compared to linear (∆AIC = 10.224; 
AICw = .005) and quadratic functions (∆AIC = 2.824; AICw = .195), whereas the 
development of controls was best defined by a quadratic function. Based on these function 
differences, it is possible that at later ages (170 months and above) the response time latency 
of MPS-IVa patients will diverge from healthy development, becoming slower as a 
consequence. However, this observation should be interpreted with caution due to the small 
number of patient data points used to construct the patient trajectory 
 
Figure 5.2.2: MPS-IVa simple reaction time developmental trajectories. Mean simple reaction time (RTmean) 
developmental trajectories of Morquio patients (blue line) and healthy developing controls (red line). Morquio 
patient raw scores presented as green dots. Reaction time is collapsed across target locations. The healthy 
developmental trajectory is expressed as a quadratic function with 95% CI (dashed black line) and Morquio 
developmental trajectory is expressed as a plateau function with 95% prediction bands (dotted black line).  
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Visual Search Task 
 Overall search time (VSmean) and search efficiency (VSslope; the search time 
required for each additional display item) of MPS-IVa patients on the visual search task is 
presented in Figure 5.2.3. Mean search time (VSmean) of patients was shifted towards the 
lower average range of healthy development for both feature and conjunction search.  
 
 
 
Figure 5.2.3: MPS-IVa visual search individual patient performance. Mean search time (VSmean) and search 
efficiency (VSslope) of MPS-IVa patients (green dots) and healthy developing controls (blue dots). 
Developmental trajectory of controls expressed as quadratic functions (red line) with 95% CI (dashed black 
line).  
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Table 5.2.4 displays the z-scores of individual MPS-IVa patients on the visual search 
task. For conjunction search, the efficiency of search (VSslope) of patient 8 (10.28 years : z-
score = -2.57) and patient 11 (12.05 years : z-score = -3.55) was lower than controls. As a 
result, these patients also possessed slower mean conjunction search times (VSmean) than 
controls. Interestingly, the feature search efficiency of three patients was higher than controls. 
This included patient 1 (5.27 years : z-score = -2.46), patient 8 (10.28 years : z-score = -5.99) 
and patient 11 (12.05 years : z-score = -11.25). For the latter 2 patients (patient 8 and 11) 
feature search efficiency was drastically higher than controls, therefore, it is possible that 
parallel search mechanisms are not functioning correctly in these patients. Their conjunction 
search results may be a consequence of the effects on more basic search mechanisms. 
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Table 5.2.4: MPS-IVa z-scores for mean visual search times (VSmean)  
PID 
Age 
(Years) 
Task VSmean VSslope 
1 5.27 
FS 1868  (-3.95) ** 71  (-2.46) ** 
CS 2742  (-1.37) * 88  (-0.46) 
     
2 6.44 
FS 1505  (-2.76) ** 0  (0.20) 
CS 2336  (-1.00) * 87  (-0.48) 
     
3 6.48 
FS 1131  (-0.39) 8  (-0.21) 
CS 2257  (-0.80) 99  (-0.70) 
     
4 7.77 
FS 934  (0.22) -5  (0.52) 
CS 1352  (1.32) 32  (0.59) 
     
5 9.33 
FS 959  (-0.83) 15  (-1.09) * 
CS 1860  (-1.16) * 57  (0.09) 
     
6 9.79 
FS 1109  (-2.34) ** 2  (0.00) 
CS 1525  (-0.17) 83  (-0.54) 
     
7 9.84 
FS 850  (-0.22) 7  (-0.51) 
CS 1451  (0.09) 42  (0.45) 
     
8 10.28 
FS 1134  (-2.89) ** 63  (-5.99) ** 
CS 2290  (-3.38) ** 160  (-2.57) ** 
     
9 11.71 
FS 950  (-2.15) ** -20  (2.39) ** 
CS 1385  (-0.50) 29  (0.89) 
     
10 11.78 
FS 797  (-0.74) -2  (0.39) 
CS 1650  (-1.70) * 22  (1.09) 
     
11 12.05 
FS 2051  (-12.92) ** 98  (-11.25) ** 
CS 2685  (-6.53) ** 173  (-3.55) ** 
     
12 14.39 
FS 723  (-1.26) * 10  (-1.21) * 
CS 1519  (-2.58) ** 41  (0.51) 
Note:  FS: Feature Search, CS: Conjunction Search, reponses recorded in 
milliseconds, z-scores in parentheses 
* z-score > 1, ** z-score > 2 
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Differences in visual search development between patients and healthy controls on 
feature and conjunction search were analysed separately. Patient 11 (12.05 years) was 
omitted from the trajectory analysis for having mean search times that were identified 
(Cook’s distance) as clear outliers among MPS-IVa patients. For feature search, differences 
in search efficiency (VSslope) development were checked by examining the 3-way interaction 
for Group, Setsize and Age. A model that included an interaction term (∆AIC = 1.7 ; AICw = 
.299)  was worse than a model without an interaction term (AICw = .700). Therefore, the rate 
of feature search efficiency development of patients and healthy controls did not differ. In 
addition, there was a lack of a 2-way interaction model for Group and Setsize (test-model 
∆AIC = 0.1 ; AICw = .487 ; null model ∆AIC = 0 ; AICw = .711). This means that the feature 
search efficiency of patients and controls (regardless of age) were also the same. However, a 
2-way interaction for Group and Age indicated that the rate of feature search time (VSmean) 
development differed between groups (test-model (∆AIC / AICw) = 0 / .953 ; null-model 
(∆AIC / AICw) = 9.1 / .047). Finally, a main effect for Group (test-model (∆AIC / AICw) = 0 
/ .999 ; null-model (∆AIC / AICw) = 19.1 / .001)  was found, indicating that feature search 
times, and the development of feature search times, were different between MPS-IVa patients 
and controls. Together, these results show that Morquio patients were slower overall but did 
not have a stronger effect of set size. This suggests that the difference between Morquio 
patients and controls is not due to mechanisms involved in processing search items 
sequentially, but instead, differences are likely to be due to factors that are constant across 
set-sizes, such as decision time. 
The rate of conjunction search efficiency (VSslope) development did not differ 
between patients and controls. This was shown in the lack of a 3-way iteration for Group, 
Setsize and Age (test-model (∆AIC / AICw) = 1.2 / .279 ; null-model (∆AIC / AICw) = 0 / 
.721). In addition, the lack of a 2-way interaction for Group and Setsize (test-model (∆AIC / 
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AICw) = 1.8 / .289 ; null-model (∆AIC / AICw) = 0 / .711) indicated that the overall 
conjunction search efficiency of patients and controls did not differ. Finally, the mean 
conjunction search time (VSmean) of patients and controls did differ. This was demonstrated 
by a clear main effect for Group (test-model (∆AIC / AICw) = 0 / .973 ; null-model (∆AIC / 
AICw) = 7.2 / .026). However, the rate in which mean conjunction search time developed did 
not differ between groups (Group x Age = interaction-model (∆AIC / AICw) = .1 / .487 ; 
null-model (∆AIC / AICw) = 0 / .512). Similar to feature search findings, differences between 
patients and controls were due factors that were constant across set sizes, rather than 
mechanisms involved in serial search. 
The fit of the MPS-IVa developmental trajectories to linear, quadratic or plateau 
functions was conducted to find the best description of MPS-IVa visual search development, 
and to answer how patient development differed to controls. Since differences between 
patients and controls were found for search time (VSmean), and not search slopes (VSslope), 
only the MPS-IVa developmental trajectories for feature and conjunction search times were 
defined. Results (Table 5.2.5) revealed that plateau functions offered the best description of 
MPS-IVa visual search development for both feature and conjunction search tasks. 
 
Table 5.2.5: MPS-IVa visual search task: AIC trajectory comparisons 
 
Plateau Models 
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
 
Linear Quadratic Plateau 
 
Intercept 
Rate 
Constant 
Plateau 
 
R
2
 
          
VSmean - FS 5.4 / .06 4.5 / .09 0 / .85  1864 .058 888  .77 
          
VSmean - CS 2.1 / .20 1.7 / .24 0 / .56  2797 .053 1587  .53 
          
Notes: FS: Feature Search, CS: Conjunction Search, reponses recorded in milliseconds 
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Developmental trajectory slopes of MPS-IVa patients and controls are in presented 
Figure 5.2.4. The slopes illustrate the search time differences that were identified between the 
groups. Firstly, for both feature and conjunction search, differences were evident at the 
youngest age of measurement. Compared to controls, MPS-IVa patients produced slower 
feature search (MPS-IVa = 1864ms ; Controls = 1132ms) and conjunction search responses 
(MPS-IVa = 2797ms ; Controls = 2074ms). However, this should be interpreted with caution 
since only a few patient data points occupy this region of development. Also, similar to 
simple response time latency, it is possible that the development of MPS-IVa patients may 
diverge from healthy controls during later ages, with patients becoming slower than healthy 
controls. This is due to the difference in the functions which characterise the development of 
patients (plateau function) and healthy controls (quadratic function). Therefore, compared to 
MPS-IVa patients, developmental change occurs over a longer time course in healthy 
controls. However, this should be interpreted with caution also as there are no older patient 
data points (180 – 240 months) to confirm this conclusion.
 
 
Figure 5.2.4: MPS-IVa visual search developmental trajectories. Mean search time (VSmean) developmental 
trajectories of MPS-IVa patients (blue line) and healthy developing controls (red line). MPS-IVa patient raw 
scores presented as green dots. The healthy developmental trajectories are expressed as a quadratic function 
with 95% CI (dashed black line) for all conditions. MPS-IVa development is expressed by plateau functions 
with 95% prediction bands (dotted black line).  
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5.2.2 Language 
All MPS-IVa patients completed the BPVS task during their assessments, except for 
patient 12 who did not complete the BNT due to time constraints. For the non-word learning 
task, patient 7 was unable to complete the task, also due to time constraints.  
 MPS-IVa patients displayed minor difficulties on the BPVS task but did not differ to 
healthy controls on either the BNT or the non-word learning task. Consequently, language 
results for the BPVS are presented here along with BNT (as a comparison). Non-word 
learning results are not reported. 
Production and Comprehension 
Patient verbal production scores (BNT) and verbal comprehension scores (BPVS) are 
presented in Figure 5.2.5. Patient BNT scores were evenly distributed across the predicted 
mean of healthy development (red line). Patient BPVS scores fell within the normal range of 
development. However, many patients were shifted downwards towards the lower range of 
development. 
 
Figure 5.2.5: MPS-IVa verbal production and comprehension individual patient scores. Patient (green dots) and 
healthy control (blue dots) raw scores on the Boston Naming task (BNT, left) and the British Picture Vocabulary 
Scale (BPVS, right). Healthy developing trajectories (red line) are expressed as quadratic functions for both 
BNT and BPVS. 95% confidence limits are included (black dotted-line).  
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The individual patient BNT z-scores (Table 5.2.6) show that patient 6 (9.79 years) had 
a BNT score that was below the confidence limits (z-score = -3.17) while patient 7 (9.85 
years) had a BNT score that was above the confidence limits (z-score = 2.74). The BPVS 
comprehension scores displayed in Table 5.2.6 show that no patients were outside the 
confidence limits of development (z-score > -2), however, 7/12 patients were in the lower 
average (z-score > -1).  
Table 5.2.6: MPS-IVa z-scores for verbal production and 
comprehension 
PID Age 
(Years) 
Boston Score BPVS Score 
1 5.27 27  (-0.07) 43  (-1.20) * 
2 6.44 28  (-0.99) 57  (-0.94) 
3 6.48 24  (-1.42) * 51  (-1.45) * 
4 7.77 64  (1.60) 84  (0.38) 
5 9.33 52  (-0.77) 78  (-1.06) * 
6 9.79 34  (-3.17) ** 78  (-1.34) * 
7 9.84 86  (2.74) 102  (0.69) 
8 10.28 52  (-1.40) * 77  (-1.71) * 
9 11.71 84  (1.44) 133  (2.40) 
10 11.78 57  (-1.63) * 83  (-1.98) * 
11 12.05 86  (1.48) 107  (-0.03) 
12 14.39 
 
106  (-1.16) * 
*  z-score > 1, ** z-score > 2 
 
To inspect differences in the development rate of verbal comprehension of MPS-IVa 
patients and controls, an AIC comparison was conducted to test the presence of a 2-way 
interaction between Group and Age. Here a model which included an interaction term (∆AIC 
= 0; AICw = .817) was better than a model that did not (∆AIC = 3 ; AICw = .182) However, a 
main effect of Group was not found (test-model (∆AIC / AICw) = .1 / .487 ; null-model 
(∆AIC / AICw) = 0 / .512). This means that only the rate development between patients and 
controls differed.  
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The development of verbal comprehension for MPS-IVa patients was best defined by 
a linear function (Y = 49.5 + .65 * X; ∆AIC = 0; AICw = .438) rather than a quadratic (∆AIC 
= .83 ; AICw = .288) or plateau functions (∆AIC = .95; AICw = .273). Figure 5.2.6 illustrates 
the findings from the above analysis. In general, the overall performance of patients did not 
differ to the performance of controls; all patient data points are distributed within the range of 
healthy development. This is reflected in the lack of a main effect for Group. However, MPS-
IVa patients demonstrated a steeper developmental slope than controls, which means patient 
performance may convergence with heathly control performance during later years.  
 
 
Figure 5.2.6: MPS-IVa verbal comprehension developmental trajectory. BPVS developmental trajectories of 
MPS-IVa patients (blue line) and healthy developing controls (red line). MPS-IVa patient raw scores presented 
as green dots. The healthy developmental trajectory is expressed as a quadratic function with 95% CI (dashed 
black line) and MPS-IVa developmental trajectory is expressed as a linear function with 95% prediction bands 
(dotted black line).  
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5.2.3 Oculomotor 
Eleven of the 12 Morquio patients completed the fixation task. The youngest patient 
was unable to complete the task due to being highly inattentive during the testing session and 
was unable to be calibrated. Patients 5 and 7 could only complete the fixation task due to 
irritability and patients 2, 3, 4 and 11 could not complete the anti-saccade and smooth pursuit 
task due to fatigue.  
Results from the fixation task and anti-saccade task are presented only. No patients 
exhibited impairments on the pro-saccade and smooth pursuit tasks. Fixation task 
performance will be described on an individual and group basis. Anti-saccade task 
performance will be described on an individual basis only due to the smaller sample size. 
 
Fixation Task 
The average fixation duration (FixDwell) of MPS-IVs patients is presented in Figure 
5.2.7. For the left, right, and bottom target locations the majority of patients exhibited 
fixation durations that were clearly outside the confidence limits of healthy development. 
These fixation deficits were present in both younger and older patients. Fewer patients 
appeared to produce clear deficits for the top target location. However, even in this condition 
all patients were below the predicted mean of development (red line).  
 
 
 
 
 113 
 
 
Figure 5.2.7: MPS-IVa fixation duration individual patient performance. Average fixation duration (FixDwell; 
ms) for MPS-IVa patients (green dots) and healthy controls (blue dots). Horizontal target locations are shown in 
the top row of graphs and vertical target locations are shown in the bottom row of graphs. The healthy 
developmental trajectory (red line) is expressed as a plateau function. 95% confidence limits (black dotted-line) 
are presented.  
 
 
Table 5.2.7 displays the FixDwell z-scores of individual patients. When FixDwell was 
averaged across the 4 target locations, 8/11 patients exhibited clear fixation duration deficits 
(z-score > 2). Five of these 8 patients presented very clear deficits (z-score > 3), while patient 
11 (12.39 years) displayed extremely low fixation durations (z-score = -9.22).  
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Table 5.2.7: MPS-IVa z-score for mean fixation duration (FixDwell) 
  Target Position  
PID Age 
(Years) 
Left Right Bottom Top Avg 
2 6.44 2197  (-3.57) ** 2680  (-2.72) ** 1158  (-5.39) ** 3337  (-2.05) ** 2343  (-3.59) ** 
3 6.48 4377  (0.23) 4243  (0.23) 2002  (-3.97) ** 4129  (-0.71) 3502  (-1.49) * 
4 7.77 2487  (-4.49) ** 2449  (-4.57) ** 2423  (-4.63) ** 2599  (-3.59) ** 2478  (-4.76) ** 
5 9.33 3343  (-3.66) ** 3295  (-3.78) ** 3272  (-3.85) ** 3771  (-2.03) ** 3458  (-3.49) ** 
6 9.79 4148  (-1.79) * 3531  (-3.39) ** 4631  (-0.53) 4719  (-0.31) 4257  (-1.56) * 
7 9.84 4453  (-1.00) * 3744  (-2.86) ** 3369  (-3.85) ** 4569  (-0.60) 3957  (-2.38) ** 
8 11.71 4129  (-2.24) ** 3556  (-3.91) ** 3107  (-5.24) ** 4741  (-0.34) 3883  (-2.99) ** 
9 11.78 2921  (-5.79) ** 4453  (-1.30) * 3540  (-3.98) ** 4373  (-1.21) * 3743  (-3.42) ** 
10 12.05 3912  (-2.93) ** 3108  (-5.30) ** 3918  (-2.91) ** 3861  (-2.46) ** 3700  (-3.59) ** 
11 12.39 1805  (-9.30) ** 2143  (-8.26) ** 1092 (-11.44)** 2324  (-6.33) ** 1841  (-9.22) ** 
12 14.39 4643  (-0.86) 4946  (0.09) 4754  (-0.51) 4803  (-0.25) 4786  (-0.43) 
Note: MS, Milliseconds; *  z-score > 1, ** z-score > 2 
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The average frequency of intrusive saccades during fixations (FixSacc¸ i.e. the 
number of saccades made away from the target) produced by MPS-IVa patients is presented 
in Figure 5.2.8.  For all target locations the majority of patients exhibited a higher number of 
intrusive saccades than expected.  
 
Figure 5.2.8:MPS-IVa intrusive saccade individual patient performance. Average number of saccades away 
from the visual stimulus (FixSacc) produced by Morquio patients (green dots) and healthy controls (blue dots). 
Horizontal target locations are shown in the top row of graphs and vertical target locations are shown in the 
bottom row of graphs. The healthy developmental trajectory (red line) is expressed as a plateau function. 95% 
confidence limits (black dotted-line) are also presented.  
Results in Table 5.2.8 display the FixSacc performance of MPS-IVa patients 
averaged across target locations. Here 7/11 patients produced a greater number of intrusive 
saccades than would be predicted for healthy development (z-score > 2). In addition, the age 
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of the patients who produced an abnormal number of intrusive saccades covered the age 
range of patients; abnormal performance was not exclusive to the youngest or oldest patients. 
Interestingly, these 7 patients also produced fixation duration (FixDwell) deficits, which 
suggest the difficulties with fixation maintenance are likely to be driven by problems 
suppressing intrusive saccades. One exception was patient 7 (9.84 years), who was within the 
normal healthy developing range for FixSacc but not FixDwell. Therefore it is unlikely that 
fixation maintenance deficits in Morquio syndrome are caused solely by difficulties 
suppressing saccades.  
 
Table 5.2.8: MPS-IVa z-score for mean intrusive saccade frequency (FixSacc) 
  Target Position  
PID Age 
(Years) 
Left Right Bottom Top Avg 
2 6.44 4  (-2.54)  ** 3  (-1.42) * 3  (-0.90) 3  (-2.52) ** 3  (-2.44) ** 
3 6.48 1  (1.14) - 2  (0.42) 3  (-1.61) * 2  (0.29) 
4 7.77 4  (-2.65) ** 2  (-0.69) 3  (-1.37) * 3  (-3.34) ** 3  (-2.71) ** 
5 9.33 2  (-0.96) 3  (-3.42) ** 4  (-4.46) ** 2  (-0.52) 2  (-3.04) ** 
6 9.79 3  (-2.05) ** 2  (-1.59) * 2  (-0.28) 1  (0.73) 2  (-1.31) * 
7 9.84 2  (-0.18)  2  (-0.51) 2  (-0.29) 1  (0.73) 1  (-0.35)  
8 11.71 2  (-0.57) 3  (-4.06) ** 2  (-1.67) * 2  (-1.00) * 2  (-2.70) ** 
9 11.78 3  (-4.26) ** 2  (-2.60) ** 2  (-0.61) 2  (-2.54) ** 2  (-3.74) ** 
10 12.05 2  (-1.91) * 4  (-9.08) ** 2  (-1.75) * 2  (-2.62) ** 3  (-5.48) ** 
11 12.39 3  (-4.71) ** 5  (-12.97) ** 3  (-4.12) ** 5  (-10.68) ** 4  (-11.78) ** 
12 14.39 1  (0.55) 1  (0.31) 1  (0.34) 1  (0.40) 1  (0.67) 
Note: MS, Milliseconds; 
*  z-score > 1, ** z-score > 2 
 
 
Performance of patient 7 and 11 (along with age-matched controls) on the fixation 
task are shown in Figure 5.2.9. The temporal data of eye movements presented here 
illustrates the fixation deficits reported in these patients.  
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Figure 5.2.9: MPS-IVa fixation task raw temporal data. Eye movements of patient 7 and 11 during the fixation 
task. Both patients showed fixation duration deficits (FixDwell), while only patient 11displayed saccade 
frequency deficits (FixCount).  The visual stimulus (blue line) is presented along with eye position of the 
patients (black line) and age-matched healthy controls (red dashed line). Horizontal and vertical eye movements 
are presented in the top and bottom panels respectively.  
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Patient 7 (9.84 years) displayed a fixation duration deficit (z-score = -2.38) but not a 
saccade frequency deficit (z-score = -0.35). The eye movements of patient 7 shown in Figure 
5.2.9 demonstrate that this is due to disengagement from right and bottom presented targets 
near to the end of trials (disengagement from a bottom target is illustrated above). In contrast, 
patient 11 (12.39 years) presented with both a fixation duration (z-score = -9.22) and saccade 
frequency deficit (z-score = -11.78). Figure 5.2.9 highlights that both deficits are clearly due 
to the frequency of saccades during the task. A notable feature of patient 11’s eye movements 
is that the patient continually shifts their gaze between the target and the screen centre. 
The comparison of MPS-IVa and healthy developmental trajectories during the 
fixation task was examined through the comparison of AIC model values. First, to determine 
whether the overall rate of development (regardless of target location) for sustained fixation 
duration differed between patients and controls, an AIC comparison was conducted. There 
was insufficient evidence for a 3-way interaction of Group, TargetLocation and Age (test-
model (∆AIC / AICw) = 1 / .38 ; null-model (∆AIC / AICw) = 0 / .62), but there was 
evidence of a 2-way interaction between Group and Age (test-model (∆AIC / AICw) = 0 / .73 
; null-model (∆AIC / AICw) = 2 / .27). Together, these results suggest that while patients and 
controls exhibit slightly different rates of development, the influence of target location on 
developmental change was the same for patients and controls. In terms of overall 
developmental differences between patients and controls, there was substantial evidence for a 
main effect of Group (test-model (∆AIC / AICw) = 0 / .99 ; null-model (∆AIC / AICw) = 11 / 
<.01) and an interaction of Group and Targetlocation (test-model (∆AIC / AICw) = 0 / .98 ; 
null-model (∆AIC / AICw) = 9 /.02). This means that overall developmental differences 
existed between groups and this difference varied across the four target locations. To identify 
whether overall developmental differences were systematically grouped, the AIC of the 
following 6 models were compared. A 1-term model with a single trajectory representing all 
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target locations (‘Combined’ model), a 2-term model with separate trajectories for horizontal 
and vertical targets (‘Hori/Vert’ model), and four 2-term models which each specified a 
separate trajectory for the four targets (‘Left’,’Right’,’Top’,’Bottom’ models). The ∆AIC 
values of each model are presented in Table 5.2.9. Here, the ‘Top’ model was the best model 
(∆AIC / AICw = 0 / .87). This means that the magnitude of the difference between patients 
and controls was not the same for top target location in comparison to the other target 
locations.  
 
Table 5.2.9: MPS-IVa mean fixation duration (FixDwell) – AIC condition comparisons 
FixDwell    
Model ∆AIC AICw Evidence ratio 
    
Top 0 .87 1 
Left 6 .04 20 
Right 6 .04 20 
Bottom 6 .04 20 
Hori/Vert 15 <.01 >1000 
Combined 32 <.01 >1000 
    
 
Since the developmental onset differences between patients and controls were 
uniform across left, right, and bottom targets, the fit of the MPS-IVa developmental 
trajectories to linear, quadratic or plateau functions was analysed separately for the top target 
location. A separate developmental trajectory was defined for fixation duration based on the 
combined performance on left, right, and bottom targets (‘L / R / B’ development). Results 
revealed linear functions to clearly offer the best description of development for both the top 
target and the remaining targets locations (Table 5.2.10). Intercept parameter estimates, and 
the developmental slopes of MPS-IVa patients and controls (Figure 5.2.10), show that the 
difference between groups was smaller for the top target location (MPS-IVa = 3572ms ; 
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controls = 4319ms) in comparison to the other targets (MPS-IVa = 2664ms ; controls = 
4001ms). In all locations, the Morquio patients were showing gradual improvement at an age 
where controls had plateaued. 
Table 5.2.10: MPS-IVa mean fixation duration (FixDwell) – AIC trajectory comparisons 
   
Linear Models   
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
Linear Quadratic Plateau  Intercept Slope   R
2 
          
Top 0 / .61 2.3 / .19 2.3 / .19  3572 96   .08 
          
L / R / B 0  / .76 2.3 / .24 -  2664 169   .22 
          
   
 
 
Figure 5.2.10: MPS-IVa fixation duration developmental trajectories. Mean fixation duration (FixDwell) 
developmental trajectories of MPS-IVa patients (blue line) and healthy developing controls (red line). MPS-IVa 
patient raw scores presented as green dots. The healthy developmental trajectory is expressed as a plateau 
function with 95% CI (dashed black line) and Morquio developmental trajectory is expressed as a linear 
function with 95% prediction bands (dotted black line).  
The comparison of MPS-IVa and healthy developmental trajectories for the frequency 
of intrusive saccades (FixSacc) was examined with the same AIC model comparison 
procedure. Here, AIC comparisons for 2- and 3- way interactions, and main effects, provided 
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insufficient evidence of effects of group, target location and age. Therefore, the rate of 
development for intrusive saccades did not differ between MPS-IVa and healthy controls. 
 
Pro-saccade Task 
 The reflexive saccade properties (saccade initiation latency (SaccOnset) and saccade 
velocity (SaccVelo)) were within range of normal healthy controls for all Morquio Patients. 
Consequentially these results are not presented here. 
 
Anti-saccade Task 
 Five MPS-IVa patients completed the anti-saccade task. Seven patients did not 
complete the task due to irritability which prevented adequate calibration of the eye tracker. 
The time taken to locate the anti-saccade target (AntiOffset) was within the normal range of 
healthy development for the 5 patients. However, the proportion of corrected errors 
(AntiCorr) of several patients was below the lower limit range of healthy controls. The 
proportion of corrected anti-saccade errors (AntiCorr) of individual MPS-IVa patients is 
presented in Figure 5.2.11. In terms of deficits for specific target locations, no discernible 
pattern was observed; deficits were not more common for inner versus outer targets, or 
horizontal versus vertical targets. 
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Figure 5.2.11:MPS-IVa anti-saccade error correction individual patient performance. Proportion of corrected 
pro-saccade errors for each target location for MPS-IVa patients (green dots). The healthy developmental 
trajectories of healthy controls (red line) are presented alongside 95% confidence limits (black dotted-line).  
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Table 5.2.11 displays the z-scores of individual MPS-IV patients. Patient 12 (14.39 
years) corrected fewer saccadic errors than healthy developing controls (z-score > -2) on all 
inner target locations and the outer bottom target. Patient 8 (11.71 years) corrected fewer 
saccadic errors than healthy developing controls (z-score > -2) for all inner-target locations 
(patient 8 made no errors for the inner bottom target) and outer-right presented target 
locations. Finally, it was found that 2/5 Morquio patients produced fewer corrected errors 
than controls when patients’ proportion of corrected errors was averaged across target 
locations. 
 
Table 5.2.11: MPS-IVa z-scores for anti-saccade error corrections (AntiCorr) 
   Target Position  
PID Age 
(Years) 
Task Left Right Bottom Top Avg 
6 9.79 
Inner 1.00 (0.69) 1.00  (0.67) 0.75  (-0.49) 1.00  (0.64) 
0.92  (0.23) 
Outer 0.83  (-0.41) 1.00  (0.67) 0.75  (-0.49) 1.00  (0.64) 
        
8 11.71 
Inner 0.00  (-5.80) ** 0.33  (-3.75) ** - 0.00  (-6.50) ** 
0.58  (-2.88) ** 
Outer 1.00  (0.49) 0.50  (-2.73) ** 1.00  (0.79) 1.00  (0.53) 
        
9 11.78 
Inner 1.00  (0.48) 1.00  (0.56) 0.66  (-1.21) * 1.00  (0.53) 
0.91  (-0.13) 
Outer 1.00  (0.48) 0.83  (-0.68) 1.00  (0.79) 0.80  (-1.03) * 
        
10 12.05 
Inner 0.66 (-1.77) * 0.83  (-0.71) 0.75  (-0.79)  1.00  (0.52) 
0.89  (-0.36) 
Outer 1.00  (0.45) 1.00  (0.55) 1.00  (0.77) 0.80  (-1.08) * 
        
12 14.39 
Inner 0.00  (-7.22) ** 0.60  (-2.93) ** 0.50  (-2.79) ** 0.50  (-4.61) ** 
0.54  (-4.83) ** 
Outer 0.50  (-3.53) * 0.80  (-1.27) * 0.40  (-3.45) ** 1.00  (0.50) 
*  z-score > 1, ** z-score > 2 
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5.2.4 Conclusions: Morquio Syndrome (MPS-IVa) 
 Few studies have investigated the cognitive functioning of Morquio syndrome (MPS-
IVa). This is primarily due to reports of normal intellectual functioning during clinical 
observations (Dvorak-Ewell et al., 2010; Wraith, 2006). However, in the current study we 
demonstrate the existence of attention deficits on several tasks. These were most prominent 
for the fixation task, where fixation maintenance was disrupted by a high frequency of 
disruptive saccades. Deficits of simple response time and visual search time were also 
present, and were characterised by slower reaction time latencies on both tasks. However, 
these were mild in comparison to the fixation deficits.  In addition, two patients produced 
larger search slopes than controls during feature and conjunction search. This highlights that 
the mechanisms of visual search (parallel and serial search) are potentially impaired in some 
MPS-IVa patients. Finally, MPS-IVa displayed borderline verbal comprehension difficulties 
on the BPVS task. 
 The current findings support and expand on the previous study by Davison et al. 
(2012), where MPS-IVa patients exhibited mild verbal comprehension deficits, and 
difficulties with concentration and attention (the latter reported by parents). In particular, 
findings from the current fixation task fit with these parental reports, since concentration 
problems could be reflected by difficulties maintaining attention on a visual stimulus. 
Previous neuroimaging reports from MPS-IVa children have pointed to presence of 
frontal brain region abnormalities (Davison et al. 2012). Therefore, the prominence of 
attention deficits in the current cohort could be the result of from the disruption of frontal 
brain region functioning. In particular, the frontal eye fields (FEF) and the dorsal lateral 
prefrontal cortex (DLPC) have a role in suppressing reflexive saccades during fixation 
maintenance (Tinsley & Everling, 2002). The FEF are also associated with the production of 
exploratory eye movements during visual search (Booth et al., 2003), so FEF dysfunction 
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may relate to the observed search slope deficits. Other frontal regions that may be disrupted 
are the anterior cingulate and the orbitofrontal cortex, which have roles in response inhibition 
and decision making respectively (Bechara, Damasio, & Damasio, 2000; Booth et al., 2003; 
Rolls & Grabenhorst, 2008; Schoenbaum, Roesch, & Stalnaker, 2006). This is because of the 
general slowing of mean response time during the simple reaction time and visual search 
tasks that were observed in the majority of patients. However, from the present findings there 
is insufficient evidence to demonstrate which brain regions are disrupted in MPS-IVa. 
Therefore, to validate these findings it is important that future studies employ imaging 
techniques (such as fMRI) to examine the function of frontal regions during fixation and 
visual search tasks. 
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5.3 Hurler Syndrome (MPS-IH) 
 MPS-IH is caused by the deficiency of the enzyme α-L-iduronidase which in turn 
leads to the accumulation of dermatan and heparin sulphate. In general, two phenotypes 
exists: a severe early onset form (MPS-IH) and a later onset attenuated form (MPS-IA).The 
neurological manifestations of MPS-IH are very severe, with patients presenting with 
progressive learning difficulties and mental retardation. However, the severity of neurological 
systems in MPS-IH can be managed through the treatment of allogenic haematopoietic stem 
cell transplantation (HSCT) and enzyme replacement therapy (ERT). MPS-IA is associated 
with a variable cognitive and somatic profile, with the standard treatment being ERT.  
Since treatments exist that address the cognitive features of these diseases, several 
studies exist (Shapiro et al., 2009, 2012; Souillet et al., 2003) that report the cognitive 
outcomes of patients in response to HSCT and/or ERT. Neuropsychological findings for 
MPS-IH and MPS-IA have revealed deficits in attention, executive functioning, and lower 
than average verbal IQ, with attention deficits being more pronounced in MPS-IH (Shapiro et 
al., 2009, 2012). It is believed that the broad range of cognitive deficits in the MPS-IH/IA are 
the result of both delayed myelination and progressive demyelination through the course of 
the disease (Müller-Forell et al., 2007). It has been argued that the differences in attention 
between MPS-IH and MPS-IA are the result of compromised white matter integrity caused 
by chemotherapy MPS-IH patients receive as part of HCT treatment (Shapiro et al., 2012). 
Several studies have linked white matter abnormalities to deficits of sustained attention, 
processing speed, and psychomotor speed (F. S. Anderson, Kunin-Batson, Perkins, & Baker, 
2008; Shapiro et al., 2012). Therefore, in the current study it is predicted that patients will 
demonstrate deficits over a large range of tasks, with deficits being more pronounced for 
MPS-IH patients. 
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Patients 
Two patients diagnosed with MPS-IH (2 males; 10.60 and 12.35 years) and 1 patient 
diagnosed with MPS-IA (female; age: 14.65 years) were recruited by a research nurse at 
Birmingham Children’s Hospital (patient demographics in Table 5.3.1). Both MPS-IH 
patients had received a late diagnosis at 18-months of age, and received an HCT transplant at 
2 years of age. All 3 patients were treated with ERT.  Cognitive assessments were conducted 
at the Welcome Trust Clinical Research Facility at Birmingham Children’s Hospital. Consent 
for all children was obtained from the children’s parents prior to testing.  
 
Table 5.3.1: MPS-I summary of patient demographics 
PID Gender CA (Years) BPVS MA 
(Years) 
Linguistic Profile 
IH 1 M 10.60 6.50 ML - English 
IH 2 M 12.35 6.16 ML - English 
IA 3 F 14.65 8.16 ML - English 
Note: ML, monolingual, BL, bilingual 
 
 
Table 5.3.2 provides a summary of findings that will be described in this section. 
Similar to Morquio patients, patients displayed clear deficits on the attention tasks (simple 
reaction time task, visual search task, fixation task, and anti-saccade task). Patients also 
showed difficulties on the language tasks. No deficits were evident on the pro-saccade or 
smooth pursuit task 
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Table 5.3.2: MPS-I summary of deficits across domains 
Domain Task  Notes 
Attention 
Simple RT Task * RTmean  
Visual Search Task ** VSmean 
    
Language 
BNT *  
BPVS **  
Non-Word Task ** NonProd, NonComp 
    
Ocular Motor 
Fixation Task ** FixDwell, FixSacc 
Prosaccade Task -  
Antisaccade Task * AntiCorr 
Smooth Pursuit -  
    
Note: RTmean, Mean Reaction Time; VSmean, Mean Visual Search Time; NonProd, Total Produced Non-
Words; NonComp, Total Comprehended Non-Words; FixDwell, Fixation Duration Time; FixSacc, Fixation 
Count; AntiCorr; Frequency of Error Correction; 
*  possible deficit, ** Consistent deficit 
 
5.3.1 Attention 
Two of the three patients completed the attention tasks. Patient 2 (12.35 years), a 
MPS-IH patient, was unable to complete the attention tasks due to time constraints placed on 
the testing session by their clinic visit.  
Simple Reaction Time Task 
Comparison of the mean simple reaction time (RTmean) of the individual patients to 
the developmental trajectory of the healthy developing control population is shown in Figure 
5.3.1. MPS-IH patient 1 (10.6 years) produced average response times that were clearly 
below the confidence limits (z-score > 2) of the healthy developmental trajectory on all 4 
conditions (Table 5.3.3). In contrast, the MPS-IA patient (14.65 years) was within the 95% 
CI of the healthy developing trajectory for all target locations. 
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Figure 5.3.1: MPS-I simple reaction time individual patient performance. Mean simple reaction time (RTmean) 
of MPS-IH patients (green dots), MPS-IA patients (red dots) and healthy developing controls (blue dots) in 
comparison to a healthy developmental trajectory (red line). Reaction time is collapsed across target location for 
controls and the control developmental trajectory is expressed as a quadratic function with 95% CI (dashed 
black line).  
 
Table 5.3.3: MPS-I z-score of simple reaction time (RTmean) 
PID Age 
(Years) 
Bottom Left Bottom Right Top Left Top Right Avg 
       
IH 1 10.6 784  (-5.67) ** 749  (-6.16) ** 885  (-7.10) ** 719  (-5.64) ** 783  (-5.77) ** 
       
IA  14.65 343  (-0.54) 388  (-1.45) * 339  (-0.46) 323  (-0.19) 348  (-0.69) 
       
Note: Reponses recorded in milliseconds IH: MPS-IH , IA: MPS-IA , z-scores in parentheses 
*  z-score > 1, ** z-score > 2 
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Visual Search Task 
 The visual search performance of the 2 patients was examined in relation to healthy 
controls in terms of mean search time (VSmean) and search efficiency (VSslope) for target 
present trials. Patients’ performance for the feature search and conjunction search is 
presented in Figure 5.3.2. 
 
Figure 5.3.2: MPS-I visual search individual patient performance. Mean search time (VSmean) and search 
efficiency (VSslope) of MPS-IH patients (green dots), MPS-IA patients (red dots) and healthy developing 
controls (blue dots). Developmental trajectory of controls expressed as quadratic functions (red line) with 95% 
CI (dashed black line).  
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Table 5.3.4 displays the z-scores of patients on the visual search task. MPS-IH patient 
1 (10.6 years) produced clear VSmean deficits for both feature (z-score = -25.63) and 
conjunction search (z-score = -16.70). MPS-IA patient 3 (14.65 years) produced search times 
that were within the normal range. No VSslope deficits were observed in either patient. 
Table 5.3.4: MPS-I z-score for mean visual search time (VSmean) and 
search efficiency (VSslope) 
PID 
Age 
(Years) 
Task VSmean VSslope 
     
IH 1 10.6 
FS 3704  (-25.63) ** -114  (10.83) 
CS 5566  (-16.70) ** 26  (0.90) 
     
IA 14.65 
FS 658  (-0.66) 11  (-1.34) * 
CS 1289  (-1.43) * 72  (-0.81) 
     
Note: FS: Feature Search, CS: Conjunction Search, reponses recorded in 
milliseconds,  z-scores in parentheses 
*  z-score > 1, ** z-score > 2 
 
To further clarify the reported visual search findings, response time slopes of the two 
patients are displayed in Figure 5.3.3.  
 
Figure 5.3.3: MPS-I visual search mean search times. Mean response latencies (ms) on each set size for feature 
search (left panel) and conjunction search tasks (right panel) for MPS-IH patient 1 (green line) and the MPS-IA 
patient (red line). Predicted performance of healthy controls (relative to patients’ age) is shown by dash-lines. 
Error bars represent the 95% CI of healthy developing controls.  
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For MPS-IH patient 1, set size did not appear to produce search efficiency deficits for 
either feature or conjunction search. However, search times here are extremely slow in 
comparison to healthy controls which are likely to be due in part to the simple reaction time 
deficits reported previously. The MPS-IA patient demonstrated typical feature and 
conjunction search response latency slopes whereby response times increase as a function of 
set size for conjunction search only. Interestingly the conjunction response time slope 
between 8 and 12 items appeared steeper than controls. This could suggest that the MPS-IA 
patient may have exhibited clear search proficiency deficits if a larger array of target items ( 
> 12) were presented. 
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5.3.2 Language 
All 3 patients completed the 3 language tasks. No alterations were made to the study 
protocol in order for the patients to complete the tasks. Language deficits were observed on 
all 3 tasks. 
Production and Comprehension 
Patient verbal production scores (BNT) and verbal comprehension scores (BPVS) are 
reported in Figure 5.3.4 and Table 5.3.5. 
 
 
Figure 5.3.4: MPS-I verbal production and comprehension individual patient scores. MPS-IH Patient (green 
dots), MPS-IA (red dots) and healthy control (blue dots) raw scores on the Boston Naming task (left) and the 
British Picture Vocabulary Scale (right). Healthy developing trajectories (red line) are expressed as quadratic 
functions for both BNT and BPVS. 95% confidence limits also included (black dashed-line).  
On the Boston Naming task (BNT) MPS-IH patient 2 (12.35 years) and the MPS-IA 
patient (14.65 years) obtained scores that were below the 95% CI (z-score > 2) of the healthy 
developing trajectory. MPS-IH patient 1 produced a BNT score that was within the lower 
range of the healthy developing trajectory (z-score > 1). Deficits were clearer for verbal 
comprehension for both MPS-IH patients (patient 1 and 2) and the MPS-IA patient (patient 3) 
whose scores were below the 95% CI of the healthy developing trajectory (z-score > 2). 
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Table 5.3.5: MPS-I z-scores for verbal production and 
comprehension 
PID Age 
(Years) 
BNT BPVS 
IH 1 10.6 57  (-1.01) * 66  (-2.83) ** 
IH 2 12.35 45  (-3.19) ** 63  (-3.97) ** 
IA 14.65 39  (-4.34) ** 84  (-3.11) ** 
Note: z-scores in parentheses 
*  z-score > 1, ** z-score > 2 
 
Non-word Learning Task 
The non-word learning performance of patients for the 5 non-words (monsters) is 
displayed in Figure 5.3.5 and Table 5.3.6.  
 
Figure 5.3.5: MPS-I non-word production and comprehension individual patient score. MPS-IH patients (green 
dots), MPS-IA patient (red dot), and healthy controls (blue dots) total non-word production and comprehension 
scores in relation to healthy developing trajectories (red lines). Production and comprehension scores are shown 
in the left and right panels respectively. 95% confidence limits (black dashed-lines) are included   
 
The sum of produced monster names, over the 6 iterations of the learning phase (max 
score: 30), was clearly below the 95% healthy developing CI for the 2 MPS-IH patients. The 
MPS-IA patient (patient 3) displayed a borderline production deficit (z-score = -1.93).  
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Similarly, the sum of comprehended monsters was below the 95% healthy developing CI for 
the MPS-IH patients only. 
 
Table 5.3.6: MPS-I z-scores for non-word production and 
comprehension 
PID Age 
(Years) 
NonProd NonComp 
IH 1 10.6 8  (-3.93) ** 21  (-8.34) ** 
IH 2 12.35 10  (-3.05) ** 18  (-9.86) ** 
IA 3 14.65 18  (-1.93) * 30  (0.66) 
Note: z-scores in parentheses 
*  z-score > 1, ** z-score > 2 
 
 
The raw learning scores of the 3 patients compared to age-matched controls are 
presented in Figure 5.3.6. These data highlight the problems patients have for the production 
and comprehension of non-words. During production learning iterations, MPS-IH patients (1 
and 2) were unable to correctly produce more than 2 monster names. Interestingly the MPS-
IA patient (patient 3) correctly produced the names of 3 monsters during the first iteration, 
but was not able to name more than 2 monsters correctly in any of the remaining iterations. 
The comprehension slopes show that the MPS-IA patient correctly identified all 5 monsters 
in all 6 learning iterations. Therefore, the MPS-IA non-word production difficulties are not 
due to a non-word comprehension deficits. In contrast, the MPS-IH patients displayed 
difficulties recognising more than 4 monsters, so it is likely that MPS-IH production deficits 
relate in part to comprehension difficulties. 
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Figure 5.3.6: MPS-I non-word learning performance of individual patients. Number of monsters named and 
identified for by MPS-IH and MPS-IA patients for production (left panel) and comprehension (right panel) 
respectively. Learning slopes indicate performance during 6 successive learning iterations. Predicted 
performance of healthy controls (relative to patients’ age) is shown by dash-lines. 
 
5.3.3 Oculomotor 
All ocular motor tasks were completed by the MPS-IA patient. MPS-IH patient 2 was 
unable to complete any of the ocular motor tasks due to photophobia that prevented adequate 
eye tracking. MPS-IH patient 1 (10.6 years) completed only the fixation task due to fatigue.  
Results here are presented for the fixation task and anti-saccade task. The MPS-IA 
patient did not differ to healthy controls on the pro-saccade task and smooth pursuit task; 
these results are not reported here. 
Fixation Task 
The average duration (ms) that the patients fixated on the visual stimulus (FixDwell) 
for the 4 target locations is presented in Figure 5.3.7 and Table 5.3.7. Deficits (z-score > -2) 
were evident on horizontal target locations for both MPS-IH and MPS-IA patients. For 
vertical locations, patients produced shorter fixation durations than controls for bottom 
targets only. Borderline FixDwell deficits were found for the top locations for both patients. 
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However, even in this condition all patients were below the predicted mean of development 
(red line). The average fixation duration collapsed across locations was shorter than controls 
for patient 1 (3375 ms ; z-score = -4.20) and patient 3 (3935 ms ; z-score = -3.09). 
 
 
Figure 5.3.7: MPS-I fixation duration individual patient performance. Average fixation duration (FixDwell; ms) 
for MPS-IH patients (green dots), MPS-IA patients (red dots) and healthy controls (blue dots). The healthy 
developmental trajectory (red line) is expressed as a plateau function. 95% confidence limits (black dashed-line) 
are also presented.  
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Table 5.3.7: MPS-I z-score for fixation duration (FixDwell) 
  Target Position  
PID Age 
(Years) 
Left Right Bottom Top Avg 
       
1 10.6 3383  (-4.10) ** 3411  (-4.02) ** 2435  (-6.73) ** 4270  (-1.28) * 3375  (-4.20) ** 
       
3 14.65 3393  (-4.80) ** 4114  (-2.52) ** 3935  (-3.09) ** 4297  (-1.69) * 3935  (-3.09) ** 
       
Note: Durations recorded in milliseconds; z-scores in parentheses 
*  z-score > 1, ** z-score > 2 
 
The average frequency of intrusive saccadic eye movements (FixSacc) is presented in 
Figure 5.3.8. Here patients displayed FixSacc deficits, or borderline FixSacc deficits, on all 
target locations.  
 
Figure 5.3.8: MPS-I intrusive saccade individual patient performance. Average frequency of intrusive saccades 
(FixSacc) produced by MPS-IH patients (green dots), MPS-IA patients (red dots) and healthy controls (blue 
dots). The healthy developmental trajectory (red line) is expressed as a plateau function. 95% confidence limits 
(black dashed-line) are also presented.  
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Table 5.3.8 shows that patients produced an average of 2 intrusive saccades when 
performance was collapsed across target locations (MPS-IH patient 1 (z-score) = - 3.39 ; 
MPS-IA patient (z-score) = -4.36). The temporal eye movement data of both patients (Figure 
5.3.9) shows that the FixDwell deficits exhibited by the 2 patients were primarily due to 
difficulties suppressing intrusive saccades (FixSacc). The onset and velocity of the initial eye 
movements towards the target did not appear to differ between patients and controls. This 
means that the FixDwell deficits were not the result of patients’ gaze reaching the target later 
than controls.  
Table 5.3.8: MPS-I z-scores for intrusive saccades (FixSacc) 
  Target Position  
PID Age 
(Years) 
Left Right Bottom Top Avg 
       
IH 1 10.6 2  (-1.38) * 2  (-1.98) * 3  (-3.30) ** 2  (-2.19) ** 2  (-3.39) ** 
       
IA 14.65 3  (-4.83) ** 2  (-2.06) ** 2  (-1.04) * 2  (-3.22) ** 2  (-4.36) ** 
       
Note: z-scores in parentheses 
*  z-score > 1, ** z-score > 2 
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Figure 5.3.9: MPS-I fixation task raw temporal data. Fixation performance of MPS-IH patient 1 and the MPS-
IA patient. The visual stimulus (blue line) is presented along with eye position (black line). For each patient the 
above graph shows horizontal target conditions and the below graph shows vertical conditions.  
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Pro-saccade Task 
 As expected from the eye movements shown during the fixation task (Figure 5.1.11), 
the reflexive properties of saccades (saccade initiation latency (SaccOnset) and saccade 
velocity (SaccVelo)) were within range of normal healthy controls for both patients. 
Consequentially these results are not presented here. 
 
Anti-saccade Task 
Only the MPS-IA patient completed the anti-saccade task and did not present deficits 
for the time taken to locate the anti-saccade target (AntiOffset). The proportion of corrected 
errors (AntiCorr) that the MPS-IA patient produced is displayed in Figure 5.3.10. For 5 of the 
8 target locations the MPS-IA patient corrected fewer errors than the expected (z-score > 2). 
These target locations included both bottom targets (inner = .40 and outer = .20), the outer 
top (.75), inner left (.50) and outer right targets (.40). The average proportion of corrected 
errors across conditions was below the 95% CI of the healthy developing controls (AntiCorr 
= .59 ; z-score = -4.52). 
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Figure 5.3.10: MPS-I anti-saccade error correction individual patient performance. Proportion of corrected pro-
saccade errors exhibited by the MPS-IA patient. Target amplitudes of 4° (inner) are shown in the top four panels 
and target amplitudes of 8° (outer) vertical are shown in the bottom fours panels.  
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5.3.4 Conclusions: Hurler Syndrome (MPS-I) 
 The present study investigated the cognitive functioning of 3 patients (2 MPS-IH, 1 
MPS-IA) diagnosed with Hurler syndrome on measures of attention, language and 
oculomotor function. MPS-IH, and the less severe form MPS-IA, is a lysosomal storage 
disorder that has been associated with a wide range of neuropsychological deficits. These 
include deficits in attention, executive function, and verbal comprehension (Biernacka et al., 
2010; Shapiro et al., 2009). Consistent with previous studies, patients from the current study 
demonstrated clear deficits on measures of attention and language. 
Attention deficits were characterised by delayed response latencies for simple reaction 
time and visual search, and difficulties suppressing intrusive saccades during fixation 
maintenance. Verbal production and comprehension deficits were demonstrated on the BNT 
and BPVS tasks respectively. In addition, the learning of non-words was abnormal in MPS-
IH patients, with difficulties for recognition and production being identified. In most tasks, 
reported deficits were more pronounced for MPS-IH in comparison to MPS-IA. 
 The global nature of deficits reported in the present study supports is concurrent with  
findings that the white matter integrity of MPS-IH is compromised (Müller-Forell et al., 
2007; Shapiro et al., 2012). Therefore, it is recommended that future analysis of the cohort 
implement imaging methods (such as fMRI and DTI) to elucidate the precise cortical regions 
that are disrupted in MPS-IH. In addition, the frequency of medical events, such as number of 
required transplants to obtain engraftment for HCT treatment, has been shown to correlate 
with white matter integrity. This is because the treatment involves the use of chemotherapy, 
which can lead to the degradation of white matter (Anderson et al., 2008).  
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5.4 Maroteaux-Lamy Syndrome (MPS-VI) 
Maroteaux-Lamy Syndrome (MPS VI) is caused by a deficiency or dysfunction of the 
enzyme N-acetylgalactosamine- 4-sulfatase,  which is required for the degradation of 
dermatan –sulphate (Wraith, 2006). The resulting presentation is primarily structural, 
including reduced growth velocity, enlarged head and chest deformities (de Almeida-Barros 
et al., 2012; Giugliani et al., 2007). MPS-VI is not associated with any cognitive 
manifestations, thus no studies exists detailing the neuropsychological profile of this 
population. It is hypothesised that functioning will be normal on the majority of tasks and that 
deficits may be present on measures that require motor responses, such as the simple reaction 
time and visual search tasks. 
Patients 
Two patients (siblings) diagnosed with Maroteaux-Lamy syndrome (MPS-VI) were 
recruited by a research nurse at Birmingham Children’s Hospital (patient demongraphics 
shown in Table 5.4.1). Both patients completed the assessment during a routine clinic visit. 
All assessments were conducted at the Welcome Trust Clinical Research Facility at 
Birmingham Children’s Hospital. Consent for all children was obtained from the children’s 
parents prior to testing.  
 
Table 5.4.1: MPS-VI summary of patient demongraphics 
PID Gender CA (Years) BPVS MA 
(Years) 
Linguistic Profile 
1 M 8.96 7.42 BL - English / Pashto 
2 M 14.86 10.16 BL - English / Pashto 
Note: ML, monolingual, BL, bilingual 
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Unlike MPS-IVa and MPS-IH, the function of MPS-VI patients was normal on most 
measures. The only exception was a mild verbal comprehension deficit on the BPVS. 
 
5.4.1 Attention 
Simple reaction time, as measured by the mean (RTmean) of simple response time, 
was normal for both patients. In addition the mean search time (VSmean) and search 
efficiency (VSslope) on the visual search task were within range of healthy development.  
 
5.4.2 Language 
 Due to times constraints placed on the testing session due to clinic appointments that 
the patients had on the day of testing, only a measure of verbal comprehension (BPVS) was 
taken. 
 
Production and Comprehension 
 The verbal comprehension scores of the 2 MPS-VI patients are displayed in Figure 
5.4.1. Scores of both patients were below the predicted mean of healthy development (red 
line) and patient 2 (14.86 years) exhibited borderline difficulties. Table 5.4.2 indicated that 
these 2 patients were both within the lower range (z-score > 1) of healthy development, with 
patient 2 being close to exhibiting a comprehension deficits (z-score = -1.93). 
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Figure 5.4.1: MPS-VI verbal production and comprehension individual patient performance. Patient (green dots) 
and healthy control (blue dots) raw scores on the Boston Naming task (left) and the British Picture Vocabulary 
Scale (right). Healthy developing trajectories (red line) are expressed as quadratic functions for both BNT and 
BPVS. 95% confidence limits are included (black dashed-line).  
 
Table 5.4.2: MPS-VI z-scores for verbal 
comprehension. 
PID Age 
 (Years) 
BPVS 
1 8.96 76  (-1.02) * 
2 14.86 99  (-1.93) * 
*  z-score > 1, ** z-score > 2 
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5.4.3 Ocular Motor 
 Both MPS-VI displayed no deficits on any measure of oculomotor function. This was 
true for tasks that contained attentional components (fixation task and anti-saccade task) and 
tasks which measured the properties of ocular motor movement (pro-saccade task and 
smooth-pursuit task). 
5.4.4 Conclusions: Maroteaux-Lamy Syndrome (MPS-VI) 
 The current study represented the first detailed investigation of cognitive function in 
children diagnosed with Maroteaux-Lamy syndrome (MPS-VI). Cognitive functioning on all 
measures was normal for the 2 patients. Only the eldest patient presented difficulties for 
verbal comprehension, and deficits here were mild. These results suggest that the cognitive 
function of MPS-VI children is unaffected by the disease. 
  
5.5 Chapter Conclusions 
 In this chapter, the performance of 3 lysosomal storage disorders was examined:  
Hurler syndrome (MPS-IH), Morquio syndrome (MPS-IVa) and Maroteaux-Lamy syndrome 
(MPS-VI). These are disorders that have been associated with distinct neuropsychological 
profiles (J Ed Wraith, 2006). Cognitive functioning in MPS-IH deteriorates with disease 
progression (Elkin et al., 2006), MPS-IVa patients possess mild cognitive deficits (Davison et 
al., 2012), and MPS-VI patients are believed to possess a normal cognitive profile (Neufeld 
& Muenzer, 2001; J Ed Wraith, 2006). Results from the patient cohorts in the present study 
are consistent with these previous findings. Therefore, it was concluded that the constructed 
test battery which contains measures of attention, language, and oculomotor function, is 
sensitive to the neurodegenerative effects of metabolic disease. 
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 In summary, both MPS-IH and MPS-IVa demonstrated prominent attention deficits. 
This was evident most clearly on the fixation task, whereby sustained attention was poorer 
for patients than controls. In addition, other attention difficulties were identified on the visual 
search task, whereby deficits were mild for MPS-IVa and severe for the MPS-IH patient who 
was assessed. This trend was similar for language tasks; mild deficits of verbal 
comprehension were apparent in MPS-IVa patients, and clear difficulties were exhibited for 
verbal production, comprehension, and non-word learning in MPS-IH. The performance of 
MPS-VI was normal on all tasks. 
 Based on the observed attention deficits in MPS-IVa and MPS-IH, it is recommended 
that future research investigate the functional properties of the brain regions that mediate 
these processes. For visual search, this would primarily involve imaging of frontal brain areas 
that have roles in exploratory eye movements (FEF), response inhibition (anterior cingulate), 
and decision making (orbitofrontal cortex). For sustained attention, the function of brain 
regions that are believed to be important for saccade suppression (DLPFC) should be 
examined.  
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6.0 TYROSINEMIA DISORDERS 
This section of the thesis will detail findings from patients diagnosed with 
Tyrosinemia Type I (T1) and Tyrosinemia Type III (T3). These are disorders that are defined 
by the dysfunction of enzymes involved in the metabolism of tyrosine. Tyrosinemia I, the 
most prevalent of the tyrosinemias, is not associated with cognitive dysfunction but recent 
findings have suggested that long term treatment with 2-nitro-4-trifluromethylbenzoyl 
(NTBC) may lead mental retardation (Bendadi et al., 2014b; Masurel-Paulet et al., 2008; 
Thimm et al., 2012). Here we attempt to identify whether NTBC treated Tyrosinemia I 
patients present cognitive deficits on tasks that measure attention, language and oculomotor 
function. In contrast, Tyrosinemia III has been associated with intellectual impairments 
(Cerone et al., 1997; Ellaway et al., 2001), however these observations have been based case 
reports only (Ellaway et al., 2001). Hence, to our knowledge, results reported here represent 
the most detailed description of cognitive function in Tyrosinemia III to date.  
 
6.1 Tyrosinemia Type I (T1) 
 Tyrosinemia I (T1) is caused by the deficiency of fumarylacetoacetase, the final 
enzyme in the tyrosine metabolic pathway, and is considered the most severe form of 
tyrosinemia due to liver and renal complications. If these symptoms are left untreated the 
accumulation of toxic metabolites, notably maleylacetoacetate and fumarylacetoace, can 
induce organ dysfunction and carcinogenesis, which are the main causes of early childhood 
death in T1. Treatment with 2-nitro-4-trifluromethylbenzoyl (NTBC) has been shown to 
greatly improve the survivability of patients but significantly increases tyrosine levels as a 
side effect. This is because NTBC biochemically switches the T1 enzymatic defect to the 
enzyme defect of tyrosinemia III, a disorder that is associated with elevated tyrosine levels. 
Due to the elevated tyrosine levels, tyrosinemia III is commonly linked with cognitive 
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deficits (Cerone et al., 1997; Ellaway et al., 2001). Therefore it is a concern that prolonged 
treatment with NTBC will lead to cognitive deficits in tyrosinemia I.  
Thimm et al. (2012) and Bendadi et al. (2014a) investigated the cognitive functioning 
of NTBC treatment T1 patients. Using standardised measures of intelligence, both studies 
found that T1 patients presented with dysfunction or retardation for language development 
and gross motor function.  Thimm et al. (2012) also investigated whether T1 patients possess 
neuroanatomical abnormalities, and found MRI findings to be normal in all patients. 
Therefore, in the current project it is expected that T1 patients will present with deficits on 
the language tasks. Since no neuroanatomical abnormalities have been reported in T1 
patients, it is unclear how patients will perform on other tasks. 
  
Patients 
Four patients diagnosed with Tyrosinemia I (3 males; mean age: 12.53 years, range: 
10.6 – 14.65 years) were recruited by a research nurse at Birmingham Children’s Hospital 
(patient demographics shown in Table 6.1.1). All patients completed the assessment during 
routine clinic visits at Birmingham Children’s Hospital. All assessments were conducted at 
the Welcome Trust Clinical Research Facility at Birmingham Children’s Hospital. Consent 
for all children was obtained from the children’s parents prior to testing.  
Table 6.1.1: T1 summary of patient demographics 
PID Gender CA (Years) BPVS MA 
(Years) 
Linguistic Profile 
1 F 7.20 ~ ML – English 
2 M 8.58 5.80 ML - English 
3 M 8.61 7.52 BL – English / Pashto 
4 M 16.13 14.24 BL – English / Pashto 
Note: ML, Monolingual, BL, Bilingual 
 
 151 
 
Table 6.1.2 provides an overview of the main findings from the current cohort of  T1 
patients. As shown in previous studies, deficits were found on language measures (verbal 
comprehension (BPVS) and non-word learning). In addition a single patient presented a 
deficit for the onset latency of reflexive saccades (SaccOnset). Patients performed 
appropriately for age on tasks that contained attentional elements (simple reaction time, 
visual search, fixation, and anti-saccade tasks). 
 
Table 6.1.2: T1 summary of deficits across domains. 
Domain Task  Measures 
Attention 
Simple RT Task -  
Visual Search Task -  
    
Language 
BNT -  
BPVS *  
Non-Word Task * NonProd 
    
Ocular Motor 
Fixation Task -  
Prosaccade Task * SaccOnset 
Antisaccade Task -  
Smooth Pursuit -  
    
Note: NonProd: Total Produced Non-Words, SaccOnset: Saccade Onset Time 
*  Possible deficit, ** Consistent deficit 
 
 
 
 
6.1.1 Attention 
Three of the four patients completed all of the attention tasks during the assessment. 
Patient 2 (8.58 years) was unable to complete the simple reaction time task due to time 
constraints placed on the testing session by their clinic visit. Findings from the attention tasks 
revealed all patients to be within range of healthy controls on the simple reaction time and 
visual search tasks. Therefore these results will not be reported here. 
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6.1.2 Language 
 Due to T1 patient assessments being conducted during patient clinic visits, not enough 
time was available to complete all language tasks. Specifically, only patient 1 and 2 
completed the British Picture Vocabulary Scale (BPVS), patients 2, 3 and 4 completed the 
non-word learning task, and no patients completed the Boston Naming task (BNT). 
Production and Comprehension 
 The verbal production scores (BPVS) of patient 1 (8.51 years) and patient 2 (8.61 
years) are displayed in Figure 6.1.1 and Table 6.1.3. Figure 6.1.1 shows that both patients 
exhibited scores that were below the predicted mean of healthy development (red line). Table 
6.1.1 identifies a borderline deficit in patient 2 (z-score = -2.24). Since the two patients are 
very close in age, it is difficult to determine whether verbal comprehension deficits would 
exist across a wider range of ages.  
 
 153 
 
 
Figure 6.1.1: T1 verbal comprehension invidual patient scores. Patient (green dots) and healthy control (blue 
dots) raw scores on the British Picture Vocabulary Scale. Healthy developing trajectory (red line) is expressed 
as quadratic function. 95% confidence limits are included (black dashed-line).  
 
 
 
 
 
 
 
Non-Word Learning Task 
The non-word learning of 5 non-words (monsters) demonstrated by T1 patients is 
presented in Figure 6.1.2 and Table 6.1.4. Figure 6.1.2 shows that the performance of patient 
Table 6.1.3: T1 z-score for verbal comprehension 
PID Age 
(Years) 
BPVS 
2 8.58 76.00  (-0.78) 
3 8.61 59.00  (-2.24) ** 
Note: z-scores in parentheses 
*  z-score > 1, ** z-score > 2 
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2 and patient 3 was within the 95% CI range of healthy development (black dashed-line) for 
both the production (left-panel) and comprehension (right-panel). Patient 4 (16.13 years) 
demonstrated a borderline deficit (z-score = -2.05) for production but not comprehension. 
The non-word learning performance of patient 4 (Figure 6.1.3) shows that their borderline 
production deficit was caused by the inability to successfully produce more than 4 monster 
names in any of the 6 learning iterations. 
 
Figure 6.1.2: T1 non-word production and comprehension individual patient scores. Total non-word production 
and comprehension scores of T1 patients (green dots) and healthy controls (blue dots) in relation to healthy 
developing trajectories (red lines). Production and comprehension scores are shown in the left and right panels 
respectively. 95% confidence limits are included (black dashed-line).  
Table 6.1.4: T1 z-scores for non-word production and 
comprehension 
PID Age 
(Years) 
NonProd NonComp 
2 8.58 17  (-0.83) 28  (-0.43) 
3 8.61 25  (0.64) 28  (-0.44) 
4 16.13 18  (-2.05) ** 29  (-0.43) 
Note: z-scores in parentheses 
*  z-score > 1, ** z-score > 2 
 
 
 155 
 
 
Figure 6.1.3: T1 non-word learning performance of an individual patient. Number of monsters named and 
identified for production (left) and comprehension (right) by patient 4 (black solid-line). Scores represent the 
learning over 6 successive training iterations. An age-matched control is also presented (black dashed-line)  
 
 
 
 
 
 
 
 
 
 
6.1.3 Oculomotor 
 All T1 patients completed the oculomotor tasks. The performance of all patients was 
within the range of healthy development for the fixation, anti-saccade, and smooth pursuit 
tasks. Therefore results from these tasks will not be presented for the T1 patient group. A 
possible deficit was detected for the onset of reflexive saccades (ProSacc) during the pro-
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saccade task. The velocity (SaccVelo) of reflexive saccades was within range of healthy 
development. 
 
Pro-saccade Task 
Comparison of the mean saccade onset latencies (ProSacc) of T1 patients to healthy 
developmental trajectories (red lines) is presented in Figure 6.1.4. The onset latencies of the 3 
youngest patients were within the healthy developing range (black dashed-line), while the 
eldest patient (patient 4: 16:13 years) exhibited borderline deficits on the majority of target 
locations. Patient z-scores for saccade onset latency (Table 6.1.5) indicated that when the 
onset latencies were averaged across conditions patient 4 demonstrated a clear deficit (z-score 
= -2.70). An examination of patient 4’s performance on individual target locations revealed 
that onset latencies were slower for 3/4 inner targets and 2/4 outer targets. This shows that the 
slower onsets that patient 4 demonstrated were not exclusive to targets positioned at specific 
amplitudes (inner / outer) or axes (vertical / horizontal). These findings are further illustrated 
by the comparison of the eye movements of patient 4 and an age-matched control which are 
presented in Figure 6.1.5. 
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Figure 6.1.4: T1 saccadic onset individual patient performance. The average saccade onset (ms) towards the 
visual stimulus at each target location for T1 patients. Target amplitudes of 4° (inner) are shown in the top four 
panels and target amplitudes of 8° (outer) vertical are shown in the bottom fours panels.  
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Table 6.1.5: T1 z-scores for pro-saccade onset (SaccOnset) 
   Target Position  
PID Age 
(Years) 
Task Left Right Bottom Top Avg 
1 7.20 
Inner 196  (0.06) 206  (-0.39) 206  (0.53) 273  (-1.02) * 
235  (-0.25) 
Outer 247  (-0.45) 293  (-1.62) * 290  (-0.24) 253  (-0.04) 
        
2 8.58 
Inner 231  (-1.19) * 203  (-0.48) 212  (0.27) 189  (0.22) 
218  (-0.22) 
Outer 235  (-0.63) 178  (0.72) 263  (-0.21) 235  (-0.00) 
        
3 8.61 
Inner 179  (0.14) 172  (0.35) 238  (-0.23) 257  (-1.10) * 
242  (-0.89) 
Outer 231  (-0.56) 237  (-0.74) 256  (-0.10) 310  (-1.30) * 
        
4 16.13 
Inner 212  (-2.39) ** 245  (-3.17) ** 280  (-3.00) ** 206  (-1.86) * 
229  (-2.70) ** 
Outer 187  (-0.55) 227  (-2.34) ** 254  (-2.08) ** 224  (-1.02) * 
Note: Saccade onsets recorded in milliseconds, z-scores in parentheses 
*  z-score > 1, ** z-score > 2 
  
 
 
Figure 6.1.5: T1 pro-saccade task raw temporal data. Saccadic eye movements of patient 4 on horizontal and 
vertical target positions. The visual stimulus (blue line) is presented along with the eye position of the patient 4 
(black line) and an age-matched control (red dotted-line).  
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6.1.4 Conclusions: Tyrosinemia I (T1) 
 The long-term cognitive outcomes of NTBC treated T1 patients were investigated to 
identify the presence of cognitive deficits using the current test battery. In the patient group 
(4 patients), the eldest patient (patient 4: 16.13 years) presented deficits on non-word 
production and reflexive saccade onset latencies. Patient 3 also presented deficits for verbal 
comprehension on the BPVS. Cognitive deficits were absent on tasks which measured 
attention and smooth pursuit eye movements. 
The presence of language deficits is in line with previous findings by Bendadi et al. 
(2014a) and Thimm et al. (2012). However, in both these studies language deficits were 
reported in a larger percentage of patients (80%) compared to the current study (50%). This 
may be due to the smaller sample size of the current study (Thimm et al. (2012) reviewed 8 
T1 patients), as a larger sample may reveal a higher percentage of patients with language 
deficits. In addition, Bendadi et al. (2014a) and Thimm et al. (2012) recorded the tyrosine 
levels, phenylalanine levels, NTBC levels, diet length, and dietary compliance of patients to 
evaluate how these factors affected cognitive function. In both studies, biochemical data and 
dietary data did not correlate with cognitive performance; patients with higher tyrosine levels 
did not necessarily obtain the lowest IQ scores. However, Thimm et al. (2012) stressed that 
future studies should monitor the biochemical data of patients to assist the interpretation of 
cognitive outcomes. This is because previous studies (Masurel-Paulet et al., 2008) have 
demonstrated that the ratio of tyrosine (raised by treatment with NTBC) to phenylalanine 
(reduced through the dietary intervention) may be important, as both metabolites compete for 
transport in the brain. A combination of high tyrosine and low phenylalanine could 
potentially lead to a decreased amount of phenylalanine available for the synthesis of protein 
and neurotransmitter. Therefore, analysing the biochemical data of the current cohort may 
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highlight why the older patients performed abnormally on several tasks while other patients 
were normal. 
Based on the current findings from tyrosinemia I patients, it is unclear whether NTBC 
results in patients becoming susceptible to cognitive decline. While the performance of many 
patients was normal on tasks of attention, several patients showed deficits on language, and a 
single patient demonstrated difficulties initiating reflexive saccades. Future analysis should 
focus on incorporating biochemical data to determine whether the cognitive deficits in this 
cohort are linked to the ratio levels of tyrosine to phenylalanine. 
   
6.2 Tyrosinemia Type III (T3) 
  Tyrosinemia Type III (T3) is a more benign form of the tyrosinemia, as it is not 
associated with the liver or renal complications which lead to reduced life expectancy. 
However, tyrosine levels are markedly elevated in T3 patients due to the deficiency of 4-
hydroxyphenylpyruvate dioxygenase, the second enzyme within the tyrosine metabolic 
pathway. T3 is the rarest of the 3 tyrosinemias, which means only a few case studies (Cerone 
et al., 1997; D’Eufemia et al., 2009; Ellaway et al., 2001) exist that document the 
neurological and intellectual complications of the disease.  However, a consistent finding is 
that the majority of patients present with intellectual impairments, which is believed to be due 
to the increase of cerebrospinal fluid tyrosine concentrations (Ellaway et al., 2001). In 
addition, cognitive deficits of T3 are more severe in patients who receive a later diagnosis. 
This is because treatment involves a tyrosine restricted diet which maintains tyrosine levels 
within a safe range.   
 The predicted cognitive performance of the current T3 cohort is difficult to 
determine. A series of case reports by Ellaway et al. (2001) provides the only description of 
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cognitive functioning for a large size sample of T3 patients (12 patients). Here, a large 
proportion of patients (8/12 patients) exhibited cognitive deficits which were characterised by 
mild to moderate learning difficulties and developmental delay. However, these reports are 
based solely on scores from standardised test batteries, rather than from more detailed 
cognitive testing. Other indicators of cognitive impairments that may be expressed by T3 
patients comes indirectly from studies of NTBC treated T1 patients. This is because NTBC 
treatment essentially transforms T1 patients into T3 patients (from a biochemical perceptive). 
T1 patients who have received long term treatment with NTBC have been reported to display 
language development impairments (Bendadi et al., 2014a; Thimm et al., 2011). Therefore 
based on previous reports of T3 (Ellaway et al., 2001), it is predicted that mild to moderate 
deficits will be revealed across multiple domains. In addition, based on findings from NTBC 
treated T1 patients (Bendadi et al., 2014a; Thimm et al., 2011), moderate language deficits 
may also be present. 
 
Patients 
Eleven patients diagnosed with Tyrosinemia Type III (3 males; mean age: 12.53 
years, range: 4.40 – 19.58 years) were recruited by a research nurse (patient demographics 
displayed in Table 6.2.1). All patients completed the assessments during appointments that 
were independent to their usual clinic visits at the Wellcome Trust Clinical Research Facility 
at Birmingham Children’s Hospital. Consent for all children was obtained from the children’s 
parents prior to testing. 
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Table 6.2.1: T3 summary of patient demographics 
PID Gender CA (Years) BPVS MA 
(Years) 
Linguistic Profile 
1 F 4.42 5.32 BL – English / Pashto 
2 M 5.23 3.08 BL – Pashto / English 
3 F 6.28 5.32 BL – English / Punjabi 
4 M 6.62 9 ML - English 
5 F 7.48 5.92 BL – English / Pashto 
6 F 7.83 5.00 BL – Pashto / English 
7 M 8.25 2.92 BL – English / Pashto 
8 M 15.81 5.32 BL – English / Pashto 
9 M 17.68 7.92 BL – Pashto / English 
10 F 19.52 6.08 BL – English / Punjabi 
11 F 19.81 10.32 BL – English / Punjabi 
Note: ML, Monolingual, BL, Bilingual 
 
Table 6.2.2 presents a brief summary of the findings from the T3 patients that will be 
discussed. Here, patients exhibited clear deficits on language tasks (BNT and BPVS). Mild 
attention deficits were also observed (RTmean, VSmean, FixDwell). 
 
Table 6.2.2: T3 summary of deficits across domains 
Domain Task  Measures 
Attention 
Simple RT Task * RTmean 
Visual Search Task * VSmean 
    
Language 
BNT **  
BPVS **  
Non-Word Task * NonProd, NonComp 
    
Ocular Motor 
Fixation Task * FixDwell 
Prosaccade Task -  
Antisaccade Task -  
Smooth Pursuit -  
    
Note: RTmean: Mean Reaction Time,  VSmean: Mean Visual Search Time, NonProd: Total Produced Non-
Words, NonComp: Total Comprehended Non-Words, FixDwell: Fixation Duration Time 
*  Possible deficit, ** Consistent deficit 
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6.2.1 Attention 
All patients completed the attention tasks. Findings from the attention tasks will be 
examined on a group and individual basis. The majority of patients produced normal response 
times on the simple reaction time task (RTmean), and several patients demonstrated deficits 
for search time latency (VSmean) on the visual search task. 
 
Simple Reaction Time Task 
A comparison of the mean reaction times (RTmean) of individual T3 patients to the 
developmental trajectories of the healthy developing controls (red lines) is displayed in 
Figure 6.2.1. In general, the distribution of patient response times (within 95% CI range) was 
evenly distributed across the predicted mean healthy development (red line) on all target 
locations. 
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Figure 6.2.1: T3 simple reaction time individual patient performance. Mean simple reaction time (RTmean) of 
T3 patients (green dots) and healthy developing controls (blue dots). Developmental trajectory of controls 
expressed as a non-linear regression (red line) with 95% CI (dotted black line).  
Three patients demonstrated slower response times (z-score > -2) when performance 
was collapsed across target locations (Table 6.2.3). These were the two youngest patients 
(patient 1 (4.40 years) and patient 2 (5.16 years)) and an older patient (patient 9: 17.64 years). 
Patient 11 (19.10 years) who exhibited a borderline response time deficit (z-score = -1.98).  
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Table 6.2.3: T3 z-scores for mean reaction time (RTmean) 
PID Age 
(Years) 
Bottom Left Bottom Right Top Left Top Right Avg 
1 4.40 1206  (-2.60) ** 1075  (-1.79) * 1654  (-5.42) ** 815  (-0.15) 1193  (-2.53) ** 
2 5.16 1119  (-3.14) ** 1204  (-3.75) ** 819  (-0.95) 822  (-0.98) 988  (-2.18) ** 
3 6.24 651  (-0.41) 797  (-1.64) * 414  (1.56) 784  (-1.53) * 661  (-0.49) 
4 6.64 381  (1.81) 332  (2.22) 320  (2.33) 376  (1.86) 354  (2.04) 
5 7.5 525  (0.07) 507  (0.26) 430  (1.01) 514  (0.18) 496  (0.36) 
6 7.08 509  (0.21) 620  (-0.87) 581  (-0.49) 457  (0.72) 542  (-0.11) 
7 8.24 450  (0.35) 480  (0.00) 590  (-1.20) * 437  (0.50) 486  (-0.06) 
8 15.40 298  (0.25) 267  (0.94) 272  (0.83) 272  (0.82) 278  (0.70) 
9 17.64 417  (-2.78) ** 404  (-2.48) ** 414  (-2.71) ** 549  (-5.75) ** 440  (-3.31) ** 
10 19.58 314  (-0.75) 257  (0.65) 266  (0.42) 294  (-0.27) 283  (-0.00) 
11 19.16 367  (-2.03) ** 341  (-1.41) * 356  (-1.77) * 395  (-2.71) ** 365  (-1.98) * 
Note: Reponses recorded in milliseconds, z-scores quotients in parentheses 
*  z-score > -1, ** z-score > -2 
 
 
Finally, AIC comparisons revealed there was insufficient evidence of 3- and 2-way 
interactions, and main effects, for Group, TargetLocation, and Age. This means that t3 simple 
response time development was not offset from the development of heathy controls, and also 
the rate of development for simple response time did not differ between T3 patients and 
controls. 
 
 
Visual Search Task 
 The performance of T3 patients on the visual search task is presented in Figure 6.2.2. 
Deficits on both feature and conjunction search tasks were identified in the younger and older 
patients for mean search time (VSmean). The 6 patients between the ages of 70-190 months 
exhibited normal search times.  
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Figure 6.2.2: T3 visual search task individual patient performance. Mean search time (VSmean) and search 
efficiency (VSslope) of T3 patients (green dots) and healthy developing controls (blue dots). Developmental 
trajectories of controls are expressed as quadratic regressions (red line) with 95% CI (dashed black line).  
 
Table 6.2.4 displays the z-scores of individual T3 patients on the visual search task. 
For conjunction search, only patient 6 (7.84 years) exhibited search efficiency (VSslope) 
difficulties (z-score = -2.83), however, their mean search time (VSmean) was still within the 
normal range (z-score = -1.16). As shown in Figure 6.2.2, mean search time (VSmean) 
deficits (z-score > -2) were evident among younger and older T3 patients on feature and 
conjunction search. Because these deficits were common for mean search time (VSmean) and 
not search proficiency (VSslope), it is likely that the visual search deficits are mediated by 
decision making, rather than serial search, deficiencies. 
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Table 6.2.4: T3 z-scores for visual search time (VSmean) and  search 
efficiency (VSslope) 
PID 
Age 
(Years) 
Task VSmean VSslope 
1 4.40 
FS 1805  (-2.82) ** -10  (0.64) 
CS 3496  (-2.69) ** -46  (1.62) 
     
2 5.23 
FS 1822  (-3.66) ** -17  (0.97) 
CS 2805  (-1.51) * -1  (1.00) 
     
3 6.28 
FS 1248  (-1.01) * -143  (7.38) 
CS 3740  (-4.92) ** 171  (-1.96) * 
     
4 6.62 
FS 650  (2.65) -15  (0.98) 
CS 1420  (1.56) 98  (-0.69) 
     
5 7.48 
FS 974  (0.09) -3  (0.37) 
CS 1697  (0.35) 29  (0.63) 
     
6 7.84 
FS 908  (0.37) -15  (1.10) 
CS 2112  (-1.16) * 200  (-2.83) ** 
     
7 8.26 
FS 719  (1.57) 19  (-1.18) * 
CS 1378  (1.04) 9  (1.10) 
     
8 15.81 
FS 635  (-0.87) -7  (1.74) 
CS 855  (0.73) 46  (0.20) 
     
9 17.68 
FS 951  (-5.55) ** -4  (1.46) 
CS 1243  (-2.82) ** 9  (2.30) 
     
10 19.52 
FS 591  (-1.66) * 3  (0.37) 
CS 1085  (-2.62) ** 58  (-1.85) * 
     
11 19.82 
FS 670  (-2.82) ** -14  (3.59) 
CS 1192  (-3.81) ** 42  (-0.57) 
Note: FS: Feature Search, CS: Conjunction Search, reponses recorded in 
milliseconds, z-scores in parentheses 
*  z-score > 1, ** z-score > 2 
 
The AIC comparisons used to test for differences between the visual search 
developmental trajectories of patients and controls revealed insufficient evidence of 3- and 2-
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way interactions for Group, SetSize, and Age. However, clear main effects for Group were 
found on feature search (test-model (∆AIC / AICw) = 0 / .999 ; null-model (∆AIC / AICw) = 
35.5 / .001)  and conjunction search (test-model (∆AIC / AICw) = 0 / .999 ; null-model 
(∆AIC / AICw) = 34.7 / .001). This means that while the rate of visual search development 
for T3 patients was normal for both mean search time and search efficiency, T3 development 
of mean search time (VSmean) was offset from the development of controls. 
 Since  differences between patients and controls were reported for search time 
(VSmean) and not search efficiency (VSslope), only the T3 developmental trajectories for 
feature and conjunction search time (VSmean) were defined  (Table 6.2.3). The fit of the 
developmental trajectories to linear, quadratic or plateau functions indicated that plateau 
functions offered the best description of development for both feature and conjunction search 
time (Table 6.2.5). 
 
Table 6.2.5: T3 visual search task – AIC trajectory comparisons 
 
Plateau Models 
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
 
Linear Quadratic Plateau 
 
Intercept 
Rate 
Constant 
Plateau 
 
R
2
 
          
VSmean - FS 9.5 / <.01 5.4 / .06 0 / .93  1948 .046 685  .74 
          
VSmean - CS 3.4 / .08 0.1 / .44 0 / .47  3594 .028 1047  .64 
          
Notes: FS: Feature Search, CS: Conjunction Search, reponses recorded in milliseconds 
 
 
Developmental slopes of T3 patients and controls are presented in Figure 6.2.3. The 
slopes and model parameters of fitted functions (Table 6.2.5) illustrate the developmental 
differences that were identified between the groups. Compared to controls, at the youngest 
age of measurement (intercept term) T3 patients produced slower feature search (T3 = 
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1948ms ; Controls = 1132ms) and conjunction search responses (T3 = 3594ms ; Controls = 
2074ms). However, this should be interpreted with caution since only a few patient data 
points occupy this time point of development. Another observation is that the development of 
T3 patients during later years diverges from healthy development, with patients becoming 
slower in comparison to healthy controls. This is because the developmental slopes of 
patients were defined by plateau functions, while control development was defined by 
quadratic functions. However, this observation should be interpreted with caution due to the 
small number of patient data points used to construct the patient trajectory 
 
 
Figure 6.2.3: T3 visual search task developmental trajectories. Mean search time (VSmean) developmental 
trajectories of T3 patients (blue line) and healthy developing controls (red line). T3 patient raw scores presented 
as green dots. The healthy developmental trajectories are expressed as a quadratic function with 95% CI (dashed 
black line) for all conditions. T3 development is expressed by plateau functions with 95% prediction bands 
(dotted black line).  
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6.2.2 Language 
Due to time constraints, patient 7 was unable to complete the BNT and 2 patients (6 & 
8) were unable to complete the non-word learning task. Findings from the language tasks will 
be examined on a group and individual basis. Language deficits were clear for many patients 
on the BNT (vocabulary production) and the BPVS (vocabulary comprehension). Non-word 
learning deficits were less clear, as abnormalities were only apparent in two older patients. 
  
Production and Comprehension 
Patient verbal production scores (BNT) and verbal comprehension scores (BPVS) are 
reported in Figure 6.2.4. On both tasks, clear deficits were evident among the older patients, 
while borderline deficits were exhibited by younger patients.  
 
 
Figure 6.2.4: T3 verbal production and comprehension individual patient scores. Patient (green dots) and healthy 
control (blue dots) raw scores on the Boston Naming task (left) and the British Picture Vocabulary Scale (right). 
Healthy developing trajectories (red line) are expressed as quadratic functions for both BNT and BPVS. 95% 
confidence limits are included (black dashed-line).  
Table 6.2.6 displays the z-scores of T3 patients on the two language tasks. Here it is 
evident that the majority of patients exhibited deficits (z-score > -2) on the BNT (6/10 
patients) and the BPVS (8/11 patients).  
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Table 6.2.6: T3 z-scores for verbal production and comprehension 
PID Age  
(Years) 
BNT BPVS 
1 4.4 12  (-0.52) 22  (-2.09) ** 
2 5.23 5  (-1.87) * 29  (-2.23) ** 
3 6.28 21  (-1.52) * 54  (-1.07) * 
4 6.62 46  (0.59)  62  (-0.67) 
5 7.48 26  (-2.18) ** 54  (-1.91) * 
6 7.84 26  (-2.51) ** 54  (-2.15) ** 
7 8.26  51  (-2.69) ** 
8 15.81 42  (-4.17) ** 81  (-3.73) ** 
9 17.68 29  (-5.36) ** 60  (-5.85) ** 
10 19.52 55  (-3.22) ** 100  (-3.11) ** 
11 19.82 37  (-4.64) ** 91  (-3.83) ** 
Note: z-scores in parentheses 
*  z-score > -1, ** z-score > -2 
 
 The comparison of patient and healthy control developmental trajectories for verbal 
production (BNT) and comprehension (BPVS) was examined using AIC comparisons. For 
BNT, a 2-way interaction of Group and Age (test-model (∆AIC / AICw) = 0 / .93 ; null-model 
(∆AIC / AICw) = 5.1 / .07) and a main effect of Group (test-model (∆AIC / AICw) = 0 / .99 ; 
null-model (∆AIC / AICw) = 26.6 / <.01) was found. This suggests that the rate of 
development and overall performance of T3 patients differed to controls. This was also found 
for the BPVS, which was shown with in a 2-way interaction of Group x Age (test-model 
(∆AIC / AICw) = 0 / .93 ; null-model (∆AIC / AICw) = 5.1 / .07) and a main effect of Group 
(test-model (∆AIC / AICw) = 0 / .99 ; null-model (∆AIC / AICw) = 56.6 / <.01). 
An AIC comparison of linear, quadratic, and plateau functions on the BNT and BPVS 
tasks for T3 patients is shown in Table 6.2.6. Comparison of AIC values (Table 6.2.7) 
revealed linear functions provided the best description of development for both the BNT and 
BPVS. Plateau functions also provided reasonably good fits to the data on the BPVS. 
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Table 6.2.7: T3 verbal production and comprehension – AIC trajectory comparisons   
   
Linear Models   
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
Linear Quadratic Plateau  Intercept Slope   R
2 
          
BNT 0 / .42 1.4 / .21 0.3 / .37  18.97 .14   .38 
          
BPVS 0 / .42 1.5 / .20 0.2 / .39  38.28 .28   .71 
          
 
 The developmental slopes of patients and healthy controls are presented in Figure 
6.2.5. For both BNT and BPVS, the gradient of development was the primary difference 
between patients and controls; the developmental slopes of controls were steeper than 
patients. As a result, verbal production and comprehension deficits were more common 
among the older patients in the cohort. In addition, for BPVS development 
 
 
Figure 6.2.5: T3 verbal production and comprehension developmental trajectories. BNT and BPVS 
developmental trajectories of T3 patients (blue line) and healthy developing controls (red line). T3 patient raw 
scores presented as green dots. The healthy developmental trajectories are expressed as quadratic functions with 
95% CI (dashed black line) and T3 developmental trajectories are expressed as linear functions with 95% 
prediction bands (dotted black line).  
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Non-Word Learning Task 
The non-word learning of 5 non-words (monsters) of the T3 patients is presented in 
Figure 6.2.6 and Table 6.2.8.  
 
Figure 6.2.6: T3 non-word production and comprehension individual patient scores. Total non-word production 
and (NonProd) comprehension scores (NonComp) of T3 patients (green dots) and healthy controls (blue dots) in 
relation to healthy developing trajectories (red lines). Production and comprehension scores are shown in the left 
and right panels respectively. 95% confidence limits are included (black dashed-line).  
 
Table 6.2.8: T3 z-scores for non-word production and comprehension 
PID Age  
(Years) 
NonProd NonComp 
1 4.4 11  (4.44) 25  (0.74) 
2 5.23 3  (-0.76) 26  (0.48) 
3 6.28 12  (-0.35) 27  (0.18) 
4 6.62 14  (-0.37) 27  (-0.03) 
5 7.48 15  (-0.75) 26  (-1.08) * 
7 8.26 23  (0.39) 28  (-0.31) 
9 17.68 0  (-7.04) ** 23  (-7.17) ** 
10 19.52 29  (0.66) 30  (0.61) 
11 19.82 15  (-3.05) ** 11  (-20.78) ** 
Note: z-scores in parentheses 
*  z-score > 1, ** z-score > 2 
 
For the production and comprehension of non-words, the performance of the majority 
of patients (7 / 9 patients) was normal. Two older patients, patient 9 (17.68 years) and patient 
11 (19.82 years) exhibited clear deficits for both non-word production and comprehension. 
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The performance of these 2 patients across the 6 learning iterations is displayed in Figure 
6.2.7 against the performance of an age-matched healthy control. Here the production 
performance of patient 9 (red line) was at floor (no monsters were successfully named on any 
learning iteration), and for comprehension they were unable to identify more than 4 monsters. 
The comprehension performance of patient 11 (blue line) was very poor, as they could not 
identify more than 2 monsters. The rate of learning for production appeared similar to that of 
healthy controls (i.e. the difference in the number of successful named monsters between the 
first and last iteration was 2). However, the number of successfully named monsters in the 
first iteration was lower than the number of monsters named by healthy controls. Finally, an 
AIC comparison of developmental trajectories indicated that the development of T3 patients 
did not differ to the development of controls. 
 
 
 
 
Figure 6.2.7: T3 non-word mean individual patient performance. Number of monsters named (left) and 
identified (right) during the non-word learning task by patient 9 (red line) and patient 11 (blue line). Learning 
slopes represent learning performance throughout the 6 training iterations. Predicted performance of a healthy 
control (relative to the age of both patients) is representesd by a black dashed-line (C). 
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6.2.3 Oculomotor 
Ten of the eleven T3 patients completed the oculomotor tasks. One patient (patient 2) 
could not complete the tasks due to postural difficulties which prevented eye tracking. 
Patients demonstrated difficulties on the fixation task (FixDwell and FixSacc) only. 
Fixation Task 
The average duration that T3 patients fixated on the visual stimulus (FixDwell) at 
each target position is presented in Figure 6.2.8. As a group, the distribution of patient data 
points was shifted below the predicted mean of healthy development (red line).  
 
Figure 6.2.8: T3 fixation duration individual patient performance.  Average fixation duration (FixDwell; ms) for 
T3 patients (green dots) and healthy controls (blue dots). The healthy developmental trajectory (red line) is 
expressed as a plateau function for left, right and bottom targets. A quadratic function is used here for top target 
development since normative predictions based on a plateau function were poor for the youngest patient. 95% 
confidence limits (black dotted-line) are presented.  
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Table 6.2.9 displays the FixDwell z-scores of individual T3 patients for specific target 
locations and for FixDwell averaged across targets. For the latter, 4 of the 10 patients (patient 
3, 6, 9, 11) exhibited fixation duration deficits. In addition, from the inspection of individual 
target locations it is clear that deficits were more prevalent on bottom targets (6 / 10 patients).  
 
Table 6.2.9: T3 z-scores for fixation duration (FixDwell) 
  Target Position  
PID Age 
(Years) 
left Right Bottom Top Avg 
1 4.40 3062  (-0.46) 2228  (-1.08) * 1748  (-1.42) * 1766  (-4.09) ** 2201  (-1.25) * 
3 6.28 1061  (-5.33) ** 3043  (-1.91) * 1875  (-3.91) ** 1096  (-6.00) ** 1762  (-4.44) ** 
4 6.62 3874  (-0.76) 4730  (0.75) 4966  (1.16) 5254  (1.06) 4706  (0.64) 
5 7.48 4665  (0.24)  4617  (0.14) 3450  (-2.25) ** 4738  (-0.04) 4367  (-0.47) 
6 7.84 3340  (-2.74) ** 3323  (-2.77) ** 3448  (-2.51) ** 3760  (-1.71) * 3468  (-2.64) ** 
7 8.26 4238  (-1.02) * 4168  (-1.18) * 4040  (-1.47) * 4593  (-0.41) 4260  (-1.06) * 
8 15.81 5017  (0.31) 4939  (0.06) 3612  (-4.16) ** 5089  (0.55) 4735  (-0.60) 
9 17.68 3433  (-4.79) ** 4050  (-2.80) ** 2818  (-6.76) ** 2500  (-6.89) ** 3200  (-5.47) ** 
10 19.52 4902  (-0.07) 5039  (0.36) 4805  (-0.38) 4920  (0.09) 4916  (-0.04) 
11 19.82 4730  (-0.62) 4813  (-0.35) 4271  (-2.10) ** 2494  (-6.10) ** 4077  (-2.71) ** 
Note: Durations recorded in milliseconds, z-Scores in parentheses 
*  z-score > 1, ** z-score > 2 
 
  The comparison of T3 patient and healthy developmental trajectories during the 
fixation task was examined through the comparison of AIC model values. A test for a 3-way 
interaction of Group, Targetlocation and Age (test-model (∆AIC / AICw) = 0 / .74 ; null-
model (∆AIC / AICw) = 2.1 / .26)  revealed that the influence of target location on the rate of 
fixation duration development differed between patients and controls. For patients alone, a 
series of 2-way interactions between Targetlocation and Age was conducted to identify how 
target location influenced patient development rate. This included a 1-term model with a 
single trajectory representing all target locations (‘Combined’ model), a 2-term model with 
separate trajectories for horizontal and vertical targets (‘Hori/Vert’ model), and four 2-term 
models which each specified a separate trajectory for the four targets 
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(‘Left’,’Right’,’Top’,’Bottom’ models), and a 3-term model with a single trajectory 
representing horizontal targets, and separate trajectories representing top and bottom targets 
(‘Hori/Top/Bottom’ model). Results of this analysis are presented in Table 6.2.10. Here the 
model that offered the best description of T3 developmental change across the target 
locations was the ‘Hori/Top/Bottom’ model (∆AIC = 0 ; AICw = .44). This means that the 
sustained fixation development of T3 patients proceeded at different rates for top, bottom and 
horizontal targets. These findings also clarify why a 3-way interaction existed; the rate of 
development in healthy controls differed only on top target (described in Chapter 4), while 
patients exhibited different developmental rates for bottom targets, in addition to top targets. 
 
Table 6.2.10: T3 fixation duration – AIC condition comparisons 
FixDwell    
Model ∆AIC AICw Evidence ratio 
    
Hori/Top/Bottom 0 .44 1 
Hori/Vert 1 .27 1.6 
Top 2 .17 2.6 
Combined 4.8 .04 10 
Right 5.1 .03 13 
Bottom 5.6 .03 16 
Left 7.5 .01 40 
    
 
Since the T3 patient development across target locations was best described by the 
‘Hori/Top/Bottom’ model,  the fit of developmental trajectories to linear, quadratic or plateau 
functions was analysed separately for the top, bottom, and horizontal target locations. Results 
revealed that a linear, quadratic and plateau function best described T3 fixation duration 
development for horizontal, top and bottom targets respectively (Table 6.2.11). The 
developmental slopes of T3 patients (blue lines) on the 3 target conditions are presented in 
Figure 6.2.9 alongside healthy developmental trajectories (red lines). Here rates of 
development appeared to be similar between patients and controls for horizontal and bottom 
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target locations. In contrast, development rates appeared to differ between T3 patients and 
controls for the top target, since the slopes diverge during later years. This is because of the 
extreme low scores produced by older T3 patients, which explain why a quadratic function 
offered a preferable fit to the patient data. On all 3 target locations, T3 developmental slopes 
were offset below the slopes of healthy controls. 
 
Table 6.2.11: T3 fixation duration – AIC trajectory comparisons   
Linear Models   
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
Linear Quadratic Plateau  Intercept Slope   R
2 
          
Horizontal 0 / .40 .8 / .26 .3 / .34  3242 103   .31 
          
Quadratic Models 
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
Linear Quadratic Plateau 
 
Intercept 
Linear 
Term 
Quadratic 
Term 
 
R
2 
          
Top .9 / .27 0 / .44 .9 / .28  1925 787 -46  .09 
          
Plateau Models 
 
AIC Results (∆AIC / AICw) 
 
Model Parameter Estimates 
 Fit 
Summary 
 
Linear Quadratic Plateau 
 
Intercept 
Rate 
Constant 
Plateau 
 
R
2 
          
Bottom .4 / .38 2.3 / .15 0 / .47   1690 .647 3917  .20 
          
 
 179 
 
 
Figure 6.2.9: T3 fixation duration developmental trajectories.  Fixation Duration (FixDwell) developmental 
trajectories of T3 patients (blue lines) and healthy controls (red lines). Patients raw scores presented as green 
dots.  
In the final stage of the analysis, the developmental trajectories of patients and 
controls were combared independently for top, bottom, and horizontal targets. Table 6.2.12 
presents the results from AIC comparisons of models that compared the main effect of Group 
and 2-way interaction for Group and Age. Main effects were very clear between groups for 
each comparison. The 2-way interactions for Group and Age were not evident for bottom or 
horizontal targets, and an interaction model was marginally better for the top target. 
However, when 3 patients (patient 2, 9 and 11) with extreme low dwell times were removed, 
a null-model was much better (test-model (∆AIC / AICw) = 2 / .27 ; null-model (∆AIC / 
AICw) = 0 /.73). Therefore, the interaction was largely due to the fixation performance of 
these 3 patients. Together these results suggest that patients' rate of development matched 
that of controls for all targets. However, the developmental trajectories of patients were 
clearly offset from those expressed by controls.  
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Table 6.2.12: T3 fixation duration – AIC condition comparison with healthy controls 
    
FixDwell    
 
Group Main effect AIC results 
(∆AIC / AICw) 
 Group x Age Interaction AIC results 
 (∆AIC / AICw) 
 Test model Null model  Test model Null model 
      
Top 0 / .99 16 / <.01  0 / .63 1.1 / .37 
      
Bottom 0 / .99 15 / <.01  2 / .27 0 / .73 
      
Horizontal 0 / .96 6 / .04  1.4 / .33 0 / .67 
      
 
 
 
 
 
 
 
 
 
 
 
 The average frequency of saccadic eye movements away from the visual stimulus that 
T3 patients produced (FixSacc) is presented in Figure 6.2.10 and Table 6.2.13. Here FixSacc 
frequencies were normal for the majority of younger patients (8/10 patients). Two older 
patients (patient 9 and 11) exhibited FixSacc deficits for multiple target locations and when 
performance was collapsed across locations (patient 9 (z-score) = -8.89; patient 11 (z-score) 
= -2.70). Interestingly these patients also exhibited FixDwell deficits, so it is likely that the 
observed FixDwell deficits resulted from FixSacc deficits. This can be seen in the temporal 
eye movement data of patient 9 (Figure 6.2.11); fixation on the target was clearly disrupted 
by disruptive saccades made towards the screen centre.  
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Figure 6.2.10: T3 intrusive saccade frequency individual patient performance.  Average number of saccades 
away from the visual stimulus (FixSacc) produced by T3 patients (green dots) and healthy controls (blue dots). 
The healthy developmental trajectory (red line) is expressed as a plateau function. 95% confidence limits (black 
dotted-line) are also presented.  
Table 6.2.13: T3 z-scores for intrusive saccades (FixSacc) 
  Target Position  
PID Age 
(Years) 
Left Right Bottom Top Avg 
1 4.4 1.50  (0.92) 2.00  (0.75) 2.00  (0.46) 2.50  (-0.48) 2.00  (0.61) 
3 6.28 1.00  (1.16) 1.00  (1.21) 0.50  (1.75) 1.50  (0.30) 1.00  (1.50) 
4 6.62 1.50  (0.50) 1.00  (1.15) 1.50  (0.39) 1.00  (1.14) 1.25  (1.01) 
5 7.48 1.00  (1.04) 1.00  (1.02) 1.00  (0.93) 1.00  (1.02) 1.00  (1.38) 
6 7.84 2.00  (-0.49) 1.75  (-0.31) 1.50  (0.10) 1.75  (-0.68) 1.75  (-0.45) 
7 8.26 1.50  (0.16) 1.00  (0.90) 1.00  (0.83) 2.00  (-1.38) * 1.38  (0.30) 
8 15.81 1.00  (0.51) 1.00  (0.27) 1.25  (-0.43) 1.00  (0.35) 1.06  (0.20) 
9 17.68 2.50  (-7.31) ** 2.00  (-6.71) ** 3.00  (-6.88) ** 1.50  (-1.67) ** 2.25  (-8.89) ** 
10 19.52 1.00  (0.52) 1.00  (0.27) 1.00  (0.31) 1.00  (0.28) 1.00  (0.51) 
11 19.82 1.50  (-2.79) ** 1.00  (0.28) 2.00  (-3.84) ** 1.00  (0.28) 1.38  (-2.70) ** 
Note: z-scores in parentheses ; *  z-score > 1, ** z-score > 2 
 182 
 
 
Figure 6.2.11: T3 fixation task raw temporal data.  Time course data of T3 patient 9 during the fixation task. The 
visual stimulus (blue line) is presented along with patient (black line) and age-matched control eye position 
(dashed red line).  
 
 Finally, the AIC comparisons of T3 patient and control developmental trajectories for 
intrusive saccade frequency revealed there was insufficient evidence of 3- and 2-way 
interactions, and main effects, for Group, SetSize, and Age. This means there were no 
differences between the developmental trajectories of T3 patients and controls for intrusive 
saccade frequency. 
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6.2.4 Conclusions: Tyrosinemia III (T3) 
 The cognitive functioning of 11 tyrosinemia III (T3) patients was investigated using 
detailed cognitive measures of attention, language, and oculomotor function. In general, 
language production (BNT) and comprehension (BPVS) deficits were clear, with 6 / 10 (55%) 
and 8 / 11 (73%) patients exhibiting deficits respectively. These deficits were most apparent 
in the older T3 patients. Attention deficits were also evident, and were characterised by 
slower overall visual search time (VSmean) and lower sustained fixation durations (FixDwell) 
in 5 / 11 (45%) and 4 / 11 (36%) patients respectively. Here, the deficits were present in the 
youngest and eldest patients. 
 To our knowledge, this study represents the first detailed cognitive assessment of T3 
patients, and highlights the predominance of language and attention impairments that are 
expressed by the group. The current findings support the previous T3 case reports by Ellaway 
et al. (2001), who reported mild to moderate intellectual impairments in a sample of 12 
patients. However, these findings were based on case reports, and were unable to provide 
specific information about the kinds of cognitive deficits patients exhibited. The prevalence 
of T3 language deficits is also interesting since this is a frequently reported cognitive feature 
of  NTBC treated T1 patients (Bendadi et al., 2014b; Thimm et al., 2011). This is because 
NTBC treatment biochemically switches T1 patients into T3 patients. Consequently, this 
finding provides indirect evidence that long-term NTBC treated T1 patients share similar 
cognitive features with T3 patients. 
 Treatment of T3 involves a strict tyrosine restricted diet, which is important for 
controlling patient’s levels of tyrosine. Elevated levels of central nervous system tyrosine 
levels are particularly damaging during the first year of life. This was demonstrated by 
Ellaway et al. (2001), whereby patients who were diagnosed and treated later presented with 
more severe symptoms. In the current study, biochemically data such as tyrosine levels at the 
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time of diagnosis or compliance with diet were not measured. Hence, it is possible that the 
heterogeneous cognitive profile of patients on some tasks (e.g. visual search and fixation 
tasks) could result from differing diet start times between patients. To clarify these 
speculations, the effect of diet start time on cognitive outcomes is currently being explored in 
a separate project. 
6.3 Chapter Conclusions 
 In this chapter, the cognitive performance of tyrosinemia type I and type III patients 
was examined on the current test battery. Tyrosinemia type I is a metabolic disorder that has 
received a relatively large amount of neuropsychological study (compared to other metabolic 
disorders) since long term treatment with NTBC is expected to produce cognitive 
impairments. In contrast, Tyrosinemia type III has enjoyed minimal attention, due to the 
rarity of the disorder, but has been associated with mental retardation based on a small 
number of case reports (Ellaway et al., 2001). Here, we reported a broad range of cognitive 
impairments in tyrosinemia III and mild deficits for a limited number of cognitive domains in 
tyrosinemia type I. In addition, we demonstrated some similarities between these two 
disorders in the form of disrupted language function. However, due to the small size of the 
tyrosinemia type I sample it was not possible to conduct a robust statistical comparison 
between the groups. Finally, there was large heterogeneity between tyrosinemia III patients 
on the current test battery. Specifically, cognitive deficits were more common among the 
youngest and eldest patients within the current cohort. In conclusion, two recommendations 
are offered for future research: First, studies should focus on integrating biochemical data 
into the cognitive assessment of these disorders to assist the interpretation of cognitive 
outcomes. Second, a comparison of a larger population of tyrosinemia I patients and 
tyrosinemia III patients to clarify whether NTBC treatment produces deficits in tyrosinemia I 
that mirror the deficits reported in tyrosinemia III.  
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7.0 CONCLUSION AND FUTURE DIRECTIONS 
7.1 Conclusions 
 The current thesis aimed to create a new battery of neuropsychological tests that were 
tailored specifically towards measuring the neurodegenerative effects of inherited metabolic 
diseases (IMDs). These are a large group of complex heterogeneous genetic disorders that 
have received minimal attention from the field of neuropsychology. This is primarily due to 
the rarity of the disorders and because, understandably, the drive of past research has focused 
on improving the survivability of patients. With the advent of treatments (such as HSCT and 
ERT) that positively influence neuropsychological outcomes, there is a need for sensitive and 
objective neuropsychological measures that allow patients to be systematically tracked in 
order to understand the efficacy of these treatments. In addition, existing descriptions of 
cognitive function in children with IMD have relied predominantly upon standardised 
intelligence tests (Davison et al., 2012; Ellaway et al., 2001; Thimm et al., 2011), which are 
better suited to providing an overall measure of cognitive function. Hence, neurodegenerative 
effects of IMD on specific cognitive domains are not always clear.  
The following demands necessitated the development of the current test battery: the 
clinical need for an instrument that can be used to accurately track disease progression; an 
objective and sensitive tool to evaluate positive and negative outcomes of therapeutic 
interventions; the research need for information on the specific impact of the 
neurodevelopmental disorders on language, motor control and attention. To determine 
whether the current battery of tests achieved these objectives, evidence gathered during the 
research is described here in the context of the following principle questions:  
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(i) What are the best measures (most sensitive and efficient) to use to track disease 
progression during different stages of the disease? 
(ii) Do some cognitive domains develop/decline differently along the time course of a 
disease? 
(iii) What is the homogeneity across and within diseases for the cognitive areas that are most 
and least affected by disease? 
 
 
 (i) What are the best measures (most sensitive and efficient) to use to track disease 
progression during different stages of the disease? 
 The cognitive functioning of IMD patients was evaluated across three cognitive 
domains: attention, language and oculomotor function. A summary of cognitive deficits for 
each of the five disorders that were assessed is shown in Table 7.1. Measures of attention 
(visual search and fixation tasks) were highly sensitive to the effects of IMD across a wide 
range of ages. This was demonstrated in several patient groups and was particularly evident 
amongst two lysosomal storage disorders, Hurler syndrome and Morquio syndrome. Here, 
prominent sustained fixation deficits were observed across the entire age range in both 
groups. Deficits of overall search time on the visual search task were also observed; however, 
for Morquio syndrome the magnitude of visual search deficits were smaller than those 
reported in the fixation task. Due to their sensitivity over a wide range of ages, the attention 
tasks used here provide a means of tracking IMD disease progression over a long-term time 
scale.   
 187 
 
 
Table 7.1.1: Summary of cognitive deficits across disorders and cognitive domains 
   Lysosomal Storage 
 Disorders 
 Tyrosinemia Disorders 
Domain  Task MPS-IH MPS-IVa MPS-VI  Tyro I Tyro III 
Attention 
 Simple 
RT Task 
* * -  - * 
 Visual 
Search Task 
** ** -  - * 
         
Language 
 BNT * - -  - ** 
 BPVS ** * *  * ** 
 Non-Word 
Task 
** - -  * * 
         
Ocular 
Motor 
 Fixation 
Task 
** ** -  - * 
 Prosaccade 
Task 
- - -  * - 
 Antisaccade 
Task 
* * -  - - 
 Smooth 
Pursuit 
- - -  - - 
         
Note: *  possible deficit, ** Consistent deficit 
Language tasks offered valuable insights into the neuropsychological profile of 
tyrosinemia diseases. Unlike attention tasks, where deficits were detectable across a wide 
range of ages, verbal production and comprehension tasks (BPVS and BNT) were most 
sensitive to impairments exhibited by older patients. In contrast, very few language 
impairments were detected by the novel non-word learning task. This was primarily due to 
the large variance exhibited by healthy controls for non-word production (which may have 
masked any subtle non-word production deficits that patients may have possessed) and the 
insensitivity of non-word comprehension to mild deficits (ceiling effect). As a result, in its 
present form, the non-word learning task is only sensitive to severe non-word learning 
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deficits. This means that, without revision, the functionality of the non-word learning task as 
a disease tracking tool is unacceptable. 
Basic eye movement measures (pro-saccade and smooth pursuit tasks) were normal in 
almost all patients from the current patient cohorts. For the pro-saccade task, the normal 
range of saccadic onset latencies expressed by healthy controls was very narrow, so the 
absence of deficits here was not due to large control variance concealing milder patient 
deficits. Despite this, properties of reflexive saccades (saccade onset and velocity) were 
informative when exploring the underpinning of sustained fixation deficits; fixation duration 
deficits, as seen in Morquio patients, were not the consequence of patients’ gaze arriving at 
the target later than controls. Finally, no smooth pursuit deficits, neither for velocity gain or 
forward saccade frequency, were identified in any patient. In summary, while the basic 
properties of eye movements have been shown to be disrupted in other IMDs (e.g. Niemann-
Pick type C and Gaucher’s disease; (Patterson et al., 2010; Vanier, 2013)), the current pro-
saccade and smooth pursuit findings suggest that the basic properties of eye movements are 
not useful measures for tracking the progression of disease of the current cohorts. However, 
these results do serve as a useful comparison to tasks where patient performance is clearly 
disrupted (e.g. sustain fixation). 
 
 
(ii) Do some cognitive domains develop/decline differently along the time course of a 
disease? 
 The AIC trajectory methodology employed here provided a rich descriptive approach 
towards evaluating any developmental differences that exist between patients and healthy 
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controls. Specifically, this approach enabled the distinction between different types of 
developmental deviation, such as whether trajectories of patients were offset or had a slower 
rate of development relative to healthy controls. By extension, this procedure permits the 
examination of how the cognitive development of patient groups differed across domains. For 
example in tyrosinemia III, simple reaction time development followed a normal 
developmental trajectory (both in terms of the rate and onset of development), while for 
verbal production and comprehension the development rate of patients was slowed in 
comparison to healthy controls, leading to the majority of older patients performed well 
below the predicted range of healthy development. 
 Detailed descriptions of patient cognitive development have several important clinical 
implications. Firstly, patient developmental trajectories provide an estimate of future patient 
performance. This is useful when evaluating the efficacy of novel therapeutic interventions, 
since cognitive outcomes can be compared against performance estimates that are 
independent of therapeutic effects, thus providing a more detailed description of treatment 
outcomes. Secondly, understanding how developmental trajectories differ across domains 
enables researchers and clinicians to choose the best age-appropriate measures to monitor 
cognitive outcomes. For example, in tyrosinemia III, language measures may serve as a 
meaningful outcome for older patients only. Finally, having representations of both patient 
and healthy development enables the tracking of individual patients against two 
developmental populations. In this way it is possible to describe how patients deviate (or do 
not deviate) from developmental trajectories representing their disorder and healthy 
developing controls. 
However, patient developmental trajectories here are based on the cross-sectional 
analysis of rare populations. Consequently, caution is required when interpreting trajectories 
based on a limited number data points. This is especially relevant for trajectories representing 
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development in patients from a group where performance is heterogeneous. Therefore, it 
would be advantageous to have longitudinal data to characterise the variability of individual 
patient profiles that contribute to population trajectories. 
(iii) What is the homogeneity across and within diseases for the cognitive areas that are most 
and least affected by disease? 
 The heterogeneous nature of IMDs, both across and within IMD, was clearly 
characterised within the current work. This was demonstrated through the comparison of 
individual patient z-scores to trajectories of healthy cognitive development, and the 
distribution of patient residuals around trajectories defined by the patient group. A clear 
example where heterogeneity was shown across disorders was for the three assessed 
lysosomal disorders. Here, three distinct cognitive profiles were identified; Hurler syndrome 
and Morquio syndrome patients exhibited severe and mild attention deficits respectively, 
while, Maroteaux-Lamy syndrome patients were normal on nearly all tasks. These findings 
were congruent with previous studies which investigated the functioning of these three 
disorders independently (Davison et al., 2012; Elkin et al., 2006; Neufeld & Muenzer, 2001; 
Wraith, 2006). This provides support for the use of the current test battery as a sensitive tool 
to assess the cognitive functioning of multiple neurodegenerative disorders with varying 
cognitive profiles. 
The within-group heterogeneity that is associated with many IMDs was characterised 
by the performance of Morquio syndrome patients. By examining size of patient residuals 
around their constructed developmental trajectories, it is possible to ascertain the conformity 
of patients to a predictable developmental trajectory. In particular, there was substantial 
variance between patients on the visual search task, with a few patients exhibiting extreme 
deficits and the remainder being within the range of healthy development. In contrast, the 
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within-group heterogeneity of Morquio syndrome patients on verbal production and 
comprehension measures was minimal; all patients fell within (or just outside) the range the 
healthy development. Thus, the within-group heterogeneous variance that patients expressed 
across different cognitive domains was captured by the current test battery. Because 
heterogeneity within and across diseases was demonstrated in many of the investigated 
diseases, it will be important that biochemical data (e.g. metabolite levels) is integrated into 
future cognitive assessments to understand whether the heterogeneity in cognitive results is 
connected to specific biochemical factors (e.g. generally high toxic metabolite levels or 
periods of crisis). 
 
7.2 Recommendation and Future Directions 
 Based on the evidence gathered over the course of the research, the following four 
recommendations are offered to researchers and clinicians who are interested in examining 
the cognitive effects of metabolic disease: 
(i) Use of biological markers to supplement interpretations of cognitive outcomes 
(ii) Alternative analysis methods:  Longitudinal tracking and Contrast group designs  
(iii) Inclusion of additional/alterative cognitive measures and assessment of other IMDs 
 
(i) Use of biological markers to supplement interpretations of cognitive outcomes 
As already stated, the heterogeneous nature (both within and across disorders) of 
IMDs means that in order to provide clearer descriptions of the neurological complications, 
there is a need for future research to incorporate sources of biological and biographical data 
in the interpretation of cognitive outcomes. For example, patients with tyrosinemia III are 
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treated with a restricted protein diet to manage their levels of tyrosine. Hence, the large 
variance demonstrated between tyrosinemia III patients on measures of attention (visual 
search and fixation tasks) could be the result of the more severely affected patients having 
higher levels of tyrosine present in their CSF. At younger ages elevated tyrosine levels could 
result from a later diagnosis, and at older ages, higher tyrosine levels could be due to poorer 
diet compliance. In addition, it could be possible that the protein restricted diet that 
tyrosinemia III patients are place presents additional risks to cognitive function. 
 
 Another possible avenue to explore is the correlation between neuroimaging findings 
and cognitive outcomes. To some extent, several studies have already utilised imaging 
techniques, such as magnetic resonance imaging (MRI), magnetic resonance spectroscopy 
(MRS) and diffusion tension imaging (DTI), in the analysis of cognitive outcomes. For 
example, in the assessment of Morquio syndrome cognitive function by Davison et al. (2012), 
MRS findings revealed a negative correlation between white matter toxic metabolite 
concentrations and cognitive indices. In another example, Shapiro et al. (2012) found that 
Hurler syndrome patients who had lower attention spans also had decreased  fractional 
anisotropy, as measured through DTI. Both studies highlight the importance of imaging 
techniques when interpreting the heterogeneity of patients’ cognitive outcomes. The majority 
of studies, to date, have inspected the structural properties of patient brains in relation to 
cognition. It is reasonable for one future approach to also examine the functional properties 
of patient brains. This would provide additional spatial and temporal information about brain 
function (allowing inspection of where and when information is processed in the brain) and 
could be accomplished through function magnetic imaging (fMRI) or electroencephalography 
(EEG).  
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(ii) Alternative analysis methods:  Longitudinal tracking and Contrast group designs. 
A cross-sectional approach was taken to defining the developmental effects of rare 
IMD. While this approach has the advantage of being more time-efficient and places less 
burden on participating patients, the rarity of the investigated diseases means that estimates of 
development are based on a limited number of data points. Consequently, caution is advised 
when interpreting development based on the current findings, especially for purpose of 
clinical decisions. Because of the rarity of these disorders, future research should consider 
longitudinal follow-up to compliment a cross-sectional approach. 
Another benefit of a longitudinal approach is the ability to inspect the heterogeneity 
of individual patient trajectories in relation to their respective population trajectory. This is 
important developmental information that a cross-sectional approach cannot provide. 
Therefore, it is not clear whether the population trajectories defined in the current work 
accurately reflect the trajectories of individual patients over time. For example, there might 
be considerable heterogeneity in the slopes of individuals that contribute to the population 
slope, which would mean that the rate of development is heterogeneous, or there could be 
different offsets in different patients, determined by severity, but a similar rate of 
development in individual patients. 
An alternative approach to comparing patient performance with developmental 
trajectories is to compare patient performance to two typically developing contrast groups: a 
chronological age-matched (CA) group and a mental age-matched (MA) group. The objective 
of this approach is to determine whether individuals, or a group of individuals, from a 
disorder group possess impairments that are characteristic of developmental delay (i.e. patient 
performance differences only to the CA-matched group) or whether patients exhibit 
developmental deviance or atypicalilty (i.e. patient performance differs from both CA and 
MA-matched groups). Group comparisons using t-test or analysis of variance are the most 
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common statistical methods employed. Consequentially, matched design comparisons may be 
ill suited to investigations where groups occupy a wide age range, since group means may 
mask a wide range of individual performances. This poses a problem when investigating rare 
neurodegenerative disorders (such as IMDs) as these patient populations inevitably occupy a 
wide age range. In addition, to perform matching correctly it is important that the 
performance of the CA-matched and MA-matched groups is within the sensitive range of the 
employed task. Therefore, establishing an appropriate MA-matched group may not be 
possible when investigating disorder groups where severe learning difficulties are present. 
 A solution which combines the developmental trajectory and matched design 
approach may be adopted that provides a description of developmental delay and deviation 
without the need for a MA-matched typically developing contrast group (Thomas et al., 
2009). This is achieved by first assessing the performance of a disorder group on an 
experimentl task (e.g. non-word learning) that relates to a cognitive domain of interest (e.g. 
language). In addition, data is collected on a further task that yields MA-equivalent 
performance levels for typically developing children. A typically developing comparison 
group is then recruited that spans from the youngest MA to the oldest CA of the disorder 
group, and the performance of these comparison individuals is assessed on the experimental 
task. Based on these data, patient performance can be compared to a typically developing 
trajectory to calculate two standardised scores: a z-score based on patient CA (as performed 
in the current work) where deviations could be indicative of developmental delay, and a z-
score based on patient MA where deviations are suggestive developmetal deviance. However, 
for this approach to be performed correctly it is important that an individual patient MA-
equivalent score are calculated for each of the cognitive domains under examination. This 
presents a problem when examining patients with servere learning disabilities on batteries of 
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neuropsychological tests since it may be unfeasiable to collect the necessary MA-equivalent 
scores within time that the patients are compliant with testing. 
 
(iii) Inclusion of additional/alternative cognitive measures and assessment of other IMDs 
Cognitive functioning was assessed on three domains. While attention and language 
tasks were sensitive to mild cognitive impairments, many of the oculomotor tasks were not. 
There might be several reasons for this: First, the difficulty of the anti-saccade task was too 
high, which meant establishing a sensitive measure that captured the healthy development of 
saccadic inhibition was not possible. Therefore, future studies intending to assess saccadic 
inhibition should use a task with less demanding testing conditions. For example, a simplier 
memory-guided saccade task would provide a measure of saccadic inhibition and data based 
on the basic properties of endogenous saccadic eye-movements (e.g. saccade onset and 
velocity). Second, the neurodegenerative effects of the investigated diseases did not manifest 
in the reflexive properties of saccades and smooth pursuit. However, it is recommended that 
the inclusion of these tasks is preserved since the saccadic system has been shown to be 
clearly compromised in other IMDs (Niemann-Pick Type C and Gaucher disease; Vanier, 
2013; Wraith et al., 2010) and they are informative when interpreting outcomes of other eye-
movement measures. 
An additional measure which researchers may consider adopting into the test battery 
is a measure of postural sway or gait stability. This is because ataxia is a commonly reported 
symptom in several IMDs, such as tyrosinemia III, Niemann-Pick Type C, and Gaucher 
disease (Ellaway et al., 2001; Paciorkowski et al., 2008; Wraith et al., 2010). In particular, 
upper limb tremor and gait instability in Niemann-Pick type C patients has been documented 
in two studies (Floyd et al., 2007; Paciorkowski et al., 2008). Here, kinematic measures 
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offered a means of capturing change in motor function over time, and a method to evaluate 
the efficacy of a new treatment (Miglustat). Therefore, a sensitive measure that is capable of 
quantifying the kinematics of postural sway and gait could compliment the current test 
battery. 
7.3  Chapter Conclusions 
The current body of work introduces new data and objective methods for studying the 
neuropsychological effects of IMDs. Findings from five patient cohorts indicated that disease 
effects were not homogeneous across tasks, and that performance on the same tasks was not 
uniform across diseases. Several measures that were sensitive to disease progression were 
identified that will provide clinicians and researchers with new tools to track how diseases 
affected cognitive function and quantify treatment benefits. In addition, the obtained data 
offers a promising basis for understanding how biochemical and biographical factors 
influence the severity and timecourse of developmental effects. Finally, the data also makes 
several clear extensions possible. This includes the correlation of cognitive performance to 
structural and functioncal brain changes by combining the current methods with data from 
brain imaging, and also, a fuller understanding of population and individual profiles is 
possible if these methods are used in longitudinal studies to understand the progression of 
development in individuals over time. 
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APPENDIX 1: Non-Word Learning Stimuli 
 Images and related non-words used as the stimuli during the non-word task. All 
images were presented on laminated card (15 x 21cm). A 2-syllable non-word name was 
assigned at random to each monster at the beginning of the thesis. Names here are presented 
along with APA phonetic representation. 
 
 
 
Nimack (nimack) 
Vargan (vargan) 
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Jiplo (yiplo) 
Teldom (teldom) 
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Gafnic (gafnic) 
